Atypical Ubiquitin Chains: Decoding Their Crucial Roles in Antiviral Immune Signaling and Therapeutic Potential

Abstract

Beyond the well-characterized K48 and K63 linkages, atypical ubiquitin chains—including linear, K6-, K11-, K27-, K29-, and K33-linked polymers—are emerging as sophisticated regulators of the antiviral innate immune response. This article synthesizes current knowledge on how these atypical chains precisely control key signaling pathways, such as RIG-I/MDA5, cGAS-STING, and NF-κB, by modulating the stability, activity, and interactions of innate immune proteins. We explore the E3 ligases and deubiquitinases (DUBs) that write and erase these signals, their functional outcomes in balancing immune activation and resolution, and the latest methodological advances for their study. Furthermore, we discuss the therapeutic implications of targeting these pathways in viral infections and immune-related diseases, providing a comprehensive resource for researchers and drug development professionals in immunology and virology.

The Atypical Ubiquitin Code: Defining the Players and Their Basic Functions in Immune Defense

Protein ubiquitination is a crucial post-translational modification that extends far beyond its initial characterization as a signal for proteasomal degradation. This modification involves the covalent attachment of the 76-amino acid protein ubiquitin to substrate proteins via a three-enzyme cascade comprising E1 (activating), E2 (conjugating), and E3 (ligating) enzymes [1]. The complexity of ubiquitin signaling arises from ubiquitin's ability to form various chain architectures through its seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or N-terminal methionine (M1) [1] [2].

While K48-linked chains remain the canonical signal for proteasomal degradation and K63-linked chains regulate signaling pathways such as NF-κB activation and DNA repair, the so-called "atypical" ubiquitin chains (K6, K11, K27, K29, K33) have emerged as critical regulators of diverse cellular processes [1] [3]. These non-canonical chains form unique structural topologies that are specifically recognized by effector proteins, enabling them to modulate essential cellular functions including immune responses, organelle quality control, and cell cycle progression [1] [3]. This review synthesizes current understanding of atypical ubiquitin chains, with particular emphasis on their roles in antiviral innate immunity.

Atypical Ubiquitin Chain Types: Structures and Functions

Characteristics and Biological Roles

The following table summarizes the key features, biological functions, and regulatory enzymes associated with each atypical ubiquitin chain type:

Table 1: Characteristics of Atypical Ubiquitin Chains

Chain Type	Known Functions	Regulatory E3 Ligases	Deubiquitinases (DUBs)	Cellular Processes
K6-linked	Mitophagy regulation, DNA damage response, innate immune activation	Parkin, HUWE1, RNF144A/B, UBE4A	USP8, USP30, OTUD1	Mitochondrial quality control, DDR, antiviral defense [1]
K11-linked	Cell cycle regulation, proteasomal degradation, innate immune modulation	APC/C (with UBE2S/UBE2C), RNF26	USP19, UCHL5	Mitosis, STING regulation, Beclin-1 degradation [1] [3] [4]
K27-linked	Innate immune signaling, NF-κB and IRF3 activation	TRIM23, RNF167	A20, OTUD1	RLR signaling, dendritic cell activation [3]
K29-linked	Proteasomal degradation (branched chains), kinase regulation	Ufd4, TRIP12, HUWE1	To be characterized	N-degron pathway, proteostasis [5]
K33-linked	Kinase regulation, intracellular trafficking	To be characterized	To be characterized	Kinase modulation, endosomal sorting [6]

Chain Architecture and Recognition

Atypical ubiquitin chains exhibit diverse structural properties that determine their functional specificity:

• Homotypic vs. Heterotypic Chains: Homotypic chains consist of a single linkage type, while heterotypic chains contain mixed linkages within the same polymer [1] [2].
• Branched Ubiquitin Chains: These complex architectures form when a single ubiquitin molecule serves as a branching point for multiple chain types, creating enhanced degradation signals or unique interaction platforms [4] [5] [7].
• Linkage-Specific Recognition: Effector proteins containing ubiquitin-binding domains (UBDs) exhibit remarkable specificity for distinct chain topologies, enabling precise decoding of ubiquitin signals [1] [6].

Atypical Ubiquitin Chains in Antiviral Innate Immunity

Regulation of Pattern Recognition Receptor Signaling

The innate immune system employs pattern recognition receptors (PRRs) including RIG-I-like receptors (RLRs) and DNA sensors to detect viral infections. Atypical ubiquitin chains play crucial roles in both activating and constraining these signaling pathways:

Figure 1: Atypical Ubiquitin Chains in RLR Signaling Regulation. K27-linked chains activate RIG-I/MDA5, while K6/K11-linked chains mediate degradation through autophagic and proteasomal pathways, respectively.

Specific Mechanisms of Immune Regulation

K6-linked ubiquitination enhances antiviral innate immunity by modifying the transcription factor IRF3, enabling its binding to type I interferon promoters [1]. OTUD1-mediated deubiquitination reverses this process, providing a regulatory switch [1]. Additionally, RNF167-mediated K6-linked ubiquitination of RIG-I and MDA5 targets these viral RNA sensors for autophagic degradation via p62 recognition, representing a distinct mechanism from proteasomal targeting [8].

K11-linked chains exhibit dual regulatory functions in innate immunity. RNF26-mediated K11-linked ubiquitination of STING inhibits its degradation, thereby potentiating type I interferon production [3]. Conversely, K11-linked ubiquitination of Beclin-1 promotes its proteasomal degradation, which subsequently enhances RIG-I/MAVS interaction and type I interferon signaling [3].

K27-linked chains assembled by TRIM23 on NEMO activate both NF-κB and IRF3 pathways downstream of RLR signaling [3]. These chains serve as platforms for recruiting regulatory proteins such as Rhbdd3, which brings the deubiquitinase A20 to suppress excessive NF-κB activation [3].

Branched ubiquitin chains represent particularly sophisticated regulatory mechanisms. K48-K63 branched chains generated by HUWE1 and TRAF6 in response to IL-1β facilitate TAB2 recognition while protecting K63 linkages from CYLD-mediated deubiquitination, thereby amplifying NF-κB signaling [7]. Similarly, K29-K48 branched chains formed by Ufd4 enhance proteasomal targeting efficiency [5].

Experimental Methods for Studying Atypical Ubiquitination

Proteomic Approaches for Ubiquitination Analysis

Comprehensive analysis of atypical ubiquitination requires specialized methodologies for enrichment, detection, and linkage determination:

Figure 2: Experimental Workflow for Ubiquitin Proteomics. Key enrichment strategies enable comprehensive analysis of atypical ubiquitination.

Detailed Methodological Protocols

4.2.1 Enrichment of Ubiquitinated Proteins Using TUBE Technology

Tandem Ubiquitin-Binding Entities (TUBEs) provide a powerful approach for enriching ubiquitinated proteins while protecting ubiquitin chains from deubiquitinating enzyme activity [6]:

Reagents Required:

• TUBE agarose beads (commercially available or prepared by coupling TUBE proteins to NHS-activated agarose)
• Lysis buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 10 mM N-ethylmaleimide (NEM)
• Protease and phosphatase inhibitor cocktails
• Wash buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% NP-40
• Elution buffer: 100 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 200 mM DTT

Procedure:

• Harvest cells and lyse in TUBE-compatible lysis buffer containing NEM to inhibit DUBs
• Clarify lysates by centrifugation at 16,000 × g for 15 minutes at 4°C
• Incubate supernatant with TUBE agarose beads for 2-4 hours at 4°C with gentle rotation
• Wash beads 3-5 times with wash buffer to remove non-specifically bound proteins
• Elute bound ubiquitinated proteins with SDS-PAGE sample buffer for immunoblotting or mass spectrometry

4.2.2 Linkage-Specific Analysis Using Middle-Down Mass Spectrometry

Ubiquitin chain linkage architecture can be determined using middle-down MS approaches such as Ub-clipping [4] [5]:

Reagents Required:

• Linkage-specific antibodies (commercially available for K6, K11, K27, K29, K33, K48, K63, M1)
• Lbpro* protease for Ub-clipping
• C18 stage tips for sample desalting
• LC-MS/MS system with high-resolution mass spectrometer

Procedure:

• Enrich ubiquitinated proteins using preferred method (immunoaffinity, TUBE, or tagged ubiquitin)
• For Ub-clipping: Digest with Lbpro* to cleave ubiquitin C-terminally after arginine residues
• Analyze cleavage products by LC-MS/MS to identify linkage types through diagnostic fragments
• For antibody-based approaches: Perform sequential immunoprecipitation with linkage-specific antibodies
• Identify ubiquitination sites and linkage types through database searching of MS/MS data

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Research Reagents for Studying Atypical Ubiquitin Chains

Reagent Category	Specific Examples	Applications	Key Features
Linkage-Specific Antibodies	K6-, K11-, K27-, K29-, K33-linkage specific	Immunoblotting, immunofluorescence, immunoprecipitation	Enable specific detection of atypical chains; some show preference for branched chains [2] [9]
UBD-Based Affinity Reagents	TUBEs (Tandem Ubiquitin-Binding Entities), ThUBDs (Tandem hybrid UBDs)	Ubiquitinated protein enrichment, DUB protection	Pan-specific ubiquitin recognition; protect chains from DUBs [2] [6]
Tagged Ubiquitin Systems	His-, HA-, Strep-, FLAG-tagged ubiquitin	Affinity purification of ubiquitinated proteins	Enable high-throughput ubiquitinome studies; may introduce artifacts [2]
Activity-Based Probes	Ub-VS, Ub-PA, branched ubiquitin probes	DUB activity profiling, mechanism studies	Covalently trap enzymatic intermediates; elucidate mechanisms [5]
Recombinant E2/E3 Enzymes	UBE2S/APC/C (K11), Parkin (K6), TRIM23 (K27), Ufd4 (K29)	In vitro ubiquitination assays	Linkage-specific chain assembly; mechanistic studies [1] [3] [5]
DUB Inhibitors	USP30 inhibitors, UCHL5 inhibitors, general DUB inhibitors	Functional studies, therapeutic development	Probe biological functions; potential therapeutic applications [1]

The study of atypical ubiquitin chains has revealed remarkable complexity in ubiquitin signaling beyond the well-characterized K48 and K63 linkages. These non-canonical modifications play essential roles in cellular homeostasis, with particularly important functions in fine-tuning antiviral immune responses. The development of sophisticated tools including linkage-specific antibodies, TUBE technologies, and advanced mass spectrometry methods has enabled researchers to decipher this complex ubiquitin code.

Future research directions will likely focus on understanding the structural basis for branched chain recognition, developing more specific chemical probes for atypical linkages, and elucidating the crosstalk between different ubiquitin chain types in integrated signaling networks. As our methodological capabilities continue to advance, so too will our understanding of how atypical ubiquitin chains contribute to both physiological immune regulation and pathological conditions, potentially revealing new therapeutic targets for immune disorders and viral diseases.

The ubiquitin system represents a sophisticated, reversible post-translational modification system that regulates virtually all aspects of eukaryotic biology, including the antiviral innate immune response [10]. While the roles of K48-linked (proteasomal degradation) and K63-linked (signal transduction) polyubiquitin chains have been extensively characterized, recent research has unveiled the critical functions of "atypical" ubiquitin chains in immune regulation [11] [12]. These atypical chains—including linear (M1-linked), K11-, K27-, K29-, and K33-linked ubiquitin polymers—create a complex "ubiquitin code" that can direct diverse functional outcomes beyond protein degradation [11] [10]. The specificity of ubiquitin signaling is largely determined by E3 ubiquitin ligases ("writers") that recognize substrates and catalyze the formation of specific chain topologies [13]. In the context of antiviral innate immunity, E3 ligases that build atypical chains have emerged as crucial regulators of intracellular signaling pathways initiated by pattern recognition receptors (PRRs) such as RIG-I-like receptors (RLRs) and cGAS-STING [11] [14]. This review comprehensively examines the key enzymatic writers of atypical ubiquitin chains, with a specific focus on their mechanisms, regulatory functions, and experimental characterization in the context of antiviral defense.

E3 Ubiquitin Ligase Families and Atypical Chain Specificity

E3 ubiquitin ligases constitute a diverse superfamily of enzymes that catalyze the final step in the ubiquitination cascade, determining substrate specificity and linkage type [13] [12]. Mammals possess more than 600 E3 ligases, which are classified into three major families based on their structural domains and catalytic mechanisms [13] [14]:

• RING-type (Really Interesting New Gene): The largest E3 subfamily, characterized by one or two conserved RING finger motifs that facilitate direct ubiquitin transfer from E2 enzymes to substrates. RING-type E3s include single polypeptide E3s, Cullin-RING ligases (CRLs), and other multisubunit complexes [13].
• HECT-type (Homologous to E6-AP Carboxyl Terminus): Contain a HECT domain that forms an E3-ubiquitin thioester intermediate before ubiquitin transfer to substrates. Based on their N-terminal domains, HECT-type E3s are subdivided into Nedd4-like, HERC, and "other" HECTs [13].
• RBR-type (RING-Between-RING): Hybrid E3s containing RING1, IBR, and RING2 domains that employ a catalytic mechanism combining features of both RING and HECT-type ligases. RBR E3s maintain autoinhibition until substrate binding releases this restraint [13].

Table 1: Major E3 Ubiquitin Ligase Families and Their Characteristics

E3 Family	Catalytic Mechanism	Representative Atypical Chain Writers	Structural Features
RING-type	Direct transfer from E2 to substrate	TRIM23, TRIM26, RNF26, RNF167	RING finger domain(s)
HECT-type	E3-ubiquitin thioester intermediate	HECTD3	HECT domain
RBR-type	Hybrid mechanism with catalytic cysteine	LUBAC (HOIP/HOIL-1L)	RING1-IBR-RING2 domain

The linkage specificity of polyubiquitin chains is determined primarily by the E2 enzyme in concert with the E3 ligase, with atypical chains (non-K48/K63) playing particularly important roles in the regulation of inflammatory and antiviral signaling pathways [11] [12]. The following sections detail the specific E3 ligases that build these atypical chains and their functions in antiviral immunity.

Linear (M1-Linked) Ubiquitin Chains and LUBAC

Biochemistry and Assembly of Linear Ubiquitin Chains

Linear ubiquitin chains, connected through the N-terminal methionine (Met1) of ubiquitin, are uniquely generated by the Linear Ubiquitin Chain Assembly Complex (LUBAC), the only known E3 ligase capable of forming this linkage type [15]. LUBAC is a multi-subunit complex composed of three essential components: HOIP (the catalytic center), HOIL-1L, and SHARPIN [15]. The RBR-type ubiquitin ligase HOIP contains a critical linear ubiquitin chain-determining domain (LDD) located C-terminal to its RING2 domain, which facilitates the transfer of ubiquitin from the conserved catalytic cysteine to the α-amino group of the acceptor ubiquitin, thereby forming the characteristic linear linkage [15]. HOIL-1L, also an RBR-type ligase, contributes to the complex's functionality, though HOIP remains the primary catalytic engine for linear ubiquitination [15].

Functional Roles in Antiviral Signaling Pathways

Linear ubiquitin chains play pivotal roles in regulating NF-κB signaling, a central pathway in antiviral and inflammatory responses [11] [15]. A key mechanism involves the interaction of linear chains with NEMO (NF-κB essential modulator, also known as IKKγ), a regulatory component of the IκB kinase (IKK) complex [11] [15]. The UBAN domain (ubiquitin binding in ABIN and NEMO) of NEMO exhibits strong binding preference for linear chains, and this interaction is essential for canonical NF-κB activation [11] [15]. Experimental evidence demonstrates that NEMO mutants incapable of binding linear chains fail to activate NF-κB upon stimulation [11]. Beyond its role as a reader, NEMO itself can be linearly ubiquitinated by LUBAC, further modulating its function [11]. Additionally, LUBAC-mediated linear ubiquitination regulates the balance between NF-κB activation and type I interferon responses by disrupting the MAVS-TRAF3 complex, thereby potentiating NF-κB signaling while inhibiting IRF3 activation and subsequent interferon production [11].

Figure 1: LUBAC-Generated Linear Ubiquitin Chains Regulate Antiviral Signaling. LUBAC assembles linear ubiquitin chains that both activate NF-κB through NEMO/IKK complex engagement and inhibit type I interferon responses by disrupting MAVS-TRAF3 interactions.

Experimental Analysis of Linear Ubiquitination

Co-immunoprecipitation and Western Blotting: To investigate LUBAC-mediated linear ubiquitination, researchers typically employ co-immunoprecipitation assays using antibodies specific for linear ubiquitin chains (e.g., DU134-21) [15]. Cells are transfected with LUBAC components (HOIP, HOIL-1L, SHARPIN) and stimulated with relevant agonists (e.g., TNF-α, viral mimics). Following immunoprecipitation of target proteins (e.g., NEMO, RIP1), linear ubiquitination is detected via Western blotting with linkage-specific antibodies [15].

Functional Assays: NF-κB activation is commonly measured using luciferase reporter assays under the control of NF-κB-responsive promoters, while type I interferon responses are assessed using ISRE (interferon-stimulated response element) reporter systems [11] [15]. To specifically interrogate the role of linear chains, researchers utilize NEMO mutants deficient in linear ubiquitin binding (UBAN domain mutants) or employ RNA interference to deplete LUBAC components [11].

K27-Linked Ubiquitin Chains and Their E3 Writers

Multifunctional Roles in Antiviral Regulation

K27-linked ubiquitin chains have emerged as particularly versatile regulators of the antiviral immune response, with multiple E3 ligases conferring substrate specificity and functional diversity [11]. Unlike linkage types with more unified functions (e.g., K48 for degradation), K27-linked ubiquitination exerts pleiotropic effects depending on the specific substrate and cellular context:

• TRIM23 catalyzes K27-linked ubiquitination of NEMO, leading to activation of both NF-κB and IRF3 pathways and subsequent antiviral gene expression [11]. Additionally, TRIM23 mediates K27-linked autoubiquitination, which activates TBK1 and induces antiviral autophagy [11].
• TRIM26 modifies itself with K27-linked chains, facilitating interaction with NEMO and enhancing type I interferon and cytokine production [11].
• RNF185 promotes K27-linked ubiquitination of cGAS, stimulating IRF3 activation and production of type I interferons and proinflammatory cytokines in response to cytosolic DNA [11].
• TRIM40 conversely acts as a negative regulator by mediating K27-linked ubiquitination of RIG-I and MDA5, targeting these sensors for proteasomal degradation and thereby inhibiting type I interferon responses [11].

Table 2: E3 Ligases Building K27-Linked Atypical Chains in Antiviral Immunity

E3 Ligase	Substrate	Functional Outcome	Regulatory Role
TRIM23	NEMO, TRIM23	NF-κB and IRF3 activation; TBK1-mediated antiviral autophagy	Positive
TRIM26	TRIM26	Enhanced type I IFN and cytokine production	Positive
RNF185	cGAS	IRF3 activation and cytokine production	Positive
AMFR	STING	TBK1 recruitment and IRF3 activation	Positive
TRIM40	RIG-I, MDA5	Proteasomal degradation; inhibition of type I IFN response	Negative
MARCH8	MAVS	Autophagy-mediated degradation; restriction of IFN response	Negative

Experimental Protocols for K27-Linked Ubiquitination

Linkage-Specific Ubiquitin Mutants: To definitively establish the formation of K27-linked chains, researchers employ ubiquitin mutants where all lysine residues except K27 are mutated to arginine (Ub-K27-only) [11]. Conversely, a K27R ubiquitin mutant (where K27 is mutated to arginine) serves as a critical control to confirm linkage specificity [11].

Mass Spectrometry-Based Identification: Advanced proteomic approaches, including diGly remnant immunoprecipitation coupled with mass spectrometry, enable system-wide identification of K27-linked ubiquitination sites [11]. Following immunoprecipitation of ubiquitinated proteins and tryptic digestion, K27-linked peptides are identified by characteristic signature peptides and fragmentation patterns.

Functional Validation: CRISPR/Cas9-mediated knockout of specific E3 ligases, followed by reconstitution with wild-type versus catalytically inactive mutants, provides definitive evidence for the functional consequences of K27-linked ubiquitination on specific substrates [11].

K11, K29, and K33-Linked Atypical Chains in Immune Regulation

K11-Linked Ubiquitination

K11-linked ubiquitin chains, traditionally associated with cell cycle regulation and proteasomal degradation, also play significant roles in innate immunity [11]. RNF26 catalyzes K11-linked ubiquitination of STING, preventing its degradation and thereby enhancing type I interferon and cytokine production in response to cytosolic DNA [11]. This stabilizing effect on STING represents a non-proteolytic function of K11-linked chains. Additionally, the deubiquitinating enzyme USP19 removes K11-linked chains from Beclin-1, stabilizing this autophagy regulator and limiting type I interferon production by disrupting RIG-I-MAVS interactions [11].

K29-Linked Ubiquitination

The SKP1-Cullin-Fbx21 E3 complex mediates K29-linked ubiquitination of ASK1 (apoptosis signal-regulating kinase 1), promoting IFN-β and IL-6 production [11]. This modification represents a signaling function for K29-linked chains beyond their known roles in proteasomal targeting. Additionally, RNF34 coordinates the formation of mixed K27/K29-linked chains on MAVS, inducing its autophagy-mediated degradation and subsequent restriction of type I interferon responses [11].

K33-Linked Ubiquitination

K33-linked ubiquitin chains represent one of the less characterized atypical linkages, with emerging roles in immune regulation. USP38 removes K33-linked chains from TBK1, preventing its degradation and thereby enhancing IRF3 activation and antiviral responses [11]. Conversely, RNF2 catalyzes K33-linked ubiquitination of STAT1, suppressing interferon-stimulated gene (ISG) transcription and creating a negative feedback loop [11]. A recent study identified HECTD3 as another E3 ligase capable of mediating K33-linked ubiquitination of PKR, disrupting its dimerization and phosphorylation and consequently accelerating RNA virus replication while promoting inflammatory responses [16].

The Scientist's Toolkit: Essential Research Reagents and Methodologies

Table 3: Essential Research Reagents for Studying Atypical Ubiquitin Chains

Reagent Category	Specific Examples	Research Application	Key Features
Linkage-Specific Antibodies	Anti-linear ubiquitin (DU134-21)	Detection of endogenous linear chains	Recognizes M1-linked linear ubiquitin chains specifically
Ubiquitin Mutants	Ub-K27-only, Ub-K27R, Ub-K0	Determining linkage specificity	Lysine-to-arginine mutations to isolate specific chain types
E3 Expression Constructs	WT and catalytically inactive E3 mutants (e.g., C823A for HECTD3)	Functional characterization	Distinguishes enzymatic vs. scaffolding functions
CRISPR/Cas9 Tools	E3-specific gRNAs, KO cell lines	Loss-of-function studies	Validates physiological relevance
Mass Spectrometry	diGly antibody, Tandem Mass Tag	Proteome-wide ubiquitination site mapping	Identifies novel substrates and linkage types
Reporter Assays	NF-κB-luc, ISRE-luc	Functional signaling output measurement	Quantifies pathway activation

Visualization of Atypical Ubiquitin Chain Signaling Networks

Figure 2: Integrated Network of Atypical Ubiquitin Chain Signaling in Antiviral Immunity. Multiple E3 ligases build atypical chains on viral sensing pathway components, creating a complex regulatory network that either activates or inhibits downstream interferon responses.

Concluding Perspectives and Future Directions

The study of E3 ligases that build atypical ubiquitin chains has revealed an extraordinary complexity in the regulation of antiviral innate immunity. Rather than operating in isolation, these enzymatic writers form intricate networks that fine-tune the magnitude, duration, and specificity of immune responses [11] [10]. The functional outcomes of atypical ubiquitination are highly context-dependent, influenced by specific E3-substrate pairs, chain topology, and cellular compartmentalization [11]. Future research directions should focus on elucidating the structural basis for linkage specificity among atypical chain-building E3s, developing more comprehensive tools for detecting and quantifying endogenous atypical chains, and understanding how heterotypic and branched ubiquitin chains incorporating atypical linkages contribute to immune regulation [11] [10]. From a therapeutic perspective, E3 ligases that build atypical chains represent promising targets for modulating antiviral immunity, with potential applications in antiviral drug development, vaccine adjuvants, and treatment of autoimmune and inflammatory diseases [15] [10]. As our understanding of the "atypical ubiquitin code" continues to expand, so too will opportunities for therapeutic intervention in infectious and immune-related diseases.

The post-translational modification of proteins by ubiquitin is a critical regulatory mechanism that controls nearly all aspects of eukaryotic cell biology, with particular significance for the antiviral innate immune response. The "ubiquitin code"—comprising monomeric ubiquitin or polyubiquitin chains of various linkages—creates a complex signaling system that is written by ubiquitin ligases, read by ubiquitin-binding domains, and erased by deubiquitinases (DUBs) [17]. While the roles of canonical K48- and K63-linked ubiquitin chains are well-established, atypical ubiquitin chains (linked via K6, K11, K27, K29, K33, and M1) have emerged as crucial regulators of immune signaling pathways [3] [17]. These atypical chains create a sophisticated regulatory network that fine-tunes the host response to viral infection, and their editing by DUBs represents a critical control point in maintaining immune homeostasis.

Within the context of antiviral immunity, the dynamic equilibrium between ubiquitination and deubiquitination precisely controls the activation and resolution of immune signaling. Pathogen recognition receptors (PRRs) including RIG-I-like receptors (RLRs), Toll-like receptors (TLRs), and DNA sensors initiate signaling cascades that converge on key adaptor proteins such as MAVS and STING, ultimately activating transcription factors (NF-κB and IRF3/7) that induce type I interferons and proinflammatory cytokines [18] [3]. Throughout these pathways, atypical ubiquitin chains perform distinct regulatory functions—from mediating protein-protein interactions to targeting substrates for proteasomal degradation—while specialized DUBs act as cellular erasers that remove these modifications to attenuate or redirect signaling outcomes [3] [19].

Atypical Ubiquitin Chains: Types and Functions in Immune Signaling

Atypical ubiquitin chains encompass all polyubiquitin linkages except for the canonical K48 and K63 connections [20] [3]. These chains are classified based on their linkage topology: homotypic chains (using the same lysine residue sequentially), mixed-linkage chains (utilizing several distinct lysines), and heterologous chains (incorporating ubiquitin-like modifiers) [20]. The following table summarizes the key characteristics and immune functions of the major atypical ubiquitin chains.

Table 1: Atypical Ubiquitin Chains in Antiviral Immune Signaling

Chain Type	Primary Functions in Immunity	Key E3 Ligases	Regulatory Outcomes
M1/Linear	NF-κB activation via NEMO binding; Inhibition of type I IFN signaling	LUBAC	Potentiates NF-κB signaling; Disrupts MAVS signalosome [3]
K11	Regulation of STING and IRF3 stability; Proteasomal targeting	RNF26	Prevents STING degradation; Limits IRF3 via autophagy [3]
K27	Platform for signalosome assembly; Balance of activation/inhibition	TRIM23	NEMO ubiquitination for RLR signaling; Recruitment of regulatory proteins like A20 [3]
K29	Proteasomal degradation; mRNA stability regulation	-	Associated with Beclin-1 degradation; HuR regulation [21]
K33	Inhibition of TBK1 activation; Post-Golgi trafficking	-	Prevents TBK1 autophosphorylation; Coronin-7 regulation [19] [21]

The structural diversity of atypical chains creates distinct three-dimensional conformations that are specifically recognized by dedicated ubiquitin-binding domains (UBDs) within signaling proteins. For instance, the UBAN domain of NEMO exhibits a strong binding preference for linear/M1-linked chains, which is essential for NF-κB activation [3]. This linkage-specific recognition enables the ubiquitin code to transmit precise information within immune signaling pathways. The functional consequences of atypical chain modification are equally diverse, ranging from the creation of interaction platforms for signalosome assembly (K27-linked chains) to targeting immune regulators for proteasomal degradation (K11-linked chains) [3] [21].

DUB Families and Their Linkage Specificities

Deubiquitinases constitute a large family of approximately 100 proteases in humans that hydrolyze the isopeptide bond between ubiquitin and substrate proteins or between ubiquitin molecules within chains [18] [19]. DUBs are classified into seven subfamilies based on their catalytic mechanisms and structural features: ubiquitin-specific proteases (USPs), ovarian tumor proteases (OTUs), ubiquitin carboxyl-terminal hydrolases (UCHs), Josephins (MJD), MIU-containing new DUB family (MIUDY), zinc-finger ubiquitin protease 1 (ZUB/ZUFSP), and JAB1/MPN/MOV34 metalloenzymes (JAMMs) [18] [22]. The JAMM family members are metalloproteases, while all other DUB families are cysteine proteases [19].

These enzymes exhibit varying degrees of linkage specificity toward atypical ubiquitin chains, which determines their biological functions in editing ubiquitin codes. The subcellular localization of DUBs—from the nucleolus (USP36, USP39) to the plasma membrane (USP6, JOSD1) and microtubules (USP21, CYLD)—further defines their substrate accessibility and functional roles [18]. The following table summarizes the key DUBs that target atypical ubiquitin chains in the context of antiviral signaling.

Table 2: DUBs Regulating Atypical Ubiquitin Chains in Antiviral Immunity

DUB	DUB Family	Target Chains	Immune Function	Mechanism
USP19	USP	K11	Negative regulator of type I IFN	Removes K11 chains from Beclin-1, stabilizing it to inhibit RIG-I/MAVS interaction [3]
USP38	USP	K33	Homeostasis of antiviral response	Cleaves K33 chains from TBK1, enabling subsequent K48 ubiquitination and degradation [19]
OTUB1/OTUB2	OTU	K48/K63 (context-dependent)	Regulation of TRAF3/6	Deubiquitinate TRAF3 and TRAF6 to modulate downstream signaling [23]
A20 (TNFAIP3)	OTU	K11, K63, M1	Negative feedback regulator	Removes K63/M1 chains from signaling proteins; also has E3 ligase activity [3]
CYLD	USP	K11, K63, M1	Negative regulator of multiple pathways	Deubiquitinates key signaling molecules including RIG-I, TBK1, and NEMO [18] [19]

The regulation of DUB activity itself occurs through multiple mechanisms, including autoinhibition, post-translational modifications, subcellular localization, and interaction with regulatory proteins [22]. For instance, the interaction between USP1 and UAF1 (USP1-associated factor 1) activates USP1's DUB activity toward K48-linked ubiquitin chains on TBK1, demonstrating how accessory proteins can modulate DUB function in immune signaling [19]. This complex regulatory landscape ensures precise spatiotemporal control of DUB activity to maintain appropriate immune responses without triggering excessive inflammation.

Experimental Approaches for Studying DUB-Atypical Chain Interactions

Methodologies for Assessing DUB Activity and Specificity

Investigating the functions of DUBs that edit atypical ubiquitin chains requires a multifaceted experimental approach combining biochemical, cellular, and genetic techniques. The following diagram illustrates a generalized workflow for characterizing DUB functions against atypical ubiquitin chains:

Diagram 1: Experimental workflow for characterizing DUB functions against atypical ubiquitin chains

In vitro DUB activity assays form the foundation for establishing linkage specificity. These assays typically employ linkage-defined ubiquitin chains (commercially available or recombinantly expressed) incubated with purified DUBs, followed by gel electrophoresis or mass spectrometry to analyze cleavage products [17]. For example, to test specificity against K11-linked chains, researchers can use di- or tetra-ubiquitin substrates exclusively linked through K11, quantifying cleavage efficiency compared to other linkage types. Activity-based probes (ABPs) containing ubiquitin with C-terminal electrophilic traps can covalently label active DUBs and are particularly valuable for profiling DUB activities in cell lysates and identifying preferred substrates [23].

Cellular validation typically involves manipulating DUB expression (overexpression or siRNA/shRNA knockdown) in immune-relevant cell lines such as HEK293T, THP-1, or primary macrophages, followed by stimulation with viral mimics like poly(I:C) (dsRNA), poly(dA:dT) (dsDNA), or specific viruses (Sendai virus, VSV) [23]. Critical readouts include ubiquitin status of immune signaling proteins assessed by immunoprecipitation and immunoblotting with linkage-specific antibodies, which are now commercially available for several atypical chains (K11, K27, K29, M1) [3] [17]. For instance, to study USP19's regulation of Beclin-1, researchers can monitor K11-linked ubiquitination of Beclin-1 following USP19 knockdown, using a K11-linkage specific antibody [3].

Functional immune assays determine the biological consequences of DUB-mediated editing of atypical chains. Dual-luciferase reporter assays for IFN-β and ISRE (interferon-sensitive response element) promoters quantify downstream signaling activity [23]. For example, in studies of USP47, overexpression suppressed SeV-induced IFN-β promoter activation in a dose-dependent manner, while USP47 knockdown enhanced it [23]. Quantitative PCR measurement of endogenous IFNB1 mRNA and cytokine genes (CXCL10, CCL5), along with phosphorylation status of key kinases (TBK1, IKKε) and transcription factors (IRF3, NF-κB), provide additional validation of DUB-mediated immune regulation [19] [23].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Studying DUBs and Atypical Ubiquitin Chains

Reagent Category	Specific Examples	Applications & Functions
Linkage-Specific Antibodies	Anti-K11, Anti-K27, Anti-K29, Anti-M1 ubiquitin	Detection of specific ubiquitin chain types in western blot, immunofluorescence, and immunoprecipitation [17]
Activity-Based Probes	HA-Ub-VS, HA-Ub-Br2, Linkage-specific ABPs	Profiling active DUBs in complex mixtures; identifying DUB substrates [23]
Defined Ubiquitin Chains	K11-diUb, K27-diUb, K29-diUb, M1-diUb	In vitro DUB activity assays; structural studies of DUB-chain interactions [17]
DUB Modulators	ML323 (USP1-UAF1 inhibitor), P22077 (USP7/47 inhibitor)	Chemical tools to perturb specific DUB activities in cells [19] [23]
Viral Stimuli	Sendai virus, Poly(I:C), Poly(dA:dT)	Activation of specific PRR pathways (RLR, TLR, DNA sensing) [23]
Reporter Systems	IFN-β-luc, ISRE-luc, NF-κB-luc	Quantification of signaling pathway activation downstream of ubiquitination events [23]

DUB Regulation of Antiviral Signaling Through Atypical Chains

The intricate relationship between DUBs and atypical ubiquitin chains is exemplified in several key antiviral signaling pathways. The following diagram illustrates how DUBs regulate innate immune signaling through editing of atypical ubiquitin chains:

Diagram 2: DUB regulation of antiviral signaling through atypical ubiquitin chains

In the RIG-I/MAVS pathway, K27-linked ubiquitination of NEMO by TRIM23 promotes the activation of both NF-κB and IRF3 signaling branches [3]. The DUB A20 negatively regulates this pathway through its ability to remove K63-linked and possibly K27-linked chains from key signaling components, creating a negative feedback loop that prevents excessive inflammation [3]. Simultaneously, K11-linked ubiquitination regulates the stability of multiple immune factors. For instance, RNF26-mediated K11-linked chains on STING prevent its degradation, thereby potentiating signaling, while K11 chains on Beclin-1 promote its degradation and enhance type I IFN production [3]. The DUB USP19 counteracts the latter by removing K11 chains from Beclin-1, stabilizing it to inhibit the RIG-I/MAVS interaction and limit IFN production [3].

In the TBK1 activation pathway, K33-linked ubiquitination plays an inhibitory role by preventing TBK1 autophosphorylation and activation [19]. The DUB USP38 cleaves K33-linked chains from TBK1, but surprisingly promotes subsequent K48-linked ubiquitination and degradation of TBK1 in an NLRP4-dependent manner [19]. This dual function allows USP38 to maintain immune homeostasis by preventing excessive TBK1 activation while ensuring its timely degradation after signal initiation. Additionally, USP2b and A20/TAX1BP1 deconjugate K63-linked chains from TBK1 to terminate its activation, demonstrating how multiple DUBs with different linkage specificities can converge on the same signaling component [19].

The STING DNA sensing pathway is similarly regulated by DUBs targeting atypical chains. While K63-linked ubiquitination of STING is well-established for its activation, K27-linked chains have also been implicated in its regulation [3]. Furthermore, USP47 has been identified as a negative regulator that targets TRAF3 and TRAF6, removing K63-linked chains to attenuate signaling downstream of MAVS and upstream of TBK1 [23]. This places USP47 as a strategic brake on both RNA and DNA sensing pathways that converge on TBK1.

Therapeutic Targeting and Future Perspectives

The critical regulatory functions of DUBs in antiviral immunity make them attractive therapeutic targets for infectious diseases, inflammatory disorders, and cancer. Several viruses have evolved to encode viral DUBs (vDUBs) or hijack cellular DUBs to suppress immune responses and promote viral replication [18] [19]. For instance, the SARS coronavirus Papain-Like Protease (PLpro) removes K63-linked ubiquitin from TRAF3 and TRAF6 to inhibit type I IFN production, while the SARS-CoV-2 M protein promotes K48-linked ubiquitination and degradation of TBK1 [19]. Understanding how viral proteins manipulate DUB activities provides insights for developing antiviral therapies that block these immune evasion strategies.

The development of selective DUB inhibitors has become an increasingly active area of research, with several compounds in preclinical development [22]. For example, ML323 is a specific inhibitor of the USP1-UAF1 complex that enhances K48-linked ubiquitination of TBK1 and reduces IFN production, potentially useful for curbing excessive inflammation [19]. P22077 and PR-619 inhibit USP7 and USP47, affecting viral entry and virion infectivity [23]. However, achieving specificity remains challenging due to structural conservation among DUB catalytic domains, particularly within subfamilies.

Future research directions should focus on elucidating the regulatory hierarchies between different ubiquitin modifications, particularly how atypical chains are integrated with canonical chains and other post-translational modifications to create hybrid signals. The development of more sophisticated tools, including branch-specific antibodies, improved mass spectrometry methods for analyzing complex ubiquitin architectures, and conditional DUB knockout models, will advance our understanding of this complex regulatory network [3] [17]. Additionally, structural studies of DUBs bound to atypical chains will provide insights for designing next-generation therapeutics with enhanced specificity and efficacy.

As our knowledge of DUBs and atypical ubiquitin chains expands, so does the appreciation of their therapeutic potential. Targeting specific DUB-chain interactions offers the possibility of precise immune modulation without globally suppressing ubiquitin signaling, representing a promising frontier for treating viral infections, inflammatory diseases, and immune-related disorders.

The innate immune system serves as the host's first line of defense against pathogenic invasion, relying on a sophisticated network of pattern recognition receptors (PRRs) that detect conserved microbial structures known as pathogen-associated molecular patterns (PAMPs). Among these PRRs, the RIG-I-like receptors (RLRs), Toll-like receptors (TLRs), and the cGAS-STING pathway represent three critical sentinel systems that coordinate initial immune responses to viral and bacterial challenges. These pathways activate downstream signaling cascades that converge on key transcription factors including NFκB and IRF3/7, ultimately inducing the production of type I interferons (IFN) and proinflammatory cytokines that establish an antiviral state and orchestrate adaptive immunity [11] [24].

The therapeutic significance of these pathways has gained considerable attention in recent years, particularly with the emergence of immunotherapies for cancer and autoimmune diseases. The innate immune pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells [25]. Agonists targeting these pathways have demonstrated profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies, though clinical success remains limited [25]. Understanding the fundamental mechanisms governing RLR, TLR, and cGAS-STING signaling therefore represents a critical frontier in immunology with far-reaching therapeutic implications.

Pathway Architectures and Signaling Mechanisms

RIG-I-Like Receptor (RLR) Pathway

The RLR family comprises cytosolic RNA sensors including RIG-I (retinoic acid-inducible gene I) and MDA5 (melanoma differentiation-associated protein 5) that recognize viral RNA patterns. RIG-I specifically detects short double-stranded RNA (dsRNA) and 5'-triphosphate RNA, while MDA5 senses long dsRNA structures. Upon ligand engagement, both receptors undergo conformational changes that facilitate interaction with the mitochondrial antiviral-signaling protein MAVS (also known as IPS-1, VISA, or Cardif) [11] [24]. This interaction triggers MAVS oligomerization on mitochondrial membranes, forming prion-like aggregates that serve as signaling platforms.

The MAVS signalosome then recruits and activates TRAF family members, leading to the activation of two kinase complexes: the IKK complex (IκB kinase) and TBK1/IKKε. These kinases phosphorylate IRF3/7 and NFκB, respectively, promoting their nuclear translocation and initiating transcription of interferon-stimulated genes (ISGs) and proinflammatory cytokines [11]. The RLR pathway is particularly crucial for controlling RNA virus infections such as influenza, hepatitis C, and SARS-CoV-2.

Toll-Like Receptor (TLR) Pathway

Toll-like receptors represent a diverse family of transmembrane receptors that survey both extracellular and endosomal compartments for microbial products. While TLR3 recognizes double-stranded RNA, TLR7/8 detect single-stranded RNA, and TLR9 responds to CpG DNA motifs. TLR signaling originates from specialized membrane compartments where ligand binding induces receptor dimerization and recruitment of adaptor proteins, primarily MYD88 (myeloid differentiation primary response 88) or TRIF (TIR-domain-containing adapter-inducing interferon-β) [24].

The MYD88-dependent pathway recruits IRAK family kinases (IRAK1, IRAK4) and TRAF6, ultimately activating TAK1 (TGF-β-activated kinase 1) and the IKK complex, leading to NFκB-mediated inflammatory cytokine production. Alternatively, the TRIF-dependent pathway activates both NFκB and TBK1-IRF3 axes, inducing type I interferon responses. TLRs bridge extracellular pathogen recognition with intracellular signaling cascades, making them essential for early host defense against diverse pathogens [24].

cGAS-STING Pathway

The cyclic GMP-AMP synthase-stimulator of interferon genes pathway represents a major DNA sensing mechanism in the cytosol. cGAS detects double-stranded DNA regardless of sequence through positively charged surface regions, undergoing conformational changes that activate its catalytic function [26] [27]. Upon DNA binding, cGAS synthesizes the second messenger 2'3'-cGAMP from ATP and GTP, which functions as a high-affinity ligand for STING (stimulator of interferon genes).

STING, an endoplasmic reticulum transmembrane protein, undergoes profound conformational changes upon cGAMP binding, leading to oligomerization and translocation from the ER to the Golgi apparatus. During this trafficking, STING recruits and activates TBK1, which phosphorylates IRF3, leading to type I interferon production [26]. Simultaneously, STING activates the IKK complex and NFκB, inducing proinflammatory cytokine expression. Beyond its role in antiviral immunity, the cGAS-STING pathway has gained prominence in cancer biology, autoimmunity, and cellular senescence, highlighting its broad physiological significance [26] [27].

Table 1: Core Components of Innate Immune Signaling Pathways

Pathway	Sensors	Adaptors	Key Kinases	Transcription Factors	Primary Output
RLR	RIG-I, MDA5	MAVS	TBK1, IKKε, IKK complex	IRF3/7, NFκB	Type I IFN, Proinflammatory cytokines
TLR	TLR3, TLR7/8, TLR9	MYD88, TRIF	IRAK1/4, TBK1, IKK complex	IRF3/7, NFκB	Type I IFN, Proinflammatory cytokines
cGAS-STING	cGAS	STING	TBK1, IKK complex	IRF3, NFκB	Type I IFN, Proinflammatory cytokines

The Regulatory Framework of Atypical Ubiquitin Chains

Ubiquitination has emerged as a central regulatory mechanism controlling the activation, duration, and termination of innate immune signaling pathways. This post-translational modification involves the covalent attachment of ubiquitin molecules to target proteins through a sequential enzymatic cascade involving E1 (activating), E2 (conjugating), and E3 (ligating) enzymes. While K48-linked and K63-linked polyubiquitin chains have been extensively characterized for their roles in proteasomal degradation and signal activation respectively, recent research has illuminated the critical functions of atypical ubiquitin chains in fine-tuning immune responses [11] [24] [28].

Atypical ubiquitin linkages include K6-, K11-, K27-, K29-, and K33-linked chains, as well as linear/M1-linked chains, each conferring distinct structural topologies and functional outcomes. The linear ubiquitin chain assembly complex (LUBAC), composed of HOIP, HOIL-1L, and SHARPIN, uniquely catalyzes the formation of M1-linked linear chains that play crucial roles in NFκB activation [11]. These atypical chains create a complex "ubiquitin code" that extends the regulatory capacity of innate immune signaling beyond what can be achieved through canonical ubiquitination alone.

Table 2: Functions of Atypical Ubiquitin Chains in Innate Immune Regulation

Ubiquitin Linkage	Regulatory Enzyme	Target Protein	Functional Outcome	Pathway Affected
Linear/M1	LUBAC	NEMO	Potentiates NFκB activation	TLR, RLR, cytokine signaling
K11	RNF26	STING	Inhibits STING degradation, enhancing IFN response	cGAS-STING
K27	TRIM23	NEMO	Leads to NFκB and IRF3 activation	RLR
K27	TRIM40	RIG-I, MDA5	Induces degradation, inhibiting IFN response	RLR
K27	RNF185	cGAS	Induces IRF3 activation and cytokine production	cGAS-STING
K29	SKP1-Cullin-Fbx21	ASK1	Induces IFNβ and IL-6 production	Multiple pathways
K33	USP38	TBK1	Prevents TBK1 degradation, enhances IRF3 activation	Multiple pathways

Regulatory Mechanisms in RLR Signaling

The RLR pathway is particularly subject to intricate regulation by atypical ubiquitination. K63-linked ubiquitination of RIG-I by TRIM25 is well-established as essential for its activation and interaction with MAVS [24]. However, emerging evidence reveals that K27-linked ubiquitination plays dual roles in RLR signaling. TRIM40 catalyzes K27-linked ubiquitination of both RIG-I and MDA5, promoting their proteasomal degradation and thus functioning as a negative regulator to prevent excessive signaling [11]. Conversely, TRIM21 mediates K27-linked ubiquitination of MAVS, enhancing type I interferon production and establishing a balancing mechanism for pathway modulation [11].

The linear ubiquitination machinery also intersects with RLR signaling through its action on NEMO (NFκB essential modulator), a component of the IKK complex. The UBAN domain of NEMO exhibits strong binding preference for linear chains, and this interaction is required for proper NFκB activation in response to RLR engagement [11]. Furthermore, LUBAC-mediated linear ubiquitination of NEMO disrupts the MAVS-TRAF3 interaction, thereby preferentially promoting NFκB activation while inhibiting IRF3 signaling and creating a signaling bias toward inflammatory cytokine production over interferon response [11].

Regulatory Mechanisms in cGAS-STING Signaling

The cGAS-STING pathway is regulated by multiple atypical ubiquitin linkages at various levels of its signaling cascade. K27-linked ubiquitination of STING by AMFR facilitates TBK1 recruitment and IRF3 activation, thereby promoting interferon production [11]. Additionally, RNF185 mediates K27-linked ubiquitination of cGAS, enhancing its ability to activate IRF3 and produce type I IFNs and proinflammatory cytokines [11]. These positive regulatory mechanisms ensure robust immune activation upon DNA detection.

Conversely, several negative feedback mechanisms employ atypical ubiquitination to constrain cGAS-STING signaling. K11-linked ubiquitination of STING by RNF26 inhibits its degradation, creating a more complex regulatory paradigm than simple degradation signals [11]. Furthermore, K48-linked ubiquitination of STING by RNF5, TRIM29, and TRIM30α targets it for proteasomal degradation, representing a canonical degradation signal that limits pathway duration and prevents excessive activation [26]. The balance between activating and inhibitory ubiquitination events ensures appropriate immune responses while minimizing potential damage from uncontrolled inflammation.

Experimental Approaches and Methodologies

Investigating Ubiquitination in Innate Immunity

The study of atypical ubiquitination in immune signaling requires specialized methodologies that can distinguish between specific linkage types amid complex cellular environments. Key experimental approaches include:

Linkage-Specific Antibodies and Binding Domains: Development of monoclonal antibodies and engineered antigen-binding fragments (sABs) that recognize particular ubiquitin linkages has been instrumental. For instance, linkage-specific sABs against K29-linked ubiquitin have enabled researchers to identify novel substrates and characterize the role of this linkage type in RNA processing and stress response pathways [28]. Similarly, antibodies specific for K63-linked and linear/M1-linked chains have facilitated the dissection of their distinct functions in NFκB activation.

Tandem Ubiquitin Binding Entities (TUBEs): These engineered protein constructs containing multiple ubiquitin-associated domains (UBA) exhibit high affinity for polyubiquitin chains and protect ubiquitinated proteins from deubiquitination and degradation during sample preparation. TUBEs coupled with mass spectrometry analysis enable comprehensive mapping of ubiquitination events under physiological conditions.

Mutagenesis Approaches: Systematic lysine-to-arginine mutations in ubiquitin and target proteins allow researchers to dissect the contribution of specific linkage types to signaling outcomes. For example, studies employing NEMO mutants unable to bind linear chains demonstrated the essential role of this interaction in NFκB activation [11].

Deubiquitinase (DUB) Profiling: Characterization of the specificity and function of DUBs that cleave atypical ubiquitin chains provides complementary insights into regulatory mechanisms. DUBs such as USP19, USP13, and USP21 have been implicated in removing specific ubiquitin linkages from innate signaling components [11].

Diagram 1: Ubiquitination Analysis Workflow

Functional Immune Signaling Assays

To evaluate the biological consequences of atypical ubiquitination in innate immunity, researchers employ a suite of functional assays:

Luciferase Reporter Assays: These experiments measure pathway activation by transfecting cells with plasmids containing interferon-stimulated response elements (ISRE) or NFκB response elements upstream of a luciferase gene. Upon pathway activation, transcription factors bind these elements and drive luciferase expression, providing a quantifiable readout of signaling strength.

Cytokine and Interferon Measurement: ELISA (enzyme-linked immunosorbent assay) and multiplex bead-based arrays (Luminex) enable precise quantification of type I interferons (IFN-α, IFN-β) and proinflammatory cytokines (TNF-α, IL-6) in cell culture supernatants or biological fluids following pathway stimulation.

Gene Silencing and Knockout Models: RNA interference (siRNA, shRNA) and CRISPR-Cas9 mediated gene editing allow functional characterization of specific E3 ligases, DUBs, and signaling components. For example, TRIM29 knockout cells demonstrate enhanced STING-TBK1-IRF3 signaling, revealing its role as a negative regulator [11].

Native Gel Electrophoresis and Size Exclusion Chromatography: These techniques analyze the oligomerization status of MAVS and STING, which serves as a key indicator of their activation state following pathogen detection.

Immunofluorescence and Confocal Microscopy: Visualization of subcellular localization and trafficking of signaling components (e.g., STING translocation from ER to Golgi) provides spatial information about pathway activation and regulation.

Diagram 2: Immune Signaling Functional Assays

Essential Research Tools and Reagents

Advancing our understanding of atypical ubiquitination in innate immunity relies on a growing toolkit of specialized reagents and methodologies. The table below summarizes key resources that enable researchers to dissect these complex regulatory mechanisms.

Table 3: Research Reagent Solutions for Studying Atypical Ubiquitination

Reagent Category	Specific Examples	Research Application	Key Features
Linkage-Specific Antibodies	Anti-K11, Anti-K27, Anti-linear ubiquitin	Detection and immunoprecipitation of specific chain types	High specificity; minimal cross-reactivity
Recombinant E3 Ligases	TRIM23, TRIM26, RNF26, RNF185	In vitro ubiquitination assays	Catalytically active forms; various tags
Deubiquitinase Inhibitors	USP-specific small molecules	Probe DUB function in signaling	Linkage-specific inhibitors emerging
Activity-Based Probes	Ubiquitin-vinyl sulfone, Ubiquitin-ABP	DUB profiling and identification	Covalently traps active DUBs
CRISPR Libraries	E3 ligase, DUB knockout collections	Functional genetic screens	Arrayed and pooled formats available
Ubiquitin Mutants	K-to-R, K-only mutants	Dissect chain type specificity	Definitive linkage assignment
Cytokine Assays	IFN-β ELISA, Multiplex cytokine panels	Measure pathway output	High sensitivity; quantitative
Reporter Cell Lines	ISRE-Luc, NFκB-Luc	High-throughput screening	Stable integration; minimal background

Therapeutic Implications and Future Perspectives

The intricate regulation of RLR, TLR, and cGAS-STING pathways by atypical ubiquitin chains presents compelling therapeutic opportunities for infectious diseases, cancer, and autoimmune disorders. Several strategic approaches are emerging:

Targeting E3 Ligases and DUBs: The specificity of E3 ligases and deubiquitinating enzymes for particular substrates and linkage types makes them attractive drug targets. Small molecule inhibitors of STING-targeting E3 ligases could potentially enhance antitumor immunity, while activators of RIG-I/MDA5-specific negative regulators might ameliorate autoimmune pathology.

Combination Therapies: Agonists of innate immune pathways are being evaluated in combination with immune checkpoint blockers, radiation, and chemotherapy to overcome resistance in "cold" tumors that lack T cell infiltration [25]. The paradoxical pro-tumor effects observed in some contexts of innate immune activation highlight the need for precise targeting strategies that consider tumor stage, pathway status, and specific cell types [25].

Precision Medicine Approaches: The heterogeneity in innate immune signaling across individuals, tumor types, and disease stages necessitates patient stratification strategies. Biomarkers that reflect pathway activity or ubiquitination status could guide selection of appropriate targeted therapies.

Nanoparticle Delivery: Challenges with the bioavailability and specificity of pathway modulators are being addressed through advanced formulation strategies. Nanoformulated cGAS-STING inhibitors show promise for inflammatory skin conditions, offering improved tissue targeting and reduced systemic exposure [26].

As research continues to unravel the complexity of atypical ubiquitination in immune regulation, several frontiers deserve particular attention: the development of more specific chemical probes for atypical chain formation and recognition; the integration of multi-omics data to map ubiquitination networks in physiological and pathological states; and the advancement of structural biology techniques to visualize dynamic ubiquitin assemblies in atomic detail. These efforts will undoubtedly expand our therapeutic arsenal and deepen our understanding of immune homeostasis.

The RLR, TLR, and cGAS-STING pathways constitute fundamental pillars of innate antiviral immunity, whose activation and resolution are precisely controlled through the sophisticated language of atypical ubiquitination. Beyond the well-characterized K48 and K63 linkages, diverse ubiquitin chain types including linear, K11, K27, K29, and K33 linkages collectively orchestrate immune responses by modulating signal strength, duration, and specificity. The evolving toolkit for studying these modifications—from linkage-specific reagents to genetic and pharmacological approaches—continues to reveal new regulatory mechanisms and therapeutic opportunities. As we deepen our understanding of how atypical ubiquitin chains shape immune signaling, we move closer to harnessing this knowledge for targeted interventions in infection, cancer, and inflammatory disease.

Tools and Techniques: Studying Atypical Ubiquitination and Its Functional Impact

The innate antiviral immune response is initiated upon detection of viral pathogens by host pattern recognition receptors (PRRs), leading to the production of type-I interferons and proinflammatory cytokines that establish an antiviral state in infected and surrounding cells [12]. This response is characterized by rapid gene expression of antiviral molecules and is triggered by major PRR classes including RIG-I-like receptors (RLRs) sensing viral RNA, Toll-like receptors (TLRs) detecting viral RNA or DNA in endolysosomes, and intracellular DNA sensors like cGAS [12]. Reversible post-translational modification by ubiquitin—a small 76-amino acid protein—has emerged as a crucial regulatory mechanism controlling the stability and signaling activity of PRRs and their downstream signaling molecules [12].

Ubiquitination involves a sequential enzymatic cascade employing E1 activating, E2 conjugating, and E3 ligase enzymes, with E3 ligases determining substrate specificity [12]. The human genome encodes more than 700 E3 ligases and approximately 100 deubiquitinating enzymes (DUBs) that fine-tune this process [12]. Perhaps most importantly, ubiquitin contains seven internal lysine residues (K6, K11, K27, K29, K33, K48, and K63) and an N-terminal methionine, each capable of forming structurally and functionally distinct polyubiquitin chains [12] [29]. While K48-linked chains typically target proteins for proteasomal degradation and K63-linked chains regulate signal transduction, the 'atypical' chain types (K6, K11, K27, K29, K33) and branched chains containing multiple linkage types play increasingly recognized roles in innate immune signaling, particularly in attenuating responses to prevent excessive inflammation [12] [29] [30].

This technical guide examines advanced methodologies for detecting these diverse ubiquitin chain types, with particular emphasis on their application in studying antiviral immune pathways and the potential for therapeutic intervention.

Linkage-Specific Antibodies

Development and Mechanism of Action

Linkage-specific ubiquitin antibodies represent a transformative advancement for interrogating the ubiquitin code in cellular signaling pathways. These immunological reagents are generated to specifically recognize unique epitopes presented by particular polyubiquitin linkage types, enabling direct detection of specific chain architectures in complex biological samples.

The foundational development of these reagents was demonstrated through antibodies targeting K63-linked and K48-linked polyubiquitin chains [30]. The molecular basis for specificity was elucidated through cocrystal structure analysis of an anti-K63 linkage Fab fragment bound to K63-linked diubiquitin, revealing how the antibody paratope recognizes the unique interface between ubiquitin monomers connected through K63 [30]. This structural insight confirmed that linkage-specific antibodies recognize conformational epitopes formed by the specific ubiquitin-ubiquitin connection rather than linear sequences.

Key Applications in Immune Signaling Research

These antibodies enabled the seminal discovery of "polyubiquitin editing" in innate immune signaling pathways. Research employing these reagents demonstrated that key signaling adaptors including RIP1 (essential for TNF-induced NF-κB activation) and IRAK1 (participating in IL-1β and Toll-like receptor signaling) undergo sequential modification with different ubiquitin chain types following pathway stimulation [30]. Both kinase adaptors initially acquire K63-linked polyubiquitin to promote signal transduction, while at later time points K48-linked polyubiquitin targets them for proteasomal degradation, providing an elegant mechanism for signal attenuation [30].

More recent applications have revealed the importance of ubiquitin chain editing in the RLR and cGAS-STING pathways central to antiviral immunity [12]. For instance, linkage-specific antibodies have helped demonstrate how K63-linked ubiquitination of RIG-I and mitochondrial antiviral signaling (MAVS) proteins facilitates the assembly of signaling complexes that activate IRF3 and NF-κB, while subsequent K48-linked ubiquitination terminates signaling to prevent excessive interferon production [12].

Table 1: Commercially Available Linkage-Specific Ubiquitin Antibodies

Specificity	Common Applications	Key Findings Enabled
K48-linkage	Protein degradation studies, proteasome substrates	Identification of proteins targeted for degradation in immune pathways
K63-linkage	Signal transduction complexes, kinase activation	Mapping NF-κB and interferon pathway activation mechanisms
K11-linkage	Cell cycle regulation, immune regulation	Role in mitotic arrest and inflammatory signaling
Linear/M1-linkage	NF-κB signaling, LUBAC substrates	Function in NEMO activation and immune receptor signaling
K6-linkage	DNA damage response, mitochondrial regulation	Connections between genome maintenance and immune signaling

Experimental Protocol: Immunoprecipitation and Immunoblotting with Linkage-Specific Antibodies

Materials Required:

• Linkage-specific ubiquitin antibodies (commercially available from various vendors)
• Cell lysis buffer (e.g., RIPA buffer supplemented with 10mM N-ethylmaleimide and protease inhibitors)
• Protein A/G agarose beads
• Standard immunoblotting equipment and reagents

Methodology:

• Cell Stimulation and Lysis: Stimulate cells with appropriate immune agonists (e.g., poly(I:C) for RLR pathway, cGAMP for STING pathway). Harvest cells and lyse in appropriate buffer containing N-ethylmaleimide to inhibit deubiquitinating enzymes and preserve ubiquitin conjugates.
• Immunoprecipitation: Pre-clear cell lysates by centrifugation. Incubate supernatant with linkage-specific antibody (typically 1-5 μg per 500 μg total protein) for 2-4 hours at 4°C with gentle rotation. Add protein A/G agarose beads and incubate for an additional 1-2 hours.
• Washing and Elution: Pellet beads and wash 3-5 times with ice-cold lysis buffer. Elute immunoprecipitated proteins by boiling in SDS-PAGE sample buffer.
• Immunoblotting: Separate proteins by SDS-PAGE and transfer to PVDF membrane. Probe with target protein-specific antibodies to detect ubiquitinated species.

Technical Considerations: Include appropriate controls using isotype-matched non-specific antibodies. Validate antibody specificity using cells expressing linkage-specific DUBs or ubiquitin mutants. Consider using pan-ubiquitin antibodies for total ubiquitination assessment alongside linkage-specific detection.

Tandem Ubiquitin Binding Entities (TUBEs)

Tandem Ubiquitin Binding Entities represent a novel class of engineered probes developed to overcome limitations of traditional ubiquitin detection methods. TUBEs consist of multiple ubiquitin-associated domains (UBA) connected in tandem, creating high-affinity ubiquitin-binding modules with dissociation constants in the nanomolar range [31]. These reagents can be generated as pan-specific binders recognizing all ubiquitin linkage types, or as linkage-selective entities with preference for particular chain architectures.

The molecular design of TUBEs exploits the natural affinity of UBA domains for ubiquitin, but connecting them in tandem creates avidity effects that dramatically increase binding strength compared to individual domains. This enhanced affinity allows TUBEs to protect polyubiquitin chains from deubiquitinating enzyme activity during cell lysis and processing, preserving the endogenous ubiquitination state that might otherwise be lost [31].

Implementation in High-Throughput Screening Assays

Chain-selective TUBEs have been successfully implemented in high-throughput screening formats to investigate context-dependent ubiquitination dynamics. A recent study demonstrated this application using RIPK2, a critical regulator of NOD2-mediated inflammatory signaling [31]. In this system, L18-MDP stimulation induced K63-linked ubiquitination of RIPK2, which was specifically captured by K63-TUBEs and pan-selective TUBEs but not by K48-TUBEs [31]. Conversely, a PROTAC targeting RIPK2 induced K48-linked ubiquitination that was captured by K48-TUBEs and pan-selective TUBEs but not K63-TUBEs [31].

This discriminatory capacity enables precise mapping of ubiquitin linkage patterns in response to different stimuli and provides a platform for screening compounds that modulate specific ubiquitination events. The technology is particularly valuable for characterizing PROTAC efficacy and mechanism of action, as it directly assesses the intended outcome—induction of K48-linked ubiquitination on target proteins [31].

Experimental Protocol: TUBE-Based Capture and Detection

Materials Required:

• Chain-specific TUBEs (commercially available or custom-produced)
• Streptavidin-coated magnetic beads (for biotinylated TUBEs)
• Lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, 10% glycerol with fresh DUB inhibitors)
• Detection antibodies for target proteins

Methodology:

• Cell Treatment and Lysis: Treat cells with experimental conditions (e.g., viral infection, immune stimuli, PROTACs). Lyse cells in appropriate buffer containing DUB inhibitors.
• TUBE Capture: Incubate cell lysates with chain-specific TUBEs (either directly immobilized or in solution followed by pull-down with appropriate beads). For 96-well plate format, coat plates with TUBEs overnight before adding lysates.
• Washing and Elution: Wash captured complexes thoroughly to remove non-specifically bound proteins. Elute bound proteins with SDS-PAGE sample buffer or specific elution buffers.
• Detection and Quantification: Detect ubiquitinated targets by immunoblotting with specific antibodies. For high-throughput applications, use immunoassay detection with fluorescent or chemiluminescent readouts.

Technical Considerations: Optimize TUBE concentration to balance signal intensity with specificity. Include control TUBEs with different linkage specificities to validate discriminatory capacity. For quantitative applications, generate standard curves using defined ubiquitinated proteins.

Table 2: Comparison of Linkage-Specific Detection Technologies

Method	Sensitivity	Throughput Potential	Linkage Discrimination	Key Applications
Linkage-Specific Antibodies	High (immunoassay amplification)	Moderate (Western) to High (ELISA)	Excellent for characterized linkages	Immunoblotting, immunohistochemistry, immunofluorescence
TUBEs	Very High (avidity effect)	High (96/384-well format)	Good with engineered variants	PROTAC screening, endogenous protein analysis, DUB studies
Mass Spectrometry	Moderate (enrichment required)	Low to Moderate	Comprehensive (all linkages)	Discovery proteomics, novel linkage identification
UbiCRest	High (enzymatic amplification)	Moderate (multiple parallel digestions)	Good with appropriate controls	Linkage validation, chain architecture analysis

Mass Spectrometry-Based Approaches

Methodological Advancements in Ubiquitin Proteomics

Mass spectrometry has emerged as a powerful tool for comprehensive ubiquitinome profiling, offering the unique advantage of unbiased identification of ubiquitination sites and linkage types without prior knowledge of specific targets. Traditional approaches rely on tryptic digestion of proteins, which for ubiquitin produces a characteristic di-glycine remnant on modified lysines that serves as a signature for ubiquitination sites.

Recent methodological advancements have significantly enhanced our ability to decipher complex ubiquitin chain architectures. Middle-down ubiquitin chain enrichment mass spectrometry (UbiChEM-MS) combines limited proteolysis with high-resolution mass spectrometry to directly visualize branched ubiquitin points within chains [29]. This approach applies minimal trypsinolysis to cleave C-terminal di-glycine residues in ubiquitin chains, generating products (Ub1-74, GG-Ub1-74, and 2xGG-Ub1-74) that represent end-capped mono-ubiquitin, non-branched ubiquitin, and branched ubiquitin, respectively [29].

Proteomic studies employing UbiChEM-MS have revealed surprising abundance of branched ubiquitin chains in eukaryotic cells. For instance, during mitotic arrest, approximately 3-4% of the total ubiquitin population consists of K11/K48 branched chains [29]. Furthermore, this technology has identified enriched K6/K48 branched ubiquitin chains produced by the Parkin E3 ligase, illustrating the utility of this approach for characterizing the output of specific E3 enzymes [29].

UbiCRest Assay for Linkage Determination

The Ubiquitin Chain Restriction (UbiCRest) assay represents a complementary biochemical approach for ubiquitin linkage determination that employs a panel of linkage-selective deubiquitinases (DUBs) to decipher chain composition [29]. This method involves incubating ubiquitinated proteins or affinity-captured ubiquitin chains with specific DUBs that cleave particular linkage types, followed by analysis of the cleavage products by immunoblotting.

The UbiCRest assay utilizes a carefully selected collection of commercially available DUBs with defined linkage preferences [29]:

• OTUB1: Preferentially cleaves K48-linked chains
• OTUD1/AMSH: Favor K63-linked chains
• OTULIN: Specific for linear/M1-linked chains
• OTUD2: Cleaves K11, K27, K29, and K33 linkages
• Cezanne: Selective for K11 linkages
• TRABID: Prefers K29, K33, and K63 linkages
• vOTU/USP21: Broad-specificity DUBs used as controls

By comparing the digestion patterns across multiple parallel reactions with different DUBs, researchers can infer the linkage composition of unknown ubiquitin chains. This approach was instrumental in confirming the composition of K6/K48 polyubiquitination produced by bacterial E3 ligase NleL [29].

Experimental Protocol: UbiChEM-MS for Branched Chain Detection

Materials Required:

• Ubiquitin affinity enrichment reagents (TUBEs or ubiquitin antibodies)
• Trypsin or other proteases for limited proteolysis
• High-resolution mass spectrometer with electron transfer dissociation capability
• Specialized software for ubiquitin peptide analysis

Methodology:

• Ubiquitin Enrichment: Isulate ubiquitinated proteins from cell lysates using TUBEs or immunoaffinity purification.
• Limited Proteolysis: Digest enriched ubiquitin conjugates with minimal trypsin to generate Ub1-74 fragments while preserving chain connectivity.
• MS Analysis: Analyze peptides by LC-MS/MS with electron transfer dissociation to preserve labile modifications.
• Data Analysis: Identify branched chains by detecting 2xGG-Ub1-74 species and mapping modification sites through fragmentation patterns.

Technical Considerations: Use ubiquitin mutants (e.g., R54A) to improve detection of specific branched chains by preserving diagnostic peptides during analysis [29]. Combine with linkage-specific antibodies for targeted analysis of particular chain types. Include appropriate controls using cells expressing defined ubiquitin mutants.

Visualizing Ubiquitin Detection Workflows

Ubiquitin Detection Method Selection Workflow

Research Reagent Solutions

Table 3: Essential Research Reagents for Ubiquitin Detection

Reagent Category	Specific Examples	Function and Application
Linkage-Specific Antibodies	Anti-K48 ubiquitin, Anti-K63 ubiquitin, Anti-linear ubiquitin	Immunodetection of specific chain types in Western blot, immunofluorescence, IHC
Engineered Binding Proteins	K63-TUBE, K48-TUBE, Pan-TUBE	High-affinity capture of ubiquitinated proteins; protection from DUBs
Activity-Based Probes	Ubiquitin vinyl sulfone, HA-Ub-VS, Biotin-Ub-PA	DUB profiling and activity monitoring in cell lysates
Ubiquitin Mutants	K48R, K63R, K48-only, K63-only	Linkage specificity controls; defining E3 ligase and DUB preferences
Deubiquitinase Panels	OTUB1 (K48-specific), OTUD1 (K63-specific), OTULIN (M1-specific)	UbiCRest analysis for linkage determination; chain editing studies
Mass Spectrometry Standards	Heavy isotope-labeled ubiquitin, Di-Gly remnant peptides	Quantitative ubiquitinomics; absolute quantification of ubiquitination
Proteasome Inhibitors	MG132, Bortezomib, Carfilzomib	Stabilization of proteasomal substrates for degradation studies
DUB Inhibitors	PR-619, G5, NSC632839	Preservation of ubiquitination states during sample preparation

The advanced detection methodologies reviewed in this technical guide—linkage-specific antibodies, TUBE-based affinity capture, and sophisticated mass spectrometry approaches—provide researchers with powerful tools to decipher the complex ubiquitin code in antiviral immune signaling. Each technology offers complementary advantages: antibodies provide exceptional specificity for characterized linkages, TUBEs enable high-throughput analysis of endogenous proteins, and mass spectrometry offers unbiased discovery potential for novel ubiquitination events.

As these technologies continue to evolve, particularly with improvements in sensitivity, throughput, and capacity to detect mixed and branched chains, they will undoubtedly yield new insights into how ubiquitination regulates innate immunity. Furthermore, these tools are already accelerating drug discovery efforts focused on ubiquitin pathway modulation, including PROTAC development and DUB inhibitor screening. The ongoing refinement of these detection platforms will continue to illuminate the intricate role of atypical ubiquitin chains in antiviral defense and inflammatory regulation, potentially revealing new therapeutic opportunities for autoimmune diseases, chronic inflammation, and antiviral interventions.

Protein ubiquitination, a pivotal post-translational modification, extends far beyond its initial characterization as a signal for proteasomal degradation. The covalent attachment of ubiquitin to substrate proteins can generate diverse polyubiquitin chains through distinct internal lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminal methionine (M1). Among these, K48-linked chains are the canonical "kiss of death" for proteasomal degradation, while K63-linked and atypical chains (K6, K11, K27, K29, K33, M1) predominantly regulate non-proteolytic signaling pathways [32] [1]. The specific topology of a ubiquitin chain—its length and linkage type—forms a complex "ubiquitin code" that dictates functional outcomes, including protein activity, complex assembly, subcellular localization, and trafficking [20] [32].

Within the context of antiviral innate immunity, the precise decoding of this ubiquitin code is fundamental to mounting an effective host response. Cytosolic pattern recognition receptors (PRRs), such as RIG-I-like receptors (RLRs) and cGAS, initiate signaling cascades upon viral detection, converging on transcription factors like NF-κB and IRF3/7 to induce type I interferons (IFNs) and pro-inflammatory cytokines [12] [3]. This rapid response is tightly regulated by ubiquitination, where atypical ubiquitin chains play critical and nuanced roles in both activating and inhibiting signaling pathways to ensure a balanced immune outcome that combats infection without causing excessive inflammation [3].

Atypical Ubiquitin Chain Linkages: Functions and Roles in Immune Signaling

The following table summarizes the key characteristics and immune-related functions of the various atypical ubiquitin chain linkages.

Table 1: Atypical Ubiquitin Chain Linkages: Functions and Roles in Immune Signaling

Linkage Type	Primary Functions	Role in Antiviral Innate Immunity	Key Enzymes (E3 Ligases / DUBs)
M1/Linear	Scaffold for signaling complexes, NF-κB activation [3] [1].	Potentiates NF-κB signaling; can disrupt MAVS signalosome to inhibit Type I IFN response [3].	LUBAC (HOIP/HOIL-1) [3].
K6	Mitophagy, DNA damage response, protein stabilization [1].	Enhances IRF3 binding to IFN gene promoters to boost antiviral immunity [1].	HUWE1, Parkin; OTUD1 (DUB) [1].
K11	Cell cycle regulation, proteasomal degradation (often with K48) [3] [1].	RNF26 uses K11 chains to stabilize STING; also implicated in autophagy-mediated regulation of IFN response [3].	RNF26, APC/C with UBE2S [3] [1].
K27	Signaling platform, balancing immune activation [3].	TRIM23 conjugates K27 chains to NEMO for RLR signaling; also serves as a platform for negative regulators [3].	TRIM23 [3].
K29	Lysosomal degradation, kinase regulation [32] [1].	Associated with proteasomal degradation of innate immune factors; specific antiviral roles under investigation.	HUWE1 [1].
K33	Kinase regulation, intracellular trafficking [32].	Role in innate immunity is less defined; implicated in T-cell receptor signaling and AMPK-related kinase regulation [32].	Not specified in search results.

Experimental Workflows for Analyzing Ubiquitin Chain Topology

Determining the topology and functional consequences of ubiquitin chains requires an integrated experimental approach. The following diagram outlines a core workflow, from sample preparation to functional validation, which will be detailed in the subsequent sections.

Sample Preparation and Ubiquitin Enrichment

The initial phase focuses on preserving the native ubiquitination state and enriching for ubiquitinated proteins.

• Cell Stimulation and Lysis: Cells (e.g., HEK293T, HeLa, or primary immune cells) are stimulated with innate immune agonists, such as synthetic viral RNA (e.g., poly(I:C)), or infected with viruses (e.g., Sendai virus, VSV) to activate antiviral signaling pathways. Subsequent lysis must be performed under fully denaturing conditions (e.g., using 1% SDS or 8 M Urea) to inactivate endogenous deubiquitinases (DUBs) and proteases that would otherwise rapidly erase the ubiquitination landscape [33].
• Enrichment of Ubiquitinated Proteins: Immunoprecipitation (IP) is the cornerstone method for enrichment.
  • Target-Specific IP: An antibody against the protein of interest (e.g., RIG-I, STING, NEMO) is used to pull it down from the denatured lysate. The resulting immunoprecipitate is then analyzed by Western blot (WB) with anti-ubiquitin antibodies to determine if the target is ubiquitinated [33].
  • Ubiquitin-Specific IP: For ubiquitinome-wide analyses, antibodies specific for the ubiquitin remnant motif (diGly-Lysine or K-ε-GG) left after tryptic digestion are used to enrich for ubiquitinated peptides prior to mass spectrometry analysis [34]. This is a critical step for system-wide studies.

Detecting and Mapping Ubiquitin Chain Topology

Once enriched, the specific linkage type of the ubiquitin chain must be identified.

• Western Blotting with Linkage-Specific Antibodies: The most accessible method involves using linkage-specific ubiquitin antibodies (e.g., anti-K63, anti-K48, anti-K11, anti-linear). After target-specific IP, Western blot analysis with these antibodies can indicate the presence of specific chain types on the protein. A characteristic "ladder" of bands with molecular weights increasing in ~8 kDa increments suggests polyubiquitination [33]. While powerful, this method can be confirmed by more precise techniques.
• Mass Spectrometry (Ubiquitinome Analysis): MS provides unparalleled precision for mapping ubiquitination sites and determining chain linkage.
  • Site Identification: Tryptic digestion of enriched proteins generates peptides with a diGly-Lysine (K-ε-GG) remnant at the site of ubiquitination. This signature is detected by MS, allowing for the precise identification of the modified lysine residue on the substrate protein [34] [33].
  • Linkage Determination: Advanced MS methods, particularly using 4D-label-free quantification (4D-LFQ) as employed in a study on maize antiviral response, can quantify changes in ubiquitination at specific sites and on specific proteins in response to stimuli like viral infection [34]. To determine which lysine within ubiquitin itself is used for chain linkage, specific MS techniques or the use of ubiquitin mutants (where all lysines except one are mutated to arginine) are required [20].

Analyzing Functional Consequences in Immune Signaling

Establishing the functional outcome of a specific ubiquitination event is crucial for decoding its biological role.

• Reporter Gene Assays: To assess the impact on antiviral signaling pathways, cells are co-transfected with a ubiquitin mutant (e.g., K63-only, where all lysines except K63 are mutated to arginine), a plasmid expressing the immune protein of interest, and reporter plasmids for the IFN-β promoter or an ISRE (Interferon-Stimulated Response Element). Luciferase activity measurements directly reveal how a specific chain type regulates pathway activation [3].
• Genetic Manipulation: The function of specific E3 ligases and DUBs is tested by knocking down (siRNA/shRNA) or knocking out (CRISPR-Cas9) the enzyme and assessing the effect on viral replication and immune signaling. Conversely, overexpression of wild-type or catalytically dead E3/DUB mutants can pinpoint their necessity and sufficiency. For example, silencing ZmGOX1 in maize was shown to facilitate viral infection, demonstrating its antiviral role [34].
• Quantitative PCR (qPCR) and ELISA: Downstream functional outputs are measured by quantifying the mRNA levels of IFN and interferon-stimulated genes (ISGs) via RT-qPCR, or by measuring the secretion of cytokines like IFN-β and TNF-α using ELISA [12] [34].

A Case Study: K27-Linked Ubiquitination in RLR Signaling

The following diagram illustrates a specific example of how an atypical chain (K27) regulates antiviral signaling, integrating the components and processes.

Experimental Validation of the Pathway:

• Immunoprecipitation: IP NEMO from virally infected cells and perform a Western blot with anti-K27-linkage specific ubiquitin antibody to confirm its modification [3] [33].
• Genetic Knockdown: Use siRNA against TRIM23. This should abolish K27-ubiquitination of NEMO and impair NF-κB activation upon viral sensing, as measured by a reporter assay [3].
• Functional Assay: Measure cytokine output (e.g., by ELISA) in control and TRIM23-deficient cells to confirm the physiological consequence of this signaling axis [3].

The Scientist's Toolkit: Key Reagents and Assay Solutions

Table 2: Essential Research Reagents for Ubiquitin Assay Development

Reagent / Assay	Function / Utility	Example Application in Antiviral Research
Linkage-Specific Ub Antibodies	Detect specific chain topologies via WB/IF after IP [33].	Determine if RIG-I or STING is modified with K63-linked chains upon activation.
K-ε-GG (diGly) Antibody	Enrich ubiquitinated peptides for mass spectrometry-based ubiquitinome analysis [34].	Identify novel ubiquitination sites on host proteins during viral infection.
Ubiquitin Mutants (K-only)	Express ubiquitin where only one lysine is functional, forcing formation of a specific chain type [20].	Test if K11-linked ubiquitination by RNF26 is sufficient for STING stabilization [3].
Proteasome Inhibitors (e.g., MG132)	Block proteasomal degradation, allowing accumulation of ubiquitinated proteins [32] [35].	Enhance detection of K48-ubiquitinated species; study non-degradative functions of other chains.
DUB Inhibitors	Chemically inhibit deubiquitinases to stabilize ubiquitination events in cells [35].	Probe the role of specific DUBs (e.g., OTUD1 for K6 chains [1]) in turning off immune signals.
Reporter Assays (IFN-β, ISRE, NF-κB)	Quantify the activation of specific innate immune signaling pathways [12].	Measure the functional outcome of manipulating a specific E3 ligase or DUB on antiviral gene expression.
Recombinant E2/E3 Enzymes	Reconstitute ubiquitination reactions in vitro to study biochemistry of chain formation [20].	Determine if a specific E2/E3 pair (e.g., MMS2-UBC13 for K63 chains [20]) has linkage specificity.

The strategic application of the biochemical and cellular assays detailed in this guide—from ubiquitin enrichment and linkage-specific detection to functional genetic and reporter assays—is essential for deciphering the complex role of atypical ubiquitin chains. As the field moves forward, integrating these methods with advanced tools like chemoproteomics and targeted protein degradation will further illuminate the "ubiquitin code" in antiviral immunity. This deeper understanding is poised to reveal novel therapeutic nodes, paving the way for innovative drug development targeting E3 ligases and DUBs in infectious diseases, cancer, and inflammatory disorders [35].

The innate immune system must achieve a precise balance: it must mount a robust defense against viral pathogens while avoiding excessive signaling that can lead to autoimmune pathology. Post-translational modification by ubiquitin, particularly through atypical chains, has emerged as a critical regulatory mechanism. This case study examines how the E3 ubiquitin ligase RNF167 orchestrates the degradation of cytosolic viral RNA sensors RIG-I and MDA5 through two distinct atypical ubiquitin linkages—K6 and K11—directing them to different proteolytic fates. This dual-pathway mechanism represents an sophisticated regulatory strategy for controlling the amplitude and duration of type I interferon responses, providing insights into the cross-talk between cellular degradation systems and expanding our understanding of the ubiquitin code in antiviral immunity.

Ubiquitination is a versatile post-translational modification that regulates numerous cellular processes, including innate immune signaling. The conjugation of ubiquitin to substrate proteins occurs through a sequential enzymatic cascade involving E1 activating, E2 conjugating, and E3 ligase enzymes. Ubiquitin contains seven lysine residues (K6, K11, K27, K29, K33, K48, K63) and an N-terminal methionine, all of which can serve as linkage sites for polyubiquitin chain formation [12] [36].

While K48-linked chains typically target proteins for proteasomal degradation and K63-linked chains function in non-proteolytic signaling, the roles of the remaining "atypical" ubiquitin chains (K6, K11, K27, K29, K33) have been less characterized until recently [20] [37]. Mass spectrometry-based proteomic studies have revealed that these atypical linkages are surprisingly abundant in cells, with K11-linked chains constituting approximately 28.0% of all polyubiquitin linkages, followed by K6-linked chains at 10.9% [38]. This discovery prompted investigation into their physiological functions, particularly in the precise regulation of antiviral signaling pathways.

The RIG-I-like receptors (RLRs), including RIG-I and MDA5, are crucial cytosolic sensors that recognize viral RNA and initiate signaling cascades that culminate in type I interferon production. The activation of these sensors must be tightly regulated to prevent excessive inflammation and autoimmune pathogenesis [8] [3]. Emerging evidence indicates that atypical ubiquitin chains play essential roles in this regulatory process, with RNF167 representing a key mediator that utilizes both K6 and K11 linkages to control RLR stability and activity.

RNF167: Identification and Role in Antiviral Immunity

Discovery as a Negative Regulator of RLR Signaling

RNF167 was initially identified as a negative regulator of type I interferon signaling through a genome-wide CRISPR/Cas9 screen [8]. Subsequent validation experiments confirmed that RNF167 expression is induced by viral infection and interferon stimulation, classifying it as an interferon-stimulated gene (ISG). This induction pattern suggested that RNF167 functions in a negative feedback loop to constrain interferon responses [8].

Functional studies demonstrated that ectopic expression of RNF167 significantly suppressed Sendai virus (SeV)-triggered activation of IFN-β, PRDI-III, and NF-κB reporters in HEK293 cells. Conversely, RNF167 knockdown reinforced promoter activities, confirming its role as a negative regulator of RLR signaling [8]. The biological significance of this regulation was evident in RNF167-deficient models, where viral infection triggered enhanced expression of antiviral genes (IFNB1, CXCL10, IFIT1) and proinflammatory genes (CXCL1, IL-6), resulting in constrained viral replication [8].

Structural Features and Known Functions

RNF167 is a transmembrane protein belonging to the PA-TM-RING family of E3 ubiquitin ligases, which characteristically contain a protease-associated (PA) domain, transmembrane (TM) domain, and RING-H2 finger domain [8]. Prior to its identification in immune regulation, RNF167 had been implicated in various cellular processes, including:

• Regulation of neurotransmission and endosomal trafficking [8]
• Control of lysosome positioning [8]
• Modulation of mTORC1 signaling in tumorigenesis through K29-linked ubiquitination and degradation of CASTOR1 [39]
• Suppression of TNF-α signaling via Tollip ubiquitination [8]

These diverse functions highlight the versatility of RNF167 as an E3 ligase and its capacity to utilize different ubiquitin linkages for distinct physiological outcomes.

Molecular Mechanisms of RNF167-Mediated RLR Regulation

Dual Ubiquitination of RIG-I and MDA5

RNF167 mediates the atypical ubiquitination of both RIG-I and MDA5 through two distinct linkage types targeted to specific protein domains:

• K6-linked polyubiquitination: Occurs within the caspase activation and recruitment domains (CARDs) of RIG-I and MDA5 [8] [40]
• K11-linked polyubiquitination: Takes place in the C-terminal domains (CTDs) of these viral RNA sensors [8] [40]

This domain-specific ubiquitination represents a sophisticated mechanism for ensuring precise regulation of RLR function, as different domains mediate distinct aspects of RLR signaling.

Direction to Dual Degradation Pathways

The specific ubiquitin linkages determine the destination of ubiquitinated RLRs through two parallel proteolytic systems:

• K6-linked chains: Recognized by the autophagy cargo adaptor p62/SQSTM1, which delivers the modified RLRs to autolysosomes for selective autophagic degradation [8] [40]
• K11-linked chains: Lead to proteasome-dependent degradation of RLRs through the ubiquitin-proteasome system (UPS) [8] [40]

This dual-pathway approach enables the cell to employ both major degradation systems simultaneously for more efficient clearance of activated RLRs, potentially providing redundancy and robustness to the regulatory mechanism.

Table 1: RNF167-Mediated Ubiquitination and Degradation Pathways

RLR Sensor	Ubiquitin Linkage	Modification Domain	Degradation Pathway	Recognition Factor
RIG-I	K6-linked	CARD domains	Autophagy-lysosome pathway	p62/SQSTM1
RIG-I	K11-linked	CTD domain	Proteasome system	Proteasome receptors
MDA5	K6-linked	CARD domains	Autophagy-lysosome pathway	p62/SQSTM1
MDA5	K11-linked	CTD domain	Proteasome system	Proteasome receptors

Structural Basis for Linkage Specificity

The mechanism by which RNF167 achieves linkage specificity remains an active area of investigation. Generally, the specificity of ubiquitin chain formation is determined by combinations of E2 enzymes and E2-E3 complexes [20] [41]. Some E2s exhibit inherent specificity for particular lysine residues, while E3 ligases can further constrain or redirect this specificity. For RNF167, the particular E2 partners that facilitate K6 versus K11 linkage formation have not been fully elucidated, representing a knowledge gap in our understanding of this pathway.

Experimental Approaches and Methodologies

Identification of RNF167 in IFN Signaling

The initial discovery of RNF167 as a regulator of interferon signaling employed a genome-wide CRISPR/Cas9 screen followed by rigorous validation:

• CRISPR/Cas9 Screening: A library of guide RNAs targeting the entire genome was used to generate knockout cells, which were screened for enhanced or suppressed IFN-β promoter activity after viral stimulation [8].
• Expression Analysis: THP-1 cells and primary bone-marrow derived macrophages (BMDMs) were treated with various immune stimuli (poly(I:C), SeV, EMCV, HSV-1, IFN-β) and RNF167 expression was monitored over time by immunoblotting [8].
• Luciferase Reporter Assays: HEK293 cells were transfected with RNF167 expression constructs or siRNA, followed by stimulation with SeV and measurement of IFN-β, PRDI-III, and NF-κB promoter activities [8].

Mapping Ubiquitination Sites and Linkages

To characterize the specific ubiquitination events catalyzed by RNF167, researchers employed several biochemical techniques:

• In Vivo Ubiquitination Assays: Cells were co-transfected with RIG-I/MDA5 constructs, RNF167, and ubiquitin plasmids. After immunoprecipitation of the sensors, ubiquitination was detected by immunoblotting with ubiquitin-specific antibodies [8].
• Linkage-Specific Ubiquitin Mutants: Ubiquitin mutants with single lysine residues (K6R, K11R, etc.) were used to determine which lysines were essential for RNF167-mediated ubiquitination [8].
• Domain Mapping: Truncation mutants of RIG-I and MDA5 lacking specific domains were tested for ubiquitination to identify modification sites [8].

Degradation Pathway Analysis

The specific degradation routes for ubiquitinated RLRs were delineated using:

• Pathway-Specific Inhibitors: Cells were treated with proteasome inhibitors (MG132, PS341) or autophagy inhibitors (bafilomycin A1, chloroquine) before assessing RLR stability [8] [38].
• Co-immunoprecipitation Studies: Interactions between ubiquitinated RLRs and adaptor proteins (p62) or proteasome components were examined [8].
• Pulse-Chase Experiments: Protein synthesis inhibitors were used in combination with degradation pathway inhibitors to monitor RLR half-lives under different conditions [8].

Table 2: Key Experimental Approaches for Studying RNF167 Function

Methodology	Application	Key Findings
Genome-wide CRISPR/Cas9 screening	Identification of novel IFN regulators	RNF167 identified as negative regulator of IFN signaling
Immunoblotting with linkage-specific antibodies	Detection of atypical ubiquitin chains	Confirmed K6 and K11 linkages on RIG-I/MDA5
Pathway-specific pharmacological inhibition	Determining degradation routes	K11-linked chains mediate proteasomal degradation; K6-linked chains mediate autophagic degradation
Immunofluorescence and confocal microscopy	Subcellular localization of ubiquitinated proteins	Colocalization of K6-ubiquitinated RLRs with autophagic markers
Quantitative mass spectrometry	Global ubiquitin linkage profiling	K11 linkages are abundant (28.0%) in ubiquitin pools [38]

Visualization of RNF167-Mediated Signaling and Degradation Pathways

Diagram 1: RNF167 in antiviral signaling regulation. This diagram illustrates the negative feedback loop where viral infection triggers type I interferon production, which induces RNF167 expression. RNF167 then mediates dual ubiquitination of RLRs, leading to their degradation via two distinct pathways and subsequent signal termination.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Studying RNF167 and Atypical Ubiquitination

Reagent/Category	Specific Examples	Research Application	Function in Experimental Design
Cell Lines	THP-1 monocytes, HEK293, BMDMs	Functional validation studies	Provide cellular context for studying RLR signaling and degradation pathways
Genetic Tools	CRISPR/Cas9 KO systems, siRNA/shRNA	Loss-of-function studies	Enable targeted disruption of RNF167 to assess functional consequences
Ubiquitin Mutants	K6R, K11R ubiquitin mutants	Linkage specificity determination	Identify essential lysine residues for RNF167-mediated ubiquitination
Pathway Inhibitors	MG132 (proteasome), Bafilomycin A1 (autophagy)	Degradation route mapping	Determine contribution of specific proteolytic pathways to RLR turnover
Antibodies	Linkage-specific ubiquitin antibodies	Detection of atypical chains	Enable specific identification of K6 and K11 linkages in ubiquitination assays
Viral Stimuli	Sendai virus (SeV), Vesicular Stomatitis Virus (VSV)	Pathway activation	Activate RLR signaling to study RNF167 function in immune responses

Discussion and Research Implications

Physiological Significance of Dual Degradation Pathways

The utilization of both major cellular degradation systems by RNF167 represents an elegant strategy for ensuring robust control of RLR signaling. This dual-pathway approach offers several potential advantages:

• Amplified Degradation Capacity: Engaging both systems simultaneously may enable more efficient clearance of activated RLRs, particularly important during high viral loads.
• Regulatory Redundancy: If one pathway is compromised, the other can still mediate RLR degradation, providing fail-safe regulation.
• Spatiotemporal Control: The autophagy-lysosome and ubiquitin-proteasome systems may be optimized for degrading RLRs at different cellular locations or activation states.

This mechanism exemplifies how cells leverage cross-talk between different quality control pathways to achieve precise regulation of immune signaling [8].

Atypical Ubiquitin Chains as Specialized Signals

The discovery that RNF167 utilizes K6 and K11 linkages expands our understanding of the functional repertoire of atypical ubiquitin chains. While K48-linked chains remain the canonical degradation signal, these findings demonstrate that multiple ubiquitin linkages can direct substrates to degradation machinery, albeit through different mechanisms. The specificity achieved through chain linkage and modification site allows for precise control over protein fate, supporting the concept of a sophisticated "ubiquitin code" that extends beyond simple degradative signaling [20] [41] [3].

Therapeutic Implications and Future Directions

Understanding RNF167-mediated regulation of RLRs opens several potential therapeutic avenues:

• Autoimmune Diseases: Enhanced RNF167 activity or expression might help constrain excessive interferon signaling in autoimmune conditions like systemic lupus erythematosus.
• Antiviral Therapeutics: Modulating RNF167 function could potentially boost antiviral responses in chronic viral infections.
• Cancer Immunotherapy: As RNF167 also regulates mTOR signaling through CASTOR1 degradation [39], its manipulation might synergize with immune checkpoint inhibitors.

Future research should focus on identifying the specific E2 partners for RNF167, structural characterization of the ubiquitination complexes, and developing specific modulators of RNF167 activity for therapeutic applications.

RNF167 represents a key regulatory node in antiviral immunity that utilizes atypical K6 and K11 ubiquitin linkages to direct RIG-I and MDA5 sensors to distinct degradation pathways. This dual-pathway mechanism enables robust control of interferon responses and illustrates the sophistication of the ubiquitin code in immune regulation. The study of RNF167 not only advances our fundamental understanding of innate immune homeostasis but also reveals potential therapeutic targets for manipulating immune responses in infection, autoimmunity, and cancer. As research on atypical ubiquitin chains continues to evolve, additional complexities and specialized functions of these non-canonical signals will undoubtedly emerge, further expanding our appreciation of ubiquitin's regulatory versatility in cellular physiology.

The recent discovery that USP53 and USP54 are active deubiquitinases (DUBs) with remarkable specificity for K63-linked polyubiquitin chains represents a paradigm shift in our understanding of both the ubiquitin-specific protease family and the regulatory mechanisms governing atypical ubiquitin chains. Previously annotated as catalytically inactive pseudoenzymes, these phylogenetically distant USP family members have now been established as key editors of the ubiquitin code with distinct mechanistic approaches to K63-chain processing. This case study examines the biochemical characterization, structural mechanisms, and functional implications of these enzymes, with particular attention to their potential roles in regulating immune signaling pathways. The findings, which directly link loss of USP53 activity to pediatric cholestasis pathology, provide not only a revised annotation of these proteins but also novel mechanistic frameworks for investigating K63-linked polyubiquitin decoding in cellular regulation and disease pathogenesis.

The ubiquitin system represents one of the most sophisticated post-translational regulatory mechanisms in eukaryotic cells, governing protein stability, localization, activity, and interactions through the covalent attachment of the small protein ubiquitin. The complexity of this system arises from the capacity to form diverse polyubiquitin chains through different linkage types between ubiquitin monomers. While K48-linked chains typically target substrates for proteasomal degradation and K63-linked chains mediate non-degradative signaling, the "atypical" ubiquitin linkages (K6, K11, K27, K29, K33) and M1-linear chains have emerged as critical regulators in specialized cellular processes, particularly in innate immune signaling [11] [42].

The antiviral innate immune response depends on precise ubiquitin-mediated regulation of pattern recognition receptors (PRRs) and their downstream signaling adapters. Intracellular sensors including RIG-I-like receptors (RLRs) and DNA sensors like cGAS initiate signaling cascades that converge on transcription factors NF-κB and IRF3/7, inducing type I interferons and proinflammatory cytokines [11] [12]. K63-linked polyubiquitination plays especially important roles in these pathways, facilitating protein-protein interactions and complex assembly rather than promoting degradation. For instance, K63-linked ubiquitination of LGP2 by the E3 ligase Riplet fine-tunes RIG-I-dependent antiviral responses through delayed feedback regulation [43]. The discovery of dedicated K63-linkage-directed deubiquitinases therefore represents a crucial advance in understanding how these signaling events are precisely controlled.

Rediscovery and Characterization of USP53 and USP54 as Active DUBs

Revision of Catalytic Inactivity

USP53 and USP54 had been consistently annotated as catalytically inactive pseudoenzymes within the ubiquitin-specific protease family due to their lack of strongly conserved residues before their catalytic histidines, failed reactivity with ubiquitin probes, and inability to hydrolyze monoubiquitin substrates in earlier studies [44]. This classification was reconsidered when researchers observed prominent enrichment of USP54 in activity-based profiling using propargylamide (PA)-based ubiquitin probes, suggesting previously undetected catalytic capability [44] [45].

Follow-up investigations using bacterially expressed and purified catalytic domains demonstrated that both USP53 and USP54 exhibit specific reactivity with ubiquitin-PA probes in a catalytic cysteine-dependent manner [44]. Functional validation through fluorogenic ubiquitin-RhoG cleavage assays confirmed concentration-dependent hydrolase activity toward ubiquitin but not other ubiquitin-like proteins (SUMO1, SUMO2, ISG15, or NEDD8), establishing both proteins as bona fide deubiquitinating enzymes [44].

Unusual Linkage Specificity

In a remarkable departure from typical USP family characteristics, where members generally display poor linkage discrimination or only moderate selectivity, both USP53 and USP54 exhibited striking specificity for K63-linked polyubiquitin chains when assayed against a comprehensive tetraubiquitin panel [44] [45]. As summarized in Table 1, USP54 demonstrated absolute specificity for K63 linkages, while USP53 showed minimal activity toward K11-linked and K48-linked chains only after extended incubation periods.

Table 1: Linkage Specificity Profiles of USP53 and USP54

Ubiquitin Linkage	USP53 Activity	USP54 Activity
K63-linked	High	High
K48-linked	Minimal (late)	None
K11-linked	Minimal (late)	None
K6-linked	None	None
K27-linked	None	None
K29-linked	None	None
K33-linked	None	None
M1-linear	None	None

This unprecedented linkage specificity within the USP family prompted further investigation into the structural and mechanistic basis for K63 recognition [44].

Mechanistic Insights into K63-Linked Polyubiquitin Decoding

Distinct Cleavage Mechanisms

A key distinction emerged between the catalytic mechanisms employed by USP53 and USP54 despite their shared linkage specificity:

• USP54 cleaves within K63-linked chains, progressively shortening them while accumulating diubiquitin as a stable end product [44]
• USP53 performs en bloc deubiquitination, removing entire K63-linked polyubiquitin chains from substrate proteins in a single coordinated activity [44] [45]

This mechanistic difference suggests divergent biological functions, with USP54 potentially modulating chain length-dependent signaling and USP53 potentially reversing ubiquitin-dependent protein relocalization or complex assembly.

Structural Basis for K63 Specificity

Biochemical and structural analyses, including a crystal structure of USP54 in complex with K63-linked diubiquitin (PDB ID: 8C61), revealed the presence of cryptic S2 ubiquitin-binding sites within the catalytic domains of both enzymes that underlie their K63 specificity [44] [46]. These secondary binding sites accommodate the distinctive topology of K63-linked chains and facilitate efficient cleavage of longer polyubiquitin structures.

Fluorescently-labeled K63-linked triubiquitin cleavage assays demonstrated that both enzymes preferentially generate non-fluorescent diubiquitin and fluorescent ubiquitin-TAMRA, confirming the S2 binding site model and explaining the observed length dependence of their activity [44]. The structural insights provide a molecular framework for understanding how these enzymes achieve unprecedented linkage specificity within the USP family.

Experimental Approaches and Methodologies

Key Experimental Protocols

The characterization of USP53 and USP54 employed multiple complementary biochemical approaches:

Activity-Based Protein Profiling

• Utilized propargylamide (PA)-based ubiquitin probes with C-terminal warheads forming vinyl thioether adducts with catalytic cysteines
• Enabled enrichment and detection of active DUBs from complex mixtures
• Critical for initial discovery of USP54 reactivity [44]

Linkage Specificity Assays

• Employed comprehensive tetraubiquitin panels encompassing all possible linkage types
• Time-resolved cleavage monitoring to distinguish primary from secondary activities
• Revealed exceptional K63 specificity for both enzymes [44]

Fluorescent Substrate Cleavage Assays

• Used ubiquitin-RhoG and specialized fluorescent triubiquitin constructs
• Enabled real-time kinetic measurements and cleavage site mapping
• Distinguished en bloc (USP53) from internal (USP54) cleavage mechanisms [44]

Structural Studies

• X-ray crystallography of USP54 in complex with K63-linked diubiquitin-PA (2.50 Å resolution)
• Identified S2 ubiquitin-binding sites and K63-specific recognition elements [46]

Experimental Workflow for USP53/USP54 Characterization

Essential Research Reagents

Table 2: Key Reagents for Studying K63-Linkage-Directed Deubiquitination

Reagent Category	Specific Examples	Applications and Functions
Activity-Based Probes	Ubiquitin-PA (propargylamide)	Covalent labeling of active DUBs; identification and enrichment
Linkage-Specific Substrates	K63-linked tetraubiquitin; K63-linked triubiquitin-TAMRA	linkage specificity profiling; cleavage mechanism analysis
Fluorogenic Reporters	Ubiquitin-RhoG (Rhodamine G)	Real-time kinetic measurements of hydrolase activity
Structural Tools	K63-linked diubiquitin-PA co-crystals; Catalytic cysteine mutants	X-ray crystallography; mechanistic studies
Disease Modeling Reagents	USP53 patient mutants (R99S, G31S, C303Y, H132Y)	Pathogenicity assessment; structure-function analysis

Connection to Human Disease and Therapeutic Implications

USP53 Mutations in Pediatric Cholestasis

The catalytic activity of USP53 has direct pathological significance, as biallelic mutations in its USP domain cause progressive familial intrahepatic cholestasis, a hereditary liver disorder in children [44] [47] [45]. A comprehensive analysis of documented missense mutations revealed clustering within the catalytic domain, prompting functional characterization of disease-associated variants.

As summarized in Table 3, mutations such as R99S, G31S, C303Y, and H132Y result in complete or severe loss of catalytic activity toward K63-linked ubiquitin chains while preserving protein folding and ubiquitin binding capability [44]. These findings directly implicate loss of DUB activity rather than structural defects in USP53-mediated pathology, suggesting that impaired K63-linked deubiquitination of specific cellular substrates underlies disease pathogenesis.

Table 3: Functional Impact of Disease-Associated USP53 Mutations

Mutation	Catalytic Activity	Protein Folding	Ubiquitin Binding	Disease Association
R99S	Abolished	Normal	Reduced but present	Progressive familial intrahepatic cholestasis
G31S	Severely impaired	Normal	Reduced but present	Progressive familial intrahepatic cholestasis
C303Y	Severely impaired	Normal	Reduced but present	Progressive familial intrahepatic cholestasis
H132Y	Severely impaired	Normal	Reduced but present	Progressive familial intrahepatic cholestasis

Cellular Substrates and Pathological Mechanisms

Proteomic analyses identified tricellular junction components, including tricellulin and LSR, as cellular substrates for USP53-mediated deubiquitination [45]. Depletion of USP53 increased K63-linked ubiquitination of these proteins, providing a mechanistic link to cholestasis pathology given that mutations in tricellular junction proteins produce similar clinical presentations. This suggests that USP53 maintains junctional integrity by removing K63-linked ubiquitin chains from structural components, with failure of this regulation leading to barrier dysfunction and liver pathology.

Implications for Antiviral Immune Response Regulation

While direct evidence connecting USP53 and USP54 to antiviral signaling remains to be fully elucidated, their specificity for K63-linked chains positions them as potential regulators of innate immunity. Multiple signaling pathways in the antiviral response employ K63-linked ubiquitination as a regulatory mechanism:

RIG-I-Like Receptor Signaling

K63-linked ubiquitination plays well-established roles in RLR pathway activation. Riplet-mediated K63-linked ubiquitination of LGP2 creates a delayed negative feedback mechanism that fine-tunes RIG-I-dependent responses [43]. The discovery of dedicated K63-directed DUBs suggests complementary regulatory mechanisms for reversing these modifications at appropriate signaling thresholds.

cGAS-STING Pathway Regulation

K63-linked and K27-linked ubiquitination of STING regulates its trafficking and activity, with several USP family members (USP13, USP18, USP21) already implicated in modulating this pathway [11]. The specificity of USP53 and USP54 for K63 linkages suggests potential roles in limiting excessive innate immune activation through similar mechanisms.

Potential Regulatory Role of USP53/USP54 in Antiviral Signaling

Speculative Model for Immune Regulation

Based on their enzymatic properties, USP53 and USP54 may contribute to immune homeostasis through several potential mechanisms:

• Signal Termination: En bloc removal of K63 chains from activated signaling complexes (potentially by USP53)
• Signal Modulation: Gradual shortening of K63 chains to adjust signal intensity (potentially by USP54)
• Spatiotemporal Control: Localized deubiquitination to restrict signal propagation
• Cross-regulation: Competition with other linkage-specific DUBs and E3 ligases

The delayed ubiquitination of LGP2 described by Kouwaki et al. [43] represents precisely the type of temporally regulated signaling event that could require dedicated K63-directed deubiquitination for proper resolution.

The reclassification of USP53 and USP54 as active, K63-linkage-directed deubiquitinases substantially expands our understanding of both the USP family and the regulatory complexity of the ubiquitin code. Their unique enzymatic properties—including unprecedented linkage specificity within the USP family and distinct cleavage mechanisms—establish a new class of deubiquitinase activity with broad implications for cellular regulation and disease pathogenesis.

Key outstanding questions and future research directions include:

• Immune Function Elucidation: Direct experimental evidence connecting USP53 and USP54 to specific antiviral signaling pathways
• Substrate Identification: Comprehensive profiling of physiological substrates beyond junctional proteins
• Structural Studies: High-resolution structures of USP53 with K63-linked ubiquitin complexes
• Therapeutic Development: Exploration of USP53 as a therapeutic target for cholestatic liver diseases
• Systematic Analysis: Investigation of potential redundancy or cooperation between USP53 and USP54

The integration of these enzymes into the broader landscape of ubiquitin-mediated immune regulation will enhance our understanding of innate immunity and identify potential therapeutic targets for immune disorders and viral pathologies.

The ubiquitin system, a crucial post-translational modification pathway, has emerged as a master regulator of antiviral innate immunity. While the roles of canonical K48- and K63-linked ubiquitin chains are well-established, recent research has unveiled the profound significance of atypical ubiquitination in immune signaling. Atypical ubiquitin chains—including K6-, K11-, K27-, K29-, K33-, and M1-linked (linear) linkages—represent a complex ubiquitin code that finely tunes the antiviral response [3]. Unlike K48-linked chains that primarily target proteins for proteasomal degradation, atypical chains function as versatile signaling scaffolds that modulate protein-protein interactions, subcellular localization, and activity of immune signaling components without necessarily triggering degradation [12] [3]. The intricate regulation of these ubiquitin linkages offers unprecedented opportunities for therapeutic intervention in infectious diseases, inflammatory disorders, and cancer.

Within the context of antiviral immunity, pattern recognition receptors (PRRs) including RIG-I-like receptors (RLRs), Toll-like receptors (TLRs), and DNA sensors initiate signaling cascades that converge on transcription factors IRF3/7 and NF-κB, driving the production of type I interferons (IFNs) and proinflammatory cytokines [48]. This antiviral signaling architecture is precisely regulated by ubiquitination, with atypical chains playing particularly important roles in balancing immune activation and resolution to ensure effective pathogen clearance while preventing excessive inflammation [8] [3]. This whitepaper examines the current landscape of atypical ubiquitination research, with a specific focus on its implications for targeted therapeutic design in antiviral applications.

The Landscape of Atypical Ubiquitin Chains in Antiviral Signaling

Diversity and Functions of Atypical Linkages

The human proteome contains seven lysine residues in ubiquitin (K6, K11, K27, K29, K33, K48, K63) plus an N-terminal methionine (M1) that can form polyubiquitin chains, creating remarkable diversity in chain architecture and function [48]. The following table summarizes the key characteristics and immune functions of the less-studied atypical chains:

Table 1: Atypical Ubiquitin Chains in Antiviral Immune Regulation

Ubiquitin Linkage	Known Immune Functions	Key E3 Ligases	Associated DUBs	Therapeutic Potential
K6-linked	Selective autophagic degradation of RIG-I/MDA5; proteostasis under stress	RNF167, BRCA1-BARD1	Unknown	Targeting viral immune evasion; autophagy modulation
K11-linked	Proteasomal degradation of innate immune factors; STING stabilization; cell cycle regulation	RNF167, RNF26, APC/C	USP19, OTUB1	Regulation of immune signaling amplitude
K27-linked	Platform for signalosome assembly; NEMO activation; balancing IFN vs. NF-κB	TRIM23, HOIP	A20, USP16	Fine-tuning immune activation thresholds
K29-linked	Proteasomal and non-proteasomal functions; Wnt signaling regulation	HUWE1, TRAF7	USP19, OTUD1	Less characterized; potential in composite chain targeting
K33-linked	Regulation of kinase activity; T-cell receptor signaling	Unknown	Unknown	Emerging role in immune signaling
M1-linked (Linear)	NF-κB activation via NEMO binding; inhibition of type I IFN signaling	LUBAC (HOIP, HOIL-1L, SHARPIN)	OTULIN, CYLD	Inflammation control; cancer immunotherapy

The functional diversity of atypical ubiquitin chains enables sophisticated regulation of immune signaling pathways. For instance, K6-linked ubiquitination mediated by the E3 ligase RNF167 directs the autophagy receptor p62/SQSTM1 to deliver viral sensors RIG-I and MDA5 to autolysosomes for degradation, thereby terminating IFN-I activation [8]. Simultaneously, RNF167 catalyzes K11-linked ubiquitination on the same substrates, targeting them for proteasomal degradation [8]. This dual degradation mechanism represents an elegant regulatory strategy employing two distinct atypical ubiquitin linkages to control immune signaling amplitude through complementary proteolytic pathways.

Signaling Pathways Regulated by Atypical Ubiquitination

Diagram: Atypical Ubiquitin Regulation in Antiviral Signaling Pathways

This diagram illustrates how atypical ubiquitination creates a sophisticated regulatory network controlling antiviral signaling. E3 ligases such as RNF167, TRIM23, and RNF26 install specific atypical ubiquitin linkages that either activate or inhibit signaling components, while deubiquitinases like USP47 remove these modifications to fine-tune the immune response [8] [3] [23]. The dynamic equilibrium between ubiquitination and deubiquitination creates a tunable signaling system that can respond appropriately to viral threats while maintaining immune homeostasis.

Experimental Approaches for Studying Atypical Ubiquitination

Methodologies for Identifying Atypical Ubiquitination

The study of atypical ubiquitination requires specialized methodologies due to the technical challenges in detecting these often low-abundance modifications alongside the more prevalent K48 and K63 linkages. The following experimental protocols represent state-of-the-art approaches for elucidating atypical ubiquitination events in antiviral signaling:

Protocol 1: Substrate Trapping for E3 Ligase Target Identification

This approach addresses the challenge of transient E3 ligase-substrate interactions by engineering catalytically inactive E3 mutants that maintain substrate binding capability [49].

• Mutant Generation: Create point mutations in the RING domain of the E3 ligase (e.g., R54P in TRIM25) that disrupt E2 binding and ubiquitin transfer while preserving substrate interaction.
• Cell Transfection: Express the substrate-trapping mutant in HEK293T cells alongside wild-type and empty vector controls.
• Immunoprecipitation: Harvest cells and perform immunoprecipitation using antibodies against the E3 ligase under native conditions.
• Mass Spectrometry Analysis: Process immunoprecipitated complexes by tryptic digestion and analyze via LC-MS/MS to identify interacting proteins.
• Bioinformatic Validation: Compare mutant versus wild-type interactomes to identify specifically enriched substrates, followed by functional validation through knockdown and ubiquitination assays.

This protocol successfully identified novel TRIM25 substrates including G3BP1/2 (stress granule formation), UPF1 (nonsense-mediated mRNA decay), NME1 (nucleoside synthesis), and PABPC4 (mRNA translation) [49].

Protocol 2: Linkage-Specific Ubiquitination Mapping

Determining the specific ubiquitin linkage type on substrates is essential for understanding the functional consequences of atypical ubiquitination.

• Ubiquitin Expression Plasmids: Utilize mutant ubiquitin plasmids where all lysines except one are mutated to arginine (e.g., K6-only, K11-only, K27-only).
• Cell-Based Ubiquitination Assay: Co-transfect substrate of interest with wild-type or linkage-specific ubiquitin mutants.
• Immunoprecipitation and Western Blot: Immunoprecipitate the substrate and probe with ubiquitin antibodies to determine which linkage-specific mutant facilitates ubiquitination.
• Linkage-Specific Antibodies: Employ recently developed linkage-specific antibodies for K6, K11, K27, K29, and K33 linkages to directly detect endogenous atypical ubiquitination.
• Functional Validation: Mutate acceptor lysines in the substrate to assess the functional consequence of specific ubiquitination events on downstream signaling.

This approach was instrumental in identifying RNF167-mediated K6 and K11-linked ubiquitination of RIG-I and MDA5, which directs these viral sensors to autophagic and proteasomal degradation pathways, respectively [8].

Computational Prediction of Ubiquitination Networks

Advanced computational methods have emerged to complement experimental approaches in mapping the ubiquitination landscape:

Deep Learning Framework for DUB-Substrate Interactions The TransDSI framework utilizes protein sequence-based deep transfer learning to predict deubiquitinase-substrate interactions (DSIs) [50]. This method involves:

• Feature Generation: Use conjoint triad method to generate protein sequence features and BLAST to construct a sequence similarity network.
• Self-Supervised Pre-training: Employ variational graph autoencoder to pre-train a Graph Convolutional Network encoder on proteome-wide evolutionary information.
• Fine-Tuning: Transfer learned parameters to initialize a predictor model that is fine-tuned on known DUB-substrate interactions.
• Explainable AI: Implement PairExplainer module to identify critical protein regions contributing to DUB-substrate interactions.

TransDSI achieved AUROC of 0.83 in cross-validation and 0.75 in independent testing, outperforming traditional machine learning methods [50]. This framework successfully predicted novel interactions, including USP11 and USP20 as DUBs for FOXP3, which were experimentally validated.

Machine Learning for Ubiquitination Site Prediction Deep learning approaches have demonstrated superior performance in predicting ubiquitination sites from protein sequence data:

• Data Collection: Curate experimentally verified ubiquitination sites from databases like dbPTM.
• Feature Engineering: Combine raw amino acid sequences with hand-crafted features including physicochemical properties.
• Model Architecture: Implement hybrid deep neural networks that process both sequence and feature information.
• Validation: Employ proper cross-validation strategies to prevent information leakage and ensure model generalizability.

These models have achieved performance metrics up to 0.902 F1-score, 0.8198 accuracy, 0.8786 precision, and 0.9147 recall, with studies revealing that longer amino acid fragments improve prediction accuracy [51].

Therapeutic Targeting Strategies

Direct Targeting of Atypical Ubiquitination Machinery

The enzymatic pathway of ubiquitination offers multiple nodes for therapeutic intervention, with E3 ligases and DUBs representing particularly attractive targets due to their substrate specificity:

Table 2: Therapeutic Strategies Targeting Atypical Ubiquitination

Therapeutic Approach	Molecular Target	Mechanism of Action	Development Stage	Antiviral Application
PROTACs	Viral or host immune proteins	Bifunctional molecules recruiting E3 ligases to target proteins for degradation	Preclinical (for respiratory viruses)	Influenza, SARS-CoV-2, RSV targeting viral entry/replication proteins
DUBTACs	DUB-recruiting chimeras	Stabilization of specific substrate proteins by recruiting DUBs	Early research	Stabilization of antiviral restriction factors
Small Molecule Inhibitors	E3 ligase catalytic domains	Block ubiquitin transfer to specific substrates	Lead optimization	RNF167, TRIM25 inhibition to enhance antiviral sensing
Monoclonal Antibodies	Linkage-specific ubiquitin chains	Interference with ubiquitin-binding domain interactions	Concept stage	Disruption of negative regulatory ubiquitination events
Activity-Based Probes	DUB enzymatic activity	Profiling and inhibition of specific DUB families	Research tools	USP47 inhibition to enhance TRAF3/6 signaling

PROTACs (Proteolysis-Targeting Chimeras) represent a particularly promising therapeutic modality that hijacks the ubiquitin-proteasome system for targeted protein degradation [52]. These bifunctional molecules consist of a warhead that binds the protein of interest, connected via a linker to an E3 ligase-recruiting ligand. The formation of the ternary complex results in polyubiquitination and subsequent degradation of the target protein. PROTACs have been designed to target viral proteins such as influenza hemagglutinin and neuraminidase, as well as SARS-CoV-2 spike protein, demonstrating the feasibility of this approach for antiviral therapy [52].

Research Reagent Solutions

The following toolkit represents essential reagents for investigating atypical ubiquitination in antiviral immunity:

Table 3: Research Reagent Solutions for Atypical Ubiquitination Studies

Reagent Category	Specific Examples	Research Application	Key Features
Linkage-Specific Antibodies	Anti-K6, Anti-K11, Anti-K27, Anti-K29, Anti-K33, Anti-M1 ubiquitin	Detection of specific atypical ubiquitin chains by Western blot, immunofluorescence	Validate linkage-specific ubiquitination events in immune signaling pathways
Ubiquitin Mutant Plasmids	K6-only, K11-only, K27-only, K29-only, K33-only ubiquitin mutants	Determination of linkage type in cell-based ubiquitination assays	Single lysine ubiquitin mutants prevent formation of mixed chains
E3 Ligase Expression Constructs	RNF167, TRIM23, TRIM25, RNF26 with catalytically inactive mutants	Functional studies of E3 ligase activity and substrate identification	Wild-type and mutant pairs distinguish catalytic versus scaffolding functions
DUB Inhibitors	USP7/USP47 inhibitors (P22077, PR-619), broad-spectrum DUB inhibitors	Investigation of deubiquitination in immune signaling pathways	Chemical tools to probe DUB function without genetic manipulation
Activity-Based Probes	Ubiquitin-based covalent probes with fluorescent or biotin tags	Profiling active DUBs in cell lysates and intact cells	Identify DUBs with altered activity during viral infection
Computational Tools	TransDSI, UbiBrowser 2.0, DeepUni, UbPred	Prediction of DUB-substrate interactions and ubiquitination sites	Prioritize experimental validation candidates based on computational predictions

The emerging understanding of atypical ubiquitination has revealed a sophisticated regulatory layer in antiviral immunity that presents compelling opportunities for therapeutic intervention. The specificity of E3 ligases for particular substrates and the linkage selectivity of the ubiquitination process create a potentially vast target space for drug development with reduced off-target effects compared to broader immunosuppressive approaches. The development of PROTAC technology, which already shows promise against respiratory viruses including influenza and SARS-CoV-2, exemplifies how harnessing the ubiquitin system can generate novel antiviral modalities [52].

Future advances in this field will depend on overcoming several key challenges, including the tissue-specific expression of E3 ligases, pharmacokinetic optimization of ubiquitin-system modulators, and the emergence of viral resistance mechanisms [52]. Additionally, the development of more specific research tools, particularly highly selective small-molecule inhibitors for individual E3 ligases and DUBs, will accelerate both basic understanding and therapeutic applications. As computational methods like TransDSI continue to improve their predictive power for DUB-substrate interactions and machine learning approaches enhance ubiquitination site prediction, the pace of discovery in atypical ubiquitination will undoubtedly accelerate [51] [50].

The integration of atypical ubiquitination research into drug discovery pipelines represents a paradigm shift in targeting the antiviral immune response. By moving beyond the traditional focus on K48 and K63 linkages, researchers can access a rich landscape of regulatory mechanisms that offer precise control over immune signaling pathways. This approach holds particular promise for developing next-generation antivirals that modulate host factors to create a broad-spectrum antiviral environment while minimizing resistance development. As our understanding of the ubiquitin code in antiviral immunity continues to expand, so too will our ability to harness this knowledge for therapeutic innovation.

Challenges and Solutions: Overcoming Hurdles in Atypical Ubiquitin Research

The ubiquitin system, a crucial post-translational modification pathway, operates through a complex code that governs virtually all cellular processes in eukaryotes. This code is orchestrated through the sequential action of E1 (activating), E2 (conjugating), and E3 (ligating) enzymes that conjugate the 76-amino acid protein ubiquitin to substrate proteins, potentially generating chains of eight distinct linkage types through its internal lysine residues or N-terminus [17]. While the roles of K48-linked (proteasomal degradation) and K63-linked (signaling) chains are well-established, recent research has unveiled the critical importance of "atypical" ubiquitin chains (linked through K6, K11, K27, K29, K33, and M1) in regulating specialized cellular functions, particularly in the antiviral innate immune response [11] [28].

The complexity of the ubiquitin code creates substantial technical challenges for researchers. The human genome encodes approximately 40 E2s and 700 E3 ligases that cooperate to selectively target thousands of substrates, creating an enormous potential for specificity, redundancy, and dynamic regulation [53]. This review examines the core technical challenges in deciphering the ubiquitin code within the context of antiviral immunity, explores advanced methodological approaches to address these challenges, and discusses the implications for therapeutic development.

Technical Challenges in Deciphering the Ubiquitin Code

The Specificity Challenge: Discriminating Genuine Substrates from Interactors

A fundamental technical hurdle in ubiquitin research lies in distinguishing bona fide ubiquitination targets from non-covalent interactors. This challenge stems from several factors:

• Transient enzyme-substrate interactions: Ubiquitination events are often brief, making them difficult to capture [53]
• Low stoichiometry of modification: Only a small fraction of a substrate may be ubiquitinated at any given time [54]
• Spatial and temporal specificity: Ubiquitination is highly dynamic and compartment-specific [53]

The problem is particularly acute in antiviral signaling pathways, where multiple E3 ligases may target the same protein with different functional outcomes. For instance, mitochondrial antiviral signaling protein (MAVS) can be modified by at least three different E3 ligases (TRIM21, MARCH8, and RNF34) with K27, K27/K29, and K27-linked chains respectively, leading to either activation or suppression of type I interferon responses [11]. Without precise tools to discriminate these events, understanding the regulatory network remains challenging.

The Redundancy Challenge: Overlapping Functions in the Ubiquitin System

The ubiquitin system exhibits considerable redundancy, with multiple E3 ligases potentially targeting the same substrate, and multiple substrates being targeted by the same E3. This redundancy creates significant obstacles for functional studies:

• Genetic compensation: Knockdown or knockout of single E3 ligases may not yield phenotypes due to compensatory mechanisms
• Context-dependent functions: E3 ligases may perform different roles depending on cellular conditions or stimulus
• Pleiotropic effects: Manipulating core ubiquitin system components affects multiple pathways simultaneously

In antiviral immunity, this redundancy is exemplified by the RIG-I-like receptor pathway, where at least five different E3 ligases (TRIM25, RNF135, RIPLET, TRIM4, and MEX3C) have been reported to regulate RIG-I activation through K63-linked ubiquitination under different conditions [24]. Disentangling the specific contributions of each requires exceptionally precise experimental approaches.

The Dynamic Nature Challenge: Capturing Transient Ubiquitination Events

Ubiquitination is not a static modification but a highly dynamic process regulated by the opposing actions of E3 ligases and deubiquitinating enzymes (DUBs). Key aspects of this challenge include:

• Rapid turnover: Many ubiquitination events are transient, with half-lives of minutes or less
• Stoichiometric limitations: The fraction of modified substrate is often very low [55]
• Signal integration: Ubiquitination frequently intersects with other post-translational modifications, particularly phosphorylation [55]

This dynamic regulation is crucial in antiviral signaling, where the strength and duration of responses must be precisely controlled to eliminate pathogens without causing excessive inflammation. For example, linear (M1-linked) ubiquitination of NEMO by LUBAC potentiates NF-κB signaling, while simultaneously disrupting the MAVS-TRAF3 complex to inhibit IRF3 activation and type I interferon production [11]. Capturing these coordinated, opposing regulatory events requires techniques capable of monitoring rapid changes in ubiquitination status.

Table 1: Technical Challenges in Studying the Ubiquitin Code

Challenge	Underlying Causes	Impact on Research
Specificity	>700 E3 ligases; transient interactions; low stoichiometry	Difficulty distinguishing true substrates from interactors
Redundancy	Multiple E3s target same substrate; pleiotropic E3 functions	Genetic approaches often fail to reveal clear phenotypes
Dynamic Nature	Rapid turnover; subcellular compartmentalization; crosstalk with other PTMs	Challenges in capturing authentic ubiquitination events

Advanced Methodologies for Ubiquitin Code Analysis

The BioE3 System: A Leap Forward in Substrate Identification

The BioE3 system represents a significant technical advance for identifying specific substrates of E3 ligases [53]. This innovative approach combines BirA-E3 ligase fusions with a bioinylated ubiquitin (bioUb) to enable proximity-dependent labeling and purification of ubiquitinated substrates.

Experimental Protocol:

• Generate stable cell lines expressing doxycycline-inducible bioGEFUb (an AviTag variant with lower BirA affinity to reduce non-specific labeling)
• Introduce BirA-E3 fusion constructs into bioGEFUb cells
• Culture cells in biotin-depleted media to control labeling timing
• Induce bioGEFUb expression with doxycycline for 24 hours
• Add exogenous biotin for time-limited labeling
• Capture biotinylated substrates using streptavidin beads
• Identify substrates via liquid chromatography-mass spectrometry (LC-MS)

This method has been successfully applied to both RING-type (RNF4, MIB1, MARCH5, RNF214) and HECT-type (NEDD4) E3 ligases, identifying both known and novel targets with high specificity [53]. The system can detect altered E3 specificity in response to chemical treatments, opening avenues for targeted protein degradation research.

BioE3 Experimental Workflow: This diagram illustrates the key steps in the BioE3 methodology for identifying E3 ligase substrates.

Advanced Mass Spectrometry Approaches for Ubiquitinome Analysis

Recent advances in mass spectrometry have dramatically improved our ability to study ubiquitination on a systems-wide scale. The data-independent acquisition (DIA) method combined with diGly antibody-based enrichment represents a particularly powerful approach [54].

Experimental Protocol:

• Treat cells of interest (e.g., with proteasome inhibitor MG132 to enrich ubiquitinated substrates)
• Extract and digest proteins to peptides
• Separate peptides by basic reversed-phase chromatography into 96 fractions
• Concatenate fractions into 8 pools, separating highly abundant K48-linked ubiquitin-derived diGly peptides
• Enrich diGly-containing peptides using anti-diGly antibodies
• Analyze using optimized Orbitrap-based DIA with comprehensive spectral libraries

This approach has identified approximately 35,000 distinct diGly peptides in single measurements of MG132-treated cells—doubling the number and quantitative accuracy compared to traditional data-dependent acquisition methods [54]. When applied to TNFα signaling, this method comprehensively captured known ubiquitination sites while adding many novel ones, demonstrating its utility for pathway analysis.

Table 2: Key Research Reagent Solutions for Ubiquitin Studies

Reagent/Tool	Function/Application	Key Features
BioE3 System [53]	Identification of E3-specific substrates	Proximity-dependent labeling; works with RING and HECT E3s
bioGEFUb [53]	Engineered ubiquitin for proximity labeling	AviTag variant with reduced BirA affinity to minimize non-specific labeling
Anti-diGly Antibodies [54]	Enrichment of ubiquitinated peptides	Recognizes diglycine remnant left after trypsin digestion
Linkage-Specific Antibodies [17]	Detection of specific chain types	Available for Met1-, Lys11-, Lys48-, Lys63-linked chains
Linkage-Specific DUBs [17]	Analysis of chain linkage	Enzymatic tools to selectively cleave specific ubiquitin linkages
DIA Mass Spectrometry [54]	Comprehensive ubiquitinome analysis	Identifies ~35,000 diGly sites in single measurements; superior quantification

Structural Biology Approaches for Molecular Mechanism Insights

Structural studies provide critical insights into the molecular mechanisms of ubiquitin signaling complexes. Recent cryo-EM work on the human HRD1 ubiquitin ligase complex illustrates how structural approaches can reveal unexpected organizational principles [56].

Key Structural Findings:

• HRD1 forms a dimer, but only one protomer carries the SEL1L-XTP3B complex, forming a 2:1:1 complex
• The complex recognizes trimmed N-glycans on misfolded proteins through XTP3B and SEL1L
• Engagement with Derlin proteins induces dramatic conformational changes, breaking the HRD1 dimer and forming a four-helix bundle that may induce local membrane curvature [56]

Such structural insights are invaluable for understanding the specificity of ubiquitin ligase complexes and may inform therapeutic strategies targeting specific E3 ligases.

Atypical Ubiquitin Chains in Antiviral Signaling: A Case Study in Technical Challenges

The study of atypical ubiquitin chains in antiviral immunity exemplifies the technical challenges outlined above while highlighting the importance of continued methodological development. The following examples illustrate both the biological significance and technical complexities involved.

K27-Linked Ubiquitination: Multiple E3 ligases create K27-linked chains with distinct functional outcomes in antiviral signaling:

• TRIM23-mediated K27-linked ubiquitination of NEMO activates both NF-κB and IRF3 pathways [11]
• TRIM26 auto-ubiquitination with K27-linked chains enhances type I interferon production [11]
• TRIM40 mediates K27-linked degradation of RIG-I and MDA5, inhibiting interferon response [11]
• MARCH8 targets MAVS for autophagy-mediated degradation via K27-linked chains [11]
• RNF185 promotes K27-linked ubiquitination of cGAS, enhancing IRF3 activation [11]

K29/K33-Linked Ubiquitination:

• RNF34 induces K27/K29-linked ubiquitination of MAVS, targeting it for autophagy-mediated degradation [11]
• SKP1-Cullin-Fbx21 mediates K29-linked ubiquitination of ASK1, inducing IFNβ and IL-6 production [11]
• RNF2 catalyzes K33-linked ubiquitination of STAT1, suppressing ISG transcription [11]

Atypical Ubiquitin Chains in Antiviral Signaling: This diagram shows how different ubiquitin linkage types regulate immune signaling pathways, with K27/K29 chains participating in both activation and attenuation processes.

The functional diversity of K27-linked chains alone demonstrates the exquisite specificity encoded within the ubiquitin system, while the overlapping targets (e.g., multiple E3s regulating MAVS) illustrates the redundancy challenge. The development of linkage-specific tools, including antibodies and ubiquitin-binding domains, has been essential for deciphering these complex regulatory networks [17].

Future Perspectives and Concluding Remarks

Deciphering the ubiquitin code remains a formidable challenge requiring continued methodological innovation. Several promising directions are emerging:

Integration of Multiple Omics Approaches: Combining ubiquitinome profiling with phosphoproteomics, transcriptomics, and metabolic analyses will provide more comprehensive views of how ubiquitination coordinates cellular responses to viral infection.

Single-Cell and Spatial Analysis: Current ubiquitinome methods require large cell numbers, averaging signals across heterogeneous populations. Developing single-cell ubiquitinomics approaches would reveal cell-to-cell variation in ubiquitin signaling, particularly important in the context of cell-type-specific antiviral responses.

Dynamic and Quantitative Modeling: Combining improved quantitative proteomics with computational modeling will help move from descriptive catalogues of ubiquitination events to predictive models of ubiquitin network behavior [55].

Targeted Ubiquitin Manipulation: The growing understanding of ubiquitin ligase specificity is enabling the development of targeted protein degradation approaches, such as PROTACs and molecular glues, that harness endogenous ubiquitin machinery for therapeutic purposes.

In conclusion, the technical challenges of specificity, redundancy, and dynamic regulation in the ubiquitin code are substantial but not insurmountable. Continued development and application of innovative methods like BioE3, advanced mass spectrometry, and structural biology are steadily illuminating the complex roles of atypical ubiquitin chains in antiviral immunity and other physiological processes. As these tools improve, so too will our ability to therapeutically modulate ubiquitin signaling for treating viral infections, cancer, and other diseases.

Within the intricate "ubiquitin code," K27-linked polyubiquitin chains represent a complex and poorly understood dialect. Once considered a minor player, emerging research reveals that K27 linkages are critical and versatile signals in the antiviral innate immune response, capable of initiating both activating and inhibitory outcomes. This whitepaper decodes this functional duality by integrating recent structural insights, detailed mechanistic studies, and methodological advances. Presented within the broader context of atypical ubiquitin chain research, this analysis provides scientists and drug development professionals with a technical framework for understanding and investigating the K27 ubiquitin chain's paradoxical role in cellular signaling and its therapeutic potential.

The ubiquitin system constitutes a vast post-translational modification language, where diverse chain topologies—linked through different lysine residues of ubiquitin—compose distinct signals to orchestrate nearly every cellular process. While the functions of K48-linked chains in proteasomal degradation and K63-linked chains in signaling are well-established, the so-called "atypical" chains (K6, K11, K27, K29, K33) represent a frontier in ubiquitin research. Among these, K27-linked ubiquitin has been particularly enigmatic due to its low abundance and historical lack of research tools [11].

K27-linked chains are now recognized as dynamic regulators in crucial pathways, most notably in the antiviral innate immune response. Intriguingly, they do not signal a single, unified outcome. Instead, K27 linkages can function as both potent activators and stringent inhibitors of immune signaling pathways, a duality that hinges on the specific substrate, cellular context, and participating enzymes [11]. This functional complexity is rooted in the unique structural and biophysical properties of the chain itself. K27-linked di-ubiquitin (K27-Ub2) exhibits a distinctive conformational ensemble and demonstrates remarkable resistance to cleavage by a broad range deubiquitinases (DUBs), including the linkage-nonspecific USP5 (IsoT) [57]. This resilience suggests that K27 linkages may act as stable, long-lasting signals or competitive inhibitors of DUB activity, thereby shaping the dynamics of the immune response.

Functional Duality: Activating and Inhibitory Roles in Immune Signaling

The functional complexity of K27-linked ubiquitination is most evident in the antiviral innate immune response, where it plays context-dependent roles in fine-tuning the output of signaling cascades. The table below summarizes key documented functions, highlighting the dual nature of this modification.

Table 1: Dual Functions of K27-Linked Ubiquitination in Antiviral Innate Immunity

Function	E3 Ligase	Substrate	Biological Outcome	Reference
Activating Signals	TRIM23	NEMO	Leads to activation of NF-κB and IRF3 transcription factors.	[11]
	TRIM26	TRIM26	Promotes interaction with NEMO, boosting type I IFN and cytokine production.	[11]
	RNF185	cGAS	Induces IRF3 activation and production of type I IFNs and proinflammatory cytokines.	[11]
	AMFR	STING	Recruits TBK1 to STING, promoting IRF3 activation and IFN production.	[11]
Inhibitory Signals	TRIM40	RIG-I and MDA5	Targets RIG-I and MDA5 for proteasomal degradation, suppressing the type I IFN response.	[11]
	MARCH8	MAVS	Induces autophagy-mediated degradation of MAVS, restricting the type I IFN response.	[11]

Activating Signaling Pathways

K27-linked chains can serve as potent activating signals, often by scaffolding the assembly of crucial signaling complexes. For instance, the E3 ligase TRIM23 conjugates K27-linked chains to NEMO (NF-κB Essential Modulator), a key regulatory subunit of the IKK complex. This modification is critical for the subsequent activation of the transcription factors NF-κB and IRF3, which drive the expression of proinflammatory cytokines and type I interferons (IFNs), respectively [11]. Similarly, RNF185-mediated K27 ubiquitination of cGAS and AMFR-mediated modification of STING are essential for initiating IRF3 activation and type I IFN production in response to cytosolic DNA, a key antiviral sensing pathway [11]. These examples position K27-linked chains as direct and non-redundant pro-inflammatory signals.

Inhibitory and Homeostatic Functions

Conversely, K27 linkages are equally capable of transmitting potent inhibitory signals that dampen the immune response, thereby preventing excessive inflammation. The E3 ligase TRIM40 attaches K27-linked chains to the cytosolic RNA sensors RIG-I and MDA5, leading to their proteasomal degradation and subsequent inhibition of the type I IFN response [11]. In a different mechanistic twist, MARCH8 uses K27 ubiquitination to tag the mitochondrial adapter protein MAVS for autophagy-mediated degradation, effectively dismantling the signaling platform for RIG-I-like receptors [11]. Furthermore, K27 ubiquitination can also play a role in feedback inhibition; for example, K27-linked chains on NEMO can recruit the deubiquitinase A20 to remove activating K63-linked chains, thereby preventing excessive NF-κB activation [11].

Figure 1: K27-Linked Ubiquitin in Antiviral Signaling. This diagram illustrates the dual role of K27-linked ubiquitination in activating (green) and inhibiting (red) the antiviral innate immune response, showing key E3 ligases and substrates.

Structural and Biophysical Underpinnings of K27 Chain Function

The unique functional properties of K27-linked ubiquitin chains are directly attributable to their distinct structural and dynamic characteristics, which set them apart from all other ubiquitin linkage types.

Unique Conformational Ensemble and Dynamics

Comprehensive structural studies using NMR spectroscopy and small-angle neutron scattering (SANS) have revealed that K27-Ub2 adopts a unique conformational ensemble. A key finding is the striking asymmetry between the two ubiquitin units. The distal Ub (whose C-terminus is linked) shows minimal chemical shift perturbations (CSPs), indicating a lack of stable non-covalent interdomain contacts. In contrast, the proximal Ub (donating the K27 side chain) exhibits the largest and most widespread CSPs among all di-ubiquitin linkages [57]. This suggests that the isopeptide linkage itself imposes significant structural constraints or dynamic changes on the proximal unit, a feature that may be critical for its recognition by downstream effector proteins.

Resistance to Deubiquitinases (DUBs)

A defining biochemical characteristic of K27-linked chains is their resistance to cleavage by most deubiquitinases. In comparative assays, K27-Ub2 was the only linkage tested that resisted disassembly by the linkage-nonspecific DUB USP5 (IsoT). It was also cleaved poorly by USP2 and the proteasome-associated DUB Ubp6 [57]. This resilience implies that K27-linked ubiquitination constitutes a relatively stable signal within the cell, potentially allowing it to exert prolonged effects or to compete with other ubiquitin signals for binding to shared receptors. This property is likely a direct consequence of its unique structure, which may prevent productive engagement with the active sites of many DUBs.

Unexpected Receptor Recognition

The structural features of K27-Ub2 can lead to unexpected cross-talk with recognition systems for other linkages. Structural data and modeling predicted that K27-Ub2 could be specifically recognized by the UBA2 domain of the proteasomal shuttle protein hHR23a, a domain known for its selectivity for K48-linked chains. This prediction was confirmed experimentally through binding studies and mutagenesis [57]. This finding highlights the remarkable versatility of polyubiquitin recognition and suggests that K27 chains could potentially interfere with or modulate K48-linked proteasomal degradation pathways under certain conditions.

Experimental Protocols for Studying K27 Linkages

Investigating the role of K27-linked ubiquitination requires specialized methodologies to overcome challenges in chain production, detection, and functional analysis.

Non-Enzymatic Chain Assembly for Biochemical Studies

The lack of highly specific E2/E3 enzyme pairs for K27 linkages has necessitated the development of chemical biology approaches.

• Core Principle: Use of mutually orthogonal, removable amine-protecting groups (Alloc and Boc) on ubiquitin's lysine residues to achieve site-specific conjugation [57].
• Detailed Workflow:
  • Ubiquitin Preparation: Recombinant ubiquitin is expressed and purified. All lysines except K27 are protected with a Boc group, while K27 is protected with an Alloc group.
  • Selective Deprotection: The Alloc group on K27 is selectively removed under mild conditions, leaving other lysines protected.
  • Activation and Conjugation: The C-terminus of a second ("donor") ubiquitin molecule is activated. The selectively deprotected K27 amine on the "acceptor" ubiquitin attacks the activated C-terminus, forming a native isopeptide linkage.
  • Final Deprotection: The remaining Boc groups are removed, yielding fully natural K27-linked di-ubiquitin (K27-Ub2) free of mutations [57].
• Key Application: This method was used to produce all non-canonical Ub2s, enabling their direct comparative biochemical and structural analysis [57].

Deubiquitinase (DUB) Susceptibility Assay

This assay is critical for characterizing the stability and turnover of K27-linked chains.

• Core Principle: Incubate purified K27-Ub2 with a panel of DUBs and monitor cleavage over time.
• Detailed Workflow:
  • Reaction Setup: Combine 5-10 µg of purified K27-Ub2 with a specific DUB (e.g., USP2, USP5, OTUB1, Cezanne, AMSH) in an appropriate reaction buffer.
  • Time Course Incubation: Allow the reaction to proceed at 37°C, removing aliquots at various time points (e.g., 0, 5, 15, 30, 60 minutes).
  • Reaction Termination: Stop the reaction by adding SDS-PAGE loading buffer and boiling.
  • Analysis: Analyze the samples by SDS-PAGE and Coomassie staining or immunoblotting with ubiquitin antibodies to visualize the conversion of di-ubiquitin to mono-ubiquitin [57].
• Key Finding: Using this protocol, researchers demonstrated that K27-Ub2 is uniquely resistant to cleavage by several DUBs, including the linkage-nonspecific USP5 [57].

Table 2: Key Reagent Solutions for K27 Ubiquitin Research

Research Reagent	Function/Application	Key Characteristics
Non-enzymatically assembled K27-Ub2	Biochemical and structural studies; DUB assays.	Contains native isopeptide bond; free of mutations; essential for pure linkage-specific studies.
Linkage-Specific DUB Panel (e.g., USP5, OTUB1, Cezanne)	Profiling ubiquitin chain stability and turnover.	Used to identify K27's unique resistance to deubiquitination.
UBA2 Domain of hHR23a	Studying ubiquitin chain receptor cross-talk.	K48-selective domain used to demonstrate unexpected binding to K27 chains.
NMR Spectroscopy with 15N-labeled Ub	Determining solution structure and dynamics.	Revealed asymmetric conformational ensemble of K27-Ub2.
E3 Ligase Tools (e.g., TRIM23, RNF185)	Cell-based signaling studies.	For investigating pathway-specific K27 ubiquitination.

Advancing research into K27-linked ubiquitination is dependent on a growing toolkit of reagents and methodologies. Table 3: Essential Research Tools for K27-Linked Ubiquitin Studies

Tool Category	Specific Example	Utility in K27 Research
Chemical Biology Tools	Non-enzymatic synthesis with orthogonal protection [57]	Production of homogeneous, native K27-linked chains for in vitro studies.
Structural Biology Techniques	NMR Spectroscopy, SANS, in silico ensemble modeling [57]	Characterization of unique conformational dynamics and lack of stable interdomain contacts.
Linkage-Specific Binders	Synthetic antigen-binding fragments (sABs) [28]	Detection and purification of K27-linked chains from complex mixtures.
Cell Biology & Proteomics	Tandem Ubiquitin Binding Entities (TUBEs), linkage-specific antibodies, quantitative mass spectrometry [11] [58]	Identification of endogenous K27 substrates and profiling chain dynamics in cells.

Figure 2: Experimental Workflow for K27 Chain Analysis. A logical flow for a comprehensive research program, from initial biochemical characterization to cellular validation.

K27-linked ubiquitin chains have emerged from obscurity to be recognized as critical and dynamic regulators of cell signaling, with a particularly complex role in the antiviral innate immune response. Their functional duality—capable of initiating both activating and inhibitory signals—is underpinned by unique structural features, including an asymmetric conformational ensemble and a pronounced resistance to deubiquitination. Future research will be greatly aided by the continued development of more sensitive linkage-specific tools, such as improved antibodies and binders, to detect and manipulate these chains in physiological settings. A deeper exploration into the role of branched ubiquitin chains that incorporate K27 linkages, and the identification of the full complement of readers dedicated to recognizing the K27 topology, will be essential to fully decode the functional complexity of this multifaceted post-translational modification. Understanding these nuances opens exciting avenues for therapeutic intervention, where modulating K27-linked ubiquitination could potentially be used to fine-tune immune responses in autoimmune diseases, chronic inflammation, and cancer.

The ubiquitin-proteasome system (UPS) and the autophagy-lysosome system represent the two primary pillars of cellular proteostasis. Historically viewed as independent pathways, emerging research reveals they function as an integrated, cooperative network. This crosstalk is critically regulated by the ubiquitin code, where distinct ubiquitin chain linkages direct substrates to the proteasome for degradation or to autophagosomes for lysosomal processing. Within the context of antiviral innate immunity, this dynamic interplay and the role of atypical ubiquitin chains enable precise regulation of immune signaling platforms. This whitepaper provides a technical examination of the mechanisms governing UPS-autophagy cross-talk, with a specific focus on its implications for antiviral defense and drug discovery.

Central to both the UPS and autophagy is the post-translational modification of proteins with ubiquitin. Ubiquitination involves the covalent attachment of the 76-amino acid protein ubiquitin to lysine residues on target proteins [59]. This process can generate diverse signals: monoubiquitination or multi-monoubiquitination can alter a protein's activity or localization, while the formation of polyubiquitin chains creates distinct degradation signals or regulatory cues [59]. Polyubiquitin chains are classified based on which of the seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminal methionine (M1) of one ubiquitin molecule is linked to the C-terminus of the next [11]. The specific topology of these chains constitutes a complex "ubiquitin code" that is decoded by cellular machinery to determine substrate fate [59].

The ubiquitin-proteasome system (UPS) is a selective proteolytic pathway where substrates tagged with specific ubiquitin chains are recognized and processively degraded by the proteasome [59]. In contrast, autophagy (specifically macroautophagy) is a bulk degradative system that uses lysosomal hydrolases to degrade proteins, organelles, and other cellular constituents [59]. Recent studies demonstrate that these systems are not independent but function as a single proteolytic network with significant functional cooperation, particularly under cellular stress [59].

The Ubiquitin-Proteasome System (UPS)

The UPS mediates the targeted degradation of short-lived proteins and abnormal proteins [60]. The process involves a cascade of enzymes: E1 (activating), E2 (conjugating), and E3 (ligating) that work in concert to tag substrates with ubiquitin [61]. The 26S proteasome then recognizes and degrades these ubiquitinated substrates into small peptides in an ATP-dependent manner [60]. The UPS is essential for regulating fundamental cellular processes, including cell cycle progression, signal transduction, and stress response [62].

The Autophagy-Lysosome System

Autophagy involves the formation of double-membraned vesicles called autophagosomes that engulf cytoplasmic cargo, which then fuse with lysosomes for content degradation [63]. While initially considered a non-selective bulk degradation process, it is now clear that autophagy can be highly selective through the action of autophagy receptors such as p62/SQSTM1, NBR1, NDP52, and optineurin [63]. These receptors contain ubiquitin-binding domains (UBDs) that recognize ubiquitinated cargo and LC3-interacting regions (LIRs) that tether the cargo to the growing autophagosomal membrane [59].

Ubiquitin as a Common Degron

Ubiquitin serves as a common degradation signal (degron) for both systems [59]. In the UPS, ubiquitin chains—particularly K48-linked chains—are recognized by proteasome-associated adaptors like RPN10 and RPN13 [59]. In autophagy, ubiquitin chains on protein aggregates, organelles, or intracellular pathogens are bound by the UBDs of autophagic adaptors like p62 and NBR1, which then link these cargoes to the autophagy machinery via LC3 [59]. This shared reliance on ubiquitin tagging provides the fundamental basis for cross-talk between the two systems.

Table 1: Primary Ubiquitin Linkages and Their Functions in Degradation Pathways

Ubiquitin Linkage	Primary Function in UPS	Primary Function in Autophagy	Key Adaptors/Receptors
K48	Primary proteasomal degron; triggers processive degradation [59]	Can serve as autophagic degron, especially when proteasome is impaired [59]	RPN10, RPN13 (UPS); p62, NBR1 (autophagy)
K63	Less common; can facilitate proteasomal processing of specific transcription factors [59]	Primary autophagic degron for protein aggregates and organelles; recruited by selective autophagy receptors [59]	p62, NBR1, HDAC6 (preferentially binds K63)
K11	Proteasomal degradation (e.g., cell cycle regulators) [59]	Limited evidence	Unknown autophagy-specific receptors
K29	Proteasomal processing (e.g., yeast UFD pathway) [59]	Limited evidence	Unknown autophagy-specific receptors
K6	Implicated in DNA damage response [11]	Implicated in autophagic degradation [59]	Limited information
K27	Regulation of innate immune signaling [11]	Autophagy-mediated degradation of immune adaptors (e.g., MAVS) [11]	MARCH8, RNF185
M1 (Linear)	Regulation of NF-κB signaling [11]	Xenophagy (clearance of intracellular pathogens) [63]	NEMO (via UBAN domain)

Mechanisms of Cross-Talk and Functional Interplay

Compensatory Regulation and Substrate Redirection

When one proteolytic system is compromised, the other can compensate to maintain proteostasis. Inhibition of the proteasome leads to the accumulation of ubiquitinated proteins that are subsequently redirected to autophagy [60]. Conversely, genetic or pharmacological inhibition of autophagy causes the accumulation of ubiquitinated protein aggregates that would normally be cleared by selective autophagy [60]. This bidirectional compensatory relationship represents a fundamental aspect of the cross-talk between these systems.

Shared Recognition Components

Several key proteins operate at the interface of both systems:

• p62/SQSTM1: This multifunctional adaptor protein contains a UBD that binds ubiquitinated cargo and an LIR domain that binds LC3 on autophagosomes. p62 can also influence proteasomal degradation, though the mechanisms are less defined [60].
• HDAC6: This histone deacetylase binds ubiquitinated proteins via its zinc-finger UBD and facilitates their transport along microtubules to aggresomes, which are subsequently degraded by autophagy [59].
• VCP/p97: This AAA-ATPase regulates both the proteasome-dependent ER-associated degradation (ERAD) pathway and aspects of autophagosome maturation through its interactions with ubiquitin and p62 [60].

Aggresome Formation as a Cross-Talk Mechanism

When ubiquitinated proteins resistant to proteasomal degradation accumulate (e.g., due to proteasome impairment or aggregation-prone proteins), they are collected by HDAC6 and transported to the microtubule-organizing center to form aggresomes [59]. These structures are then enveloped by autophagosomes and degraded through autophagy [59]. This pathway provides a clear example of how substrates are handed off from the UPS to autophagy when proteasomal capacity is exceeded.

Atypical Ubiquitin Chains in Antiviral Immune Response

Regulation of Innate Immune Signaling by Ubiquitin Chains

The antiviral innate immune response relies on pattern recognition receptors (PRRs) like RIG-I-like receptors (RLRs) and cGAS to detect viral nucleic acids [11]. The signaling cascades initiated by these receptors converge on transcription factors NF-κB and IRF3/7, which induce production of type I interferons (IFN) and proinflammatory cytokines [11]. Ubiquitination plays a crucial role in both the activation and downregulation of these pathways, with atypical ubiquitin chains (K6, K11, K27, K29, K33, M1) recently emerging as key regulators [11].

Table 2: Atypical Ubiquitin Chains in Antiviral Innate Immunity

Ubiquitin Linkage	E3 Ligase	Substrate	Functional Outcome in Immune Response
Linear (M1)	LUBAC	NEMO	Potentiates NF-κB activation [11]
K11	RNF26	STING	Inhibits STING degradation, enhancing type I IFN production [11]
K27	TRIM23	NEMO	Leads to NF-κB and IRF3 activation [11]
K27	MARCH8	MAVS	Induces autophagy-mediated degradation of MAVS, restricting IFN response [11]
K27/K29	RNF34	MAVS	Induces autophagy-mediated degradation of MAVS [11]
K29	SCF-Fbx21	ASK1	Induces IFNβ and IL-6 production [11]
K33	RNF2	STAT1	Suppresses ISG transcription [11]

Cross-Talk in Viral Pathogen Clearance: Xenophagy

Xenophagy represents a selective autophagic process that directly targets intracellular pathogens for degradation [63]. After invading cells, bacteria such as Salmonella typhimurium and Mycobacterium tuberculosis can be ubiquitinated and subsequently recognized by autophagy receptors like p62, NDP52, and optineurin [63]. These receptors bridge the ubiquitinated pathogens to LC3-positive autophagosomal membranes, leading to their encapsulation and lysosomal degradation [63]. The modification of pathogens with K48-, K63-, and linear ubiquitin chains provides "eat-me" signals for xenophagy [63]. This process demonstrates how the ubiquitin-autophagy axis serves as a critical defense mechanism against intracellular pathogens.

Experimental Approaches and Methodologies

Chain-Specific Ubiquitination Assessment Using TUBEs

Tandem Ubiquitin Binding Entities (TUBEs) are specialized affinity matrices with nanomolar affinities for polyubiquitin chains that enable the study of linkage-specific ubiquitination in high-throughput formats [62].

Protocol: Assessing RIPK2 Ubiquitination Using Chain-Specific TUBEs

• Cell Stimulation: Treat human monocytic THP-1 cells with:
  • L18-MDP (200-500 ng/mL for 30-60 min) to induce K63-linked ubiquitination of RIPK2 via NOD2 receptor activation.
  • RIPK2 PROTAC (e.g., RIPK degrader-2) to induce K48-linked ubiquitination and proteasomal targeting [62].
• Cell Lysis: Lyse cells in a buffer optimized to preserve polyubiquitination (e.g., containing N-ethylmaleimide to inhibit deubiquitinases) [62].
• TUBE-Based Capture:
  • Coat 96-well plates with K48-TUBEs, K63-TUBEs, or Pan-TUBEs.
  • Incubate cell lysates in coated wells to allow linkage-specific ubiquitin binding.
  • Wash to remove non-specifically bound proteins [62].
• Detection:
  • Elute bound proteins and detect by immunoblotting with anti-RIPK2 antibody.
  • Alternatively, detect directly in plates using HRP-conjugated antibodies [62].

Expected Results: L18-MDP stimulation produces strong signal with K63-TUBEs and Pan-TUBEs but not K48-TUBEs. RIPK2 PROTAC treatment produces signal with K48-TUBEs and Pan-TUBEs but not K63-TUBEs [62].

Functional Assessment of Proteasome-Autophagy Cross-Talk

The coordinated function of UPS and autophagy can be assessed through combinatorial inhibition studies:

Protocol: Combined Proteasome and Autophagy Inhibition in Multiple Myeloma

• Cell Treatment: Treat multiple myeloma cell lines (e.g., KMS11, RPMI-8226) with:
  • Proteasome inhibitor: Ixazomib (clinically relevant concentration)
  • Autophagy inhibitors: Bafilomycin A1 (BAF, inhibits lysosomal acidification) or Chloroquine (CQ, inhibits autophagosome-lysosome fusion) [64].
• Viability Assessment: Measure cell viability using propidium iodide (PI) staining and flow cytometry after 48-72 hours of treatment [64].
• Apoptosis Measurement: Quantify apoptotic cells using Annexin-V/PI double staining and flow cytometry [64].
• Mechanistic Validation:
  • Assess JNK activation by Western blotting for phospho-SAPK/JNK.
  • Validate JNK involvement using specific inhibitors (e.g., JNK-In-8) [64].

Expected Results: Combined proteasome and autophagy inhibition synergistically reduces cell viability and induces apoptosis in multiple myeloma cells, accompanied by JNK activation [64].

Research Reagent Solutions

Table 3: Essential Research Tools for Studying UPS-Autophagy Cross-Talk

Reagent/Tool	Function/Application	Example Use
Chain-Specific TUBEs	High-affinity capture of linkage-specific polyubiquitin chains	Differentiating K48 vs. K63 ubiquitination in PROTAC studies [62]
Proteasome Inhibitors	Block proteasomal activity to study UPS function and compensatory autophagy	Ixazomib, Bortezomib in multiple myeloma models [64]
Autophagy Inhibitors	Block autophagic flux at various stages	Bafilomycin A1 (lysosomal acidification), Chloroquine (autophagosome-lysosome fusion) [64]
Ubiquitin Mutants	Study specific chain type functions by mutating ubiquitin lysine residues	K48R, K63R mutants to determine essential chain types [62]
Autophagy Reporter Systems	Monitor autophagic flux in live cells	LC3-GFP/RFP reporters, mitophagy reporters (e.g., Keima assays)
Deubiquitinase (DUB) Inhibitors	Preserve ubiquitin signals during extraction	N-ethylmaleimide in lysis buffers [62]

The intricate cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems represents a paradigm shift in our understanding of cellular proteostasis. The ubiquitin code, particularly through the action of atypical chain linkages, serves as a universal language that directs substrate fate between these pathways. In antiviral immunity, this cross-talk enables sophisticated regulation of immune signaling platforms and pathogen clearance mechanisms. The developing methodology for studying linkage-specific ubiquitination, including TUBE-based technologies, provides powerful tools to decipher this complex regulatory network. Understanding these interactions opens new therapeutic avenues for various diseases, including cancer, neurodegenerative disorders, and infectious diseases, by simultaneously targeting multiple proteostatic pathways.

The ubiquitin-proteasome system (UPS) represents a crucial post-translational regulatory mechanism that governs nearly every aspect of cellular physiology, including the orchestration of antiviral immune responses. Ubiquitin, a highly conserved 76-amino acid polypeptide, is conjugated to target proteins through a sequential enzymatic cascade involving E1 (activating), E2 (conjugating), and E3 (ligating) enzymes [65] [66]. The specificity of substrate selection is largely determined by E3 ubiquitin ligases, of which hundreds exist in humans, forming the largest enzyme family in the human genome [13]. Conversely, deubiquitinases (DUBs) counteract this process by removing ubiquitin modifications, creating a dynamic regulatory system analogous to phosphorylation [67] [66].

The functional consequences of ubiquitination depend on both the type of ubiquitin chain linkage and the cellular context. While K48-linked polyubiquitination typically targets substrates for proteasomal degradation and K63-linked chains primarily function in signal transduction, growing evidence indicates that atypical ubiquitin chains (linked through K6, K11, K27, K29, K33, or linear/M1 linkages) play specialized roles in immune regulation [65] [13] [68]. Viruses, as obligate intracellular parasites with limited genomic capacity, have evolved sophisticated strategies to hijack the host ubiquitination machinery, particularly targeting these atypical ubiquitination pathways to evade immune detection and establish productive infections [67] [69].

The Ubiquitin Machinery: Components and Functions

The Ubiquitination Enzymatic Cascade

The ubiquitination process initiates with an E1 activating enzyme that consumes ATP to form a thioester bond with ubiquitin in an energy-dependent process [13] [70]. Humans possess only two E1 enzymes, highlighting this step as a potential vulnerability that viruses might exploit. The activated ubiquitin is then transferred to one of approximately 40 E2 conjugating enzymes, which subsequently cooperate with E3 ligases to mediate substrate-specific ubiquitination [65] [66]. The E3 ligase family, comprising more than 600 members in humans, can be categorized into three major classes based on their structural and mechanistic characteristics [13]:

• RING-type E3s: The largest subfamily, characterized by one or two conserved RING finger motifs that function as scaffolds to orient Ub-bearing E2 toward substrates
• HECT-type E3s: Form an E3-ubiquitin thioester intermediate through their HECT domain before direct substrate catalysis
• RBR-type E3s: Hybrid enzymes that contain RING domains but employ a HECT-like mechanism with their Rcat domain

The ubiquitin-like modifiers (ULMs) expand this regulatory landscape through parallel conjugation systems. These include SUMO (small ubiquitin-like modifier), ISG15 (interferon-stimulated gene 15), NEDD8 (neural precursor cell expressed, developmentally down-regulated 8), and ATG8 (autophagy-related protein 8), each with dedicated E1-E2-E3 enzymatic cascades that modify distinct substrate repertoires [70]. These ULM systems create additional layers of regulation that viruses have learned to manipulate.

Atypical Ubiquitin Chain Linkages and Their Functions

Table 1: Atypical Ubiquitin Chain Linkages and Their Immune Functions

Linkage Type	Structural Features	Known Immune Functions	Viral Exploitation Examples
K6-linked	Poorly characterized chains	DNA damage repair, mitophagy	Limited information
K11-linked	Heterogeneous chains mixed with K48	Cell cycle regulation, ER-associated degradation	Emerging target for viral evasion
K27-linked	Short, heterogeneous chains	Innate immune signaling, inflammatory pathways	AIM2 inflammasome regulation during Francisella infection [71]
K29-linked	Less abundant chains	Kinase regulation, non-degradative signaling	Potential viral target
K33-linked	Short chains in endosomal system	Kinase regulation, TCR signaling	Unknown
Linear/M1	N-terminal methionine linkage	NF-κB signaling, inflammation	Regulated by LUBAC complex [68]

The diversity of ubiquitin chain architectures enables precise control over immune signaling pathways, but also creates multiple vulnerable nodes that pathogens target. For instance, K27-linked ubiquitination has been demonstrated to regulate AIM2 inflammasome activation during Francisella novicida infection, with the E3 ligase HUWE1 mediating K27-linked polyubiquitination of AIM2 [71]. Similarly, linear ubiquitin chains assembled by the LUBAC complex regulate TNF-α signaling and apoptosis, processes frequently disrupted by viral infections [68].

Viral Exploitation of Atypical Ubiquitination Pathways

Hijacking Host E3 Ligases and DUBs

Viruses employ multiple molecular strategies to co-opt the host ubiquitination system. A common approach involves encoding viral proteins that either mimic or recruit host E3 ligases to redirect their activity toward antiviral factors. The poxvirus protein CP77, for instance, contains ankyrin repeats that bind directly to the p65 subunit of NF-κB, preventing its nuclear translocation and inhibiting proinflammatory gene expression [67]. Similarly, murid herpesvirus-4 (MuHV-4) ORF73 protein associates with the host ElonginC/Cullin5/SOCS ubiquitin-ligase complex to mediate polyubiquitination and degradation of p65/RelA, effectively suppressing NF-κB signaling [67].

The TRIM family of E3 ubiquitin ligases, which includes more than 80 members in humans, represents a particularly frequent target of viral manipulation. While many TRIM proteins function as positive regulators of antiviral signaling, viruses have evolved mechanisms to counteract their activity. For example, the influenza A virus NS1 protein directly interacts with TRIM25, blocking its E3 ligase activity and preventing TRIM25-dependent ubiquitination and activation of RIG-I, a key cytosolic RNA sensor [67]. This single molecular intervention effectively disrupts the entire IFN induction cascade, allowing the virus to replicate undetected.

Beyond E3 ligases, viruses also manipulate deubiquitinating enzymes (DUBs) to stabilize negative regulators of immune signaling or prevent activation of positive regulators. Measles virus upregulates the host DUB A20, which normally terminates TLR-dependent NF-κB activation by removing ubiquitin from ATF6, thereby prematurely shutting down inflammatory responses [67]. Several viruses, including various herpesviruses, even encode their own DUBs to directly reverse activating ubiquitination events on host immune proteins [68].

Viral Manipulation of Ubiquitin-Like Modifiers

The ubiquitin-like modification systems provide additional avenues for viral interference with host immunity. SUMOylation, catalyzed by a dedicated E1 (SAE1/SAE2) and E2 (Ubc9) enzyme pair, typically modulates protein-protein interactions and subcellular localization [70]. Ebola virus exploits this system by using its VP35 protein to promote SUMOylation of IRF7 through the cellular E3 ligase PIAS1, effectively inhibiting IFN synthesis [67]. This strategy demonstrates how viruses can redirect host ULM machinery to disrupt transcription factor function without involving the proteasomal degradation pathway.

ISG15, an interferon-induced ULM, functions both as a free cytokine and a conjugated modifier to exert antiviral activity. Viruses have accordingly developed countermeasures; for instance, influenza B virus NS1 protein binds ISG15 and inhibits its conjugation, while vaccinia virus E3 protein directly blocks ISG15 activation [70]. The ongoing evolutionary arms race between host ISG15 and viral antagonists illustrates the significance of ULM pathways in antiviral defense.

Table 2: Viral Evasion Strategies Targeting Atypical Ubiquitination

Viral Pathogen	Viral Protein	Host Target	Mechanism of Action
Influenza A virus	NS1	TRIM25	Blocks E3 ligase activity, preventing RIG-I K63-ubiquitination [67]
Ebola virus	VP35	IRF7	Promotes SUMOylation via PIAS1, inhibiting IFN synthesis [67]
HIV-1	Vif	APOBEC3G	Recruits CUL5-ELOB-ELOC E3 complex for K48-ubiquitination [70] [69]
Rotavirus	NSP1	β-TrCP	Mediates ubiquitination/degradation of β-TrCP, preventing IκB degradation [67]
Murid herpesvirus-4	ORF73	p65/RelA	Associates with E3 complex for K48-ubiquitination and degradation [67]
Poxvirus	CP77	p65/RelA	Binds NF-κB subunit, preventing nuclear translocation [67]

Experimental Approaches for Studying Viral Hijacking

DiGly Proteomics for Ubiquitinome Analysis

Mass spectrometry-based diGly proteomics has emerged as a powerful methodology for comprehensively profiling ubiquitination events during viral infection. This technique exploits the characteristic diglycine remnant that remains attached to modified lysine residues after tryptic digestion of ubiquitinated proteins [71]. The experimental workflow typically involves:

• Cell culture and infection: Primary bone marrow-derived macrophages (BMDMs) or other relevant cell types are infected with the pathogen of interest at appropriate multiplicity of infection (MOI)
• Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC): Metabolic incorporation of heavy and light isotopic labels enables quantitative comparison between experimental conditions
• Protein extraction and tryptic digestion: Cells are lysed under denaturing conditions, and proteins are digested with trypsin
• diGly peptide immunoprecipitation: Antibodies specifically recognizing the diGly remnant are used to enrich ubiquitinated peptides
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS): Enriched peptides are separated and analyzed by mass spectrometry
• Bioinformatic analysis: Computational pipelines identify and quantify ubiquitination sites, map them to specific proteins, and determine pathway enrichment

A recent application of this approach to Francisella novicida infection identified 2,491 ubiquitination sites on 1,077 proteins, revealing dynamic alterations in ubiquitination of proteins involved in cell death, phagocytosis, and inflammatory responses [71]. The study further demonstrated that type I interferon signaling significantly influenced infection-induced ubiquitination patterns, highlighting the interconnectedness of immune signaling and ubiquitin pathway regulation.

Functional Validation of Ubiquitination Events

Following proteomic identification, putative ubiquitination events require functional validation to establish their biological significance. Essential experimental approaches include:

In vitro ubiquitination assays reconstitute the ubiquitination reaction using purified E1, E2, and E3 enzymes, along with ubiquitin and the substrate protein of interest. These assays determine whether an E3 ligase can directly ubiquitinate a specific substrate and identify the linkage type formed [13].

Co-immunoprecipitation and Western blotting assess protein-protein interactions and ubiquitination status in cellulo. Critical validation steps include using ubiquitin mutants (K48R, K63R, etc.) to determine chain linkage specificity and proteasome inhibitors (MG132, bortezomib) to distinguish between degradative and non-degradative functions [72].

Gene knockdown/knockout approaches utilizing siRNA, shRNA, or CRISPR-Cas9 determine the physiological consequences of disrupting specific ubiquitination events. For instance, knockout of the E3 ligase HECTD3 impairs TRAF3 K63-linked ubiquitination and subsequent type I interferon production during F. novicida infection [71].

Diagram 1: Viral hijacking of ubiquitination pathways to evade host antiviral defense. Viruses disrupt key signaling steps through multiple mechanisms including targeted degradation, inactivation, and mislocalization of immune components.

Research Reagent Solutions for Ubiquitination Studies

Table 3: Essential Research Reagents for Studying Viral Hijacking of Ubiquitination

Reagent Category	Specific Examples	Research Applications	Key Considerations
Proteasome Inhibitors	MG132, Bortezomib, Lactacystin	Distinguish degradative vs. non-degradative ubiquitination	Multiple proteasome activities affected; may deplete free ubiquitin pools [67] [66]
Ubiquitin Mutants	K48R, K63R, K48-only, K63-only	Determine chain linkage specificity	Must be expressed in ubiquitin-deficient cells for clean interpretation
E1 Inhibitors	PYR-41, TAK-243	Block global ubiquitination	Highly toxic; limited utility in prolonged infections
DUB Inhibitors	PR-619, WP1130	Investigate deubiquitination processes	Often lack specificity; may target multiple DUBs
diGly Antibodies	Cell Signaling Technology #3925	Enrich ubiquitinated peptides for proteomics	Recognize diglycine remnant after trypsin digestion [71]
Active E2/E3 Enzymes	Recombinant UbcH5, TRIM25, TRAF6	In vitro ubiquitination assays	Require optimization of reaction conditions [13]
Ubiquitin Binding Domains	TUBEs (Tandem Ubiquitin Binding Entities)	Affinity purification of ubiquitinated proteins	Isolate endogenous ubiquitinated complexes without genetic manipulation

Concluding Perspectives and Future Directions

The intricate interplay between viruses and the host ubiquitination system represents a fascinating example of evolutionary arms race. Pathogens have developed remarkably sophisticated mechanisms to subvert atypical ubiquitination pathways, allowing them to evade immune detection and establish productive infections. The expanding repertoire of viral strategies includes encoding mimic E3 ligases and DUBs, hijacking host ubiquitination machinery, and manipulating ubiquitin-like modification systems [67] [69] [68].

Future research directions should focus on elucidating the precise functions of less-characterized atypical ubiquitin linkages (K6, K11, K29, K33) in antiviral immunity, developing more specific chemical inhibitors targeting viral ubiquitin-interacting proteins, and exploring proteolysis-targeting chimera (PROTAC) technology to artificially direct viral proteins for degradation [68]. Additionally, comparative ubiquitinome analyses across diverse viral families may reveal common vulnerability nodes that could be exploited for broad-spectrum antiviral therapeutic development.

As mass spectrometry technologies continue to advance, enabling more sensitive detection of ubiquitination dynamics in primary cells and in vivo models, our understanding of how viruses manipulate the ubiquitin code will undoubtedly deepen. These insights will not only reveal fundamental aspects of virus-host interactions but also provide novel therapeutic avenues for combating viral infectious diseases.

The ubiquitin code represents one of the most complex post-translational modification systems in eukaryotic cells, functioning as a critical regulator of innate and adaptive immune responses to viral pathogens. Comprising more than 600 E3 ligases and nearly 100 deubiquitinases (DUBs), the ubiquitin system generates an enormous diversity of signals through different chain topologies [73]. Among these, atypical ubiquitin chains—including K11/K48-branched, K11, K63, M1-linear, and other non-canonical linkages—have emerged as crucial regulators of antiviral defense mechanisms, yet they remain poorly characterized due to technological limitations. These atypical chains demonstrate remarkable functional diversity in immune signaling, from mediating the degradation of viral proteins to regulating the activity of host restriction factors [4] [74].

In the context of antiviral immunity, atypical ubiquitin chains exhibit dual roles that benefit both host defense and viral survival strategies. For instance, during HIV-1 infection, ubiquitin-like modifications (UBLs) including SUMOylation and ISG15ylation dynamically regulate both viral proteins and host restriction factors in a complex arms race [70]. The K11/K48-branched ubiquitin chains have been identified as priority degradation signals that could potentially enhance the clearance of viral proteins, while K63-linked and M1-linear chains play essential roles in activating inflammatory signaling pathways critical for antiviral responses [4] [74]. Despite their biological significance, the study of these atypical chains has been hampered by insufficient analytical tools, inadequate model systems, and limited structural information, creating critical gaps in our understanding of their precise functions in antiviral immunity.

Current Methodological Limitations and Technological Gaps

Analytical Challenges in Ubiquitin Chain Characterization

The comprehensive analysis of atypical ubiquitin chains presents substantial methodological challenges that limit progress in antiviral immunity research. Current mass spectrometry (MS)-based proteomics approaches, particularly those relying on anti-K-GG antibody enrichment, exhibit significant limitations in capturing the full complexity of the ubiquitin code. These antibodies demonstrate inherent bias toward specific amino acid contexts surrounding ubiquitination sites and fail to efficiently enrich non-lysine ubiquitination modifications [73]. Furthermore, the standard tryptic digestion used in most ubiquitomics workflows generates diGlycine (K-GG) remnants that are identical between ubiquitin, ISG15, and NEDD8 modifications, creating confounding effects in data interpretation [73].

The extraordinary structural diversity of branched ubiquitin chains compounds these analytical challenges. The K11/K48-branched ubiquitin chains have been shown to adopt different topologies in a cellular context-dependent manner, and their recognition by the proteasome involves a multivalent binding mechanism that only recently has begun to be understood [4]. Current methods struggle to distinguish between the various branched chain architectures and to quantify their relative abundances under different immunological conditions. This limitation is particularly problematic in antiviral research, where rapid changes in ubiquitin signaling occur in response to viral infection. Additionally, the low stoichiometry of these modifications, combined with their dynamic and transient nature during immune activation, creates significant obstacles for comprehensive mapping and functional characterization [73].

Limitations in Model Systems and Functional Validation

Existing model systems for studying ubiquitin in antiviral immunity fail to recapitulate the complexity of human immune responses to viral pathogens. Immune cell lines used in high-throughput screening often lack the complete repertoire of ubiquitin-system components or exhibit altered expression patterns that distort physiological signaling pathways. This is particularly problematic for studying the role of atypical ubiquitin chains in specialized immune cell types such as tissue-resident macrophages, which play crucial roles in antiviral defense but demonstrate distinct functional properties from monocyte-derived macrophages [25].

Animal models present additional limitations, as species-specific differences in ubiquitin pathway components can lead to misleading conclusions about the mechanisms of antiviral immunity. The translational gap between preclinical models and human immunology is especially pronounced for the ubiquitin system, where subtle variations in E3 ligase specificity or DUB activity can significantly alter immune outcomes. Furthermore, current models inadequately represent the dynamic interplay between different cell types during viral infection, particularly in tissue-specific microenvironments where localized immune responses occur [25]. The development of more physiologically relevant model systems, including humanized mouse models, organoid-based platforms, and sophisticated in vitro co-culture systems, is essential for advancing our understanding of atypical ubiquitin chains in antiviral defense.

Table 1: Key Technical Limitations in Atypical Ubiquitin Chain Research

Challenge Category	Specific Limitations	Impact on Antiviral Immunity Research
Analytical Methods	Anti-K-GG antibody bias toward specific amino acid contexts	Incomplete mapping of ubiquitination sites on viral and host proteins
	Inability to efficiently capture non-lysine ubiquitination	Missing regulatory modifications in immune signaling pathways
	Confounding diGlycine remnants from UBLs (ISG15, NEDD8)	Misattribution of antiviral functions between different modification types
	Difficulty in quantifying branched chain stoichiometry	Inability to determine threshold effects in immune activation
Model Systems	Immortalized cell lines with altered ubiquitin machinery	Unreliable representation of physiological antiviral responses
	Species-specific differences in ubiquitin pathways	Limited translatability from model organisms to human immunity
	Lack of tissue-specific microenvironment context	Incomplete understanding of localized immune responses to infection
	Inadequate representation of immune cell diversity	Oversimplified view of cell-type-specific ubiquitin signaling

Required Technological Advances for Next-Generation Research

Advanced Mass Spectrometry and Structural Biology Approaches

Next-generation research on atypical ubiquitin chains in antiviral immunity will require the integration of cutting-edge mass spectrometry with advanced structural biology techniques. The emerging methodology of Data-Independent Acquisition (DIA) mass spectrometry has demonstrated remarkable potential in ubiquitomics, enabling the identification of up to 110,000 ubiquitination sites in a single experiment—a significant advancement over traditional Data-Dependent Acquisition (DDA) approaches [73]. When combined with improved enrichment strategies, such as the UbiSite antibody that recognizes a 13-mer LysC digestion fragment of ubiquitin, DIA-MS can provide unprecedented coverage of the ubiquitinome during viral infection [73].

Structural biology techniques, particularly cryo-electron microscopy (cryo-EM) and cross-linking mass spectrometry (XL-MS), are essential for elucidating the molecular mechanisms by which atypical ubiquitin chains regulate antiviral immunity. Recent cryo-EM structures of the human 26S proteasome in complex with K11/K48-branched ubiquitin chains have revealed a multivalent substrate recognition mechanism involving previously unknown ubiquitin binding sites, providing critical insights into how these chains prioritize substrate degradation during viral infection [4]. XL-MS contributes complementary information by probing interacting peptides in close proximity within three-dimensional space, enabling the modeling of protein complexes and the docking of ubiquitin chains with their receptors [75]. The integration of these structural approaches with functional assays will be crucial for understanding how atypical ubiquitin chains are recognized, interpreted, and removed during antiviral immune responses.

Novel Model Systems and Functional Screening Platforms

The development of physiologically relevant model systems is paramount for advancing the study of atypical ubiquitin chains in antiviral immunity. Human organoid and tissue-chip technologies that incorporate multiple immune cell types show exceptional promise for modeling tissue-specific antiviral responses in a controlled microenvironment. These systems can capture the complexity of immune cell recruitment, activation, and effector functions while allowing precise manipulation of ubiquitin pathway components [25]. For specialized immune cells such as tissue-resident macrophages (TRMs) and microglia, which play critical roles in early antiviral defense but exhibit distinct functional properties from monocyte-derived macrophages, these advanced models may finally enable rigorous mechanistic studies [25].

CRISPR-based functional screening platforms optimized for the ubiquitin system represent another essential technological advancement. These platforms should incorporate comprehensive libraries targeting E3 ligases, DUBs, and ubiquitin receptors, combined with sophisticated readouts that can distinguish between different ubiquitin chain types. When applied in physiologically relevant model systems, such screens can identify novel components of antiviral defense mechanisms and reveal how viruses hijack specific elements of the ubiquitin system to evade immune detection. Furthermore, the development of biosensors and reporters for specific atypical ubiquitin chains would enable real-time monitoring of ubiquitin signaling dynamics during viral infection, providing unprecedented insights into the spatial and temporal regulation of these modifications in living cells.

Table 2: Essential Research Tools for Advanced Atypical Ubiquitin Chain Studies

Tool Category	Specific Technologies	Applications in Antiviral Immunity
Mass Spectrometry	Data-Independent Acquisition (DIA) MS	Comprehensive ubiquitinome mapping during viral infection
	UbiSite antibody (13-mer LysC fragment recognition)	Improved enrichment of ubiquitinated peptides with reduced bias
	Sequential PTM enrichment (ubiquitin, phosphorylation, acetylation)	Systems-level understanding of crosstalk between modifications
	TMT labeling on-beads after pulldown (UbiFast)	Multiplexed analysis of ubiquitination dynamics across conditions
Structural Biology	Cryo-electron microscopy (cryo-EM)	High-resolution structures of ubiquitin-chain/proteasome complexes
	Cross-linking MS (XL-MS)	Mapping proximity and interactions within ubiquitin-signaling complexes
	Hydrogen-deuterium exchange MS (HDX-MS)	Characterizing conformational dynamics of ubiquitin-modified proteins
	Integrated modeling with AlphaFold2 and RoseTTAFold	Predicting structures of ubiquitin-chain/receptor complexes
Model Systems	Immune-competent organoids	Studying tissue-specific antiviral responses in human systems
	Humanized mouse models	In vivo validation of antiviral mechanisms in human immune cells
	Microfluidics-based immune cell recruitment platforms	Analyzing spatial aspects of ubiquitin signaling in inflammation
	Inducible pluripotent stem cell-derived macrophages	Generating tissue-specific resident immune cells for functional studies

Experimental Approaches for Studying Atypical Ubiquitin Chains

Protocol for Comprehensive Ubiquitinome Mapping During Viral Infection

This protocol describes an integrated approach for quantifying changes in the ubiquitinome during viral infection, combining DIA mass spectrometry with sophisticated bioinformatic analysis to capture atypical ubiquitin chain dynamics.

Sample Preparation (Days 1-3):

• Cell Culture and Infection: Culture appropriate target cells (e.g., primary human macrophages or dendritic cells) in SILAC media for metabolic labeling. Infect triplicate cultures with the virus of interest at appropriate MOI, maintaining uninfected controls for comparison. Include time-course points based on the viral replication cycle (e.g., 2, 6, 12, 24 hours post-infection).
• Cell Lysis and Protein Extraction: At each time point, lyse cells in denaturing buffer (8M urea, 100mM Na₂HPO₄, pH 8.0) containing 10mM N-ethylmaleimide to preserve ubiquitination, 1x protease inhibitors, and 1x phosphatase inhibitors. Sonicate samples to disrupt nucleic acids and reduce viscosity.
• Trypsin Digestion: Reduce disulfide bonds with 5mM dithiothreitol (60 minutes, 25°C), then alkylate with 10mM iodoacetamide (30 minutes, 25°C in darkness). Dilute urea concentration to 2M with 50mM ammonium bicarbonate, then add trypsin (1:50 enzyme-to-substrate ratio) for overnight digestion at 25°C.

Ubiquitinated Peptide Enrichment (Day 4):

• Peptide Cleanup: Acidify digested peptides to pH <3 with trifluoroacetic acid, then desalt using C18 solid-phase extraction columns according to manufacturer's instructions.
• K-GG Peptide Immunoaffinity Enrichment: Resuspend peptides in immunoaffinity purification buffer (50mM MOPS, 10mM Na₂HPO₄, 50mM NaCl, pH 7.2) and incubate with anti-K-GG antibody-conjugated beads for 2 hours at 4°C with gentle rotation.
• Wash and Elution: Wash beads sequentially with IAP buffer, water, and then elute ubiquitinated peptides with 0.15% trifluoroacetic acid.

Mass Spectrometry Analysis (Day 5):

• Chromatographic Separation: Load enriched peptides onto a C18 nanoLC column (75μm × 25cm) and separate with a 120-minute gradient from 2-30% acetonitrile in 0.1% formic acid at 300nL/minute.
• DIA Mass Spectrometry: Acquire data using a DIA method consisting of one full MS1 scan (350-1650 m/z) followed by 30-50 variable windows MS2 scans. Use higher-energy collisional dissociation fragmentation with normalized collision energy of 30%.

Data Analysis (Days 6-7):

• Database Searching: Process raw files using DIA-NN software with a library-free approach against the appropriate proteome database supplemented with common contaminants.
• Ubiquitination Site Localization: Apply stringent filters (1% FDR at both peptide and protein levels) and require unambiguous localization of K-GG modifications.
• Bioinformatic Integration: Normalize ubiquitination levels to protein abundance, then perform statistical analysis to identify significantly altered ubiquitination events. Integrate with parallel phosphoproteomic and acetylomic datasets when available.

Protocol for Structural Characterization of Branched Ubiquitin Chain Complexes

This protocol describes the reconstitution and structural analysis of atypical ubiquitin chains bound to their receptors, using the example of K11/K48-branched chains with the 26S proteasome.

Sample Preparation and Complex Reconstitution:

• Ubiquitin Chain Synthesis: Generate K11/K48-branched ubiquitin chains using an engineered Rsp5 E3 ligase (Rsp5-HECT^GML) with ubiquitin K63R mutant to prevent unwanted linkage formation. Use SIC1^PY substrate (residues 1-48 of S. cerevisiae Sic1 protein) with single lysine (K40) as ubiquitination anchor.
• Proteasome Purification: Isolate human 26S proteasome from HEK293F cells using FLAG-tagged RPN11 subunit and anti-FLAG immunoaffinity chromatography, followed by size-exclusion chromatography in assay buffer (50mM HEPES, 100mM KCl, 5mM MgCl₂, 10% glycerol, 1mM ATP, pH 7.4).
• Complex Assembly: Incubate 26S proteasome (100nM) with branched ubiquitin chains (200nM) and catalytically inactive UCHL5(C88A):RPN13 complex (500nM) for 30 minutes at 25°C to stabilize the interaction.

Structural Analysis:

• Cryo-EM Grid Preparation: Apply 3.5μL of complex to glow-discharged Quantifoil R1.2/1.3 300-mesh gold grids, blot for 3-4 seconds at 100% humidity, 4°C, then plunge-freeze in liquid ethane using a Vitrobot.
• Data Collection: Acquire images using a 300kV cryo-electron microscope with K3 direct electron detector, collecting 5,000-10,000 movies at defocus range of -0.5 to -2.5μm with total dose of 50e⁻/Ų.
• Image Processing: Process data using cryoSPARC with motion correction, CTF estimation, particle picking, 2D classification, ab initio reconstruction, and heterogeneous refinement. Apply focused classification with signal subtraction to improve resolution of ubiquitin-chain binding regions.
• Model Building and Refinement: Build atomic models using Coot by docking existing structures of proteasome subunits and ubiquitin into density maps, then refine using Phenix with real-space and reciprocal-space constraints.

Future Perspectives and Concluding Remarks

The systematic investigation of atypical ubiquitin chains in antiviral immunity represents both a formidable challenge and a remarkable opportunity for therapeutic advancement. As the field moves forward, several key areas will require particular attention. First, the development of chain-specific reagents, including antibodies, affinity tools, and chemical probes that can distinguish between different atypical ubiquitin chain types, will be essential for elucidating their specific functions in immune signaling. Second, the integration of multi-omics approaches that simultaneously capture changes in the ubiquitinome, phosphoproteome, acetylome, and transcriptome during viral infection will provide a systems-level understanding of how ubiquitin signaling networks coordinate antiviral defense.

Perhaps most importantly, the translational application of basic discoveries in atypical ubiquitin chains holds tremendous promise for novel antiviral therapeutic development. Potential strategies include the development of small molecules that modulate specific E3 ligases or DUBs involved in antiviral responses, the engineering of ubiquitin variants that disrupt viral hijacking of the ubiquitin system, and the targeted delivery of ubiquitin-related therapeutics to specific immune cell populations. As our tools and model systems continue to improve, so too will our ability to harness the power of the ubiquitin system for combating viral pathogens and enhancing immune function.

Comparative Biology and Therapeutic Validation: From Bench to Bedside

Functional Comparison of Atypical Chain Types in Different Antiviral Pathways

The antiviral innate immune response constitutes the host's primary defense mechanism against viral pathogens, with its precise regulation being paramount to achieving effective viral clearance while preventing autoimmune pathology. Within this regulatory framework, ubiquitination has emerged as a critical post-translational modification that controls the stability, activity, and interactions of numerous immune signaling proteins [12]. Beyond the well-characterized K48- and K63-linked polyubiquitin chains, recent research has illuminated the significant functional roles of "atypical" ubiquitin chains, including those linked through K6, K11, K27, K29, K33, and linear (M1) linkages [3]. These atypical chains represent a sophisticated regulatory layer in antiviral signaling pathways, often exhibiting chain-type specificity and functional diversity that enables precise control over immune activation and resolution. This whitepaper provides a comprehensive technical comparison of these atypical chain types across major antiviral pathways, integrating quantitative data, experimental methodologies, and visual signaling frameworks to establish their distinct and non-redundant functions in innate immunity.

Functional Roles of Atypical Ubiquitin Chains

Atypical ubiquitin chains confer unique regulatory properties within antiviral signaling networks through their ability to form distinct structural topologies that are recognized by specific ubiquitin-binding domains. Unlike the proteasome-targeting K48 chains or the signaling-active K63 chains, the atypical linkages often serve specialized context-dependent functions [12] [3]. The functional diversity is achieved through the combinatorial action of specific E3 ligases that install these chains and deubiquitinases (DUBs) that remove them, creating dynamic modification states that precisely tune immune signaling outputs.

Table 1: Comparative Functions of Atypical Ubiquitin Chains in Antiviral Pathways

Chain Type	Key E3 Ligases	Representative Substrates	Functional Consequences	Pathway Context
K6-linked	RNF167 [8]	RIG-I, MDA5 [8]	Targets sensors to autolysosomes via p62 recognition; negative regulation [8]	RLR Signaling
K11-linked	RNF167 [8], RNF26 [3]	RIG-I/MDA5 (CTD) [8], STING [3]	Proteasomal degradation (RLRs) [8] or stabilization (STING) [3]; context-dependent negative/positive regulation	RLR Signaling, cGAS-STING
K27-linked	TRIM23 [3]	NEMO [3]	Creates platforms for effector recruitment; activates NF-κB and IRF3 [3]	RLR Signaling
K29-linked	Information not specified in search results	Information not specified in search results	Information not specified in search results	Information not specified in search results
K33-linked	Information not specified in search results	Information not specified in search results	Information not specified in search results	Information not specified in search results
Linear (M1)	LUBAC [3]	NEMO, MAVS [3]	Potentiates NF-κB signaling via NEMO binding; disrupts MAVS signalosome to inhibit type I IFN [3]	RLR Signaling, TNFα

Quantitative Data on Chain-Type Specific Effects

Systematic studies quantifying the impact of atypical ubiquitination reveal that these modifications exert profound effects on immune signaling amplitude and kinetics. Research demonstrates that K6- and K11-linked ubiquitination of RIG-I and MDA5 by RNF167 provides a particularly efficient mechanism for terminating IFN-I activation by simultaneously engaging dual degradation pathways [8]. The hierarchical organization of multi-site ubiquitination on proteins like RIG-I creates regulatory modules that exhibit superior sensitivity and robustness compared to single-site modifications [76]. For instance, mathematical modeling of RIG-I ubiquitination mechanisms revealed that hierarchical multi-site/type ubiquitination provides an optimal compromise between signaling sensitivity and robustness, with the double mutation K164R/K172R in full-length RIG-I significantly impairing ISRE activation, oligomerization, and ubiquitin conjugation compared to single mutants [76].

Table 2: Quantitative Effects of Atypical Ubiquitination on Immune Signaling

Experimental Manipulation	Signaling Output Measured	Quantitative Effect	Experimental System
RNF167 overexpression [8]	IFN-β promoter activity	Significant suppression	HEK293 cells
RNF167 knockdown [8]	IFN-β promoter activity	Enhancement	THP-1 cells
RIG-I K164/172R double mutation [76]	ISRE activation	Significant blockade	HEK293 cells with IC poly(I:C)
TRIM23-mediated K27-ubiquitination of NEMO [3]	NF-κB and IRF3 activation	Induction	RLR signaling
LUBAC-mediated linear ubiquitination [3]	NF-κB activation	Potentiation	TNFα signaling
LUBAC-mediated linear ubiquitination [3]	Type I IFN signaling	Inhibition	MAVS signalosome

Experimental Protocols for Studying Atypical Ubiquitination

Identifying Atypical Ubiquitination E3 Ligases

Genome-wide CRISPR/Cas9 Screening [8]:

• Objective: Identify novel negative regulators of IFN-I signaling.
• Procedure:
  • Perform genome-wide CRISPR knockout in a reporter cell line (e.g., THP-1 or HEK293).
  • Stimulate with viral mimetics (e.g., poly(I:C)) or viruses (e.g., Sendai virus).
  • Select cells with enhanced or suppressed IFN-responsive element activity (e.g., IFN-β-promoter-driven luciferase).
  • Validate candidates through individual sgRNA knockout and functional assays.
• Key Readouts: Luciferase activity, mRNA levels of IFNB1 and ISGs (e.g., CXCL10, IFIT1).

Validating Ubiquitination Linkage Specificity

In Vitro and Intracellular Ubiquitination Assays [8]:

• Objective: Determine specific ubiquitin linkage types catalyzed by E3 ligases.
• Procedure:
  • Co-immunoprecipitation: Express candidate E3 ligase (e.g., RNF167) with substrate (e.g., RIG-I, MDA5) and ubiquitin mutants (K6-only, K11-only, etc.) in HEK293T cells.
  • Pulldown: Immunoprecipitate substrate and probe with linkage-specific ubiquitin antibodies.
  • Mass Spectrometry: For definitive mapping, purify ubiquitinated substrates and analyze by LC-MS/MS to identify modified lysine residues and linkage types.
• Key Controls: Include catalytically inactive E3 ligase mutants (e.g., RING domain mutants).

Determining Functional Consequences

Pathway-Specific Functional Assays [8] [76]:

• Objective: Establish biological outcomes of atypical ubiquitination.
• Procedure:
  • Gene Knockout/Knockdown: Use CRISPR/Cas9 or siRNA to deplete E3 ligase in relevant cell lines (e.g., HEK293, THP-1, BMDMs).
  • Stimulation: Infect with viruses (VSV, SeV) or transfert with RNA/DNA mimetics (poly(I:C)).
  • Downstream Analysis:
    • qPCR for IFNB1, ISGs (CXCL10, IFIT1), proinflammatory genes (IL-6, CXCL1).
    • Immunoblotting for phospho-IRF3, total protein levels.
    • Viral titer quantification by plaque assay.
  • Rescue Experiments: Reconstitute with wild-type or catalytically inactive E3 ligase in knockout cells.

Research Reagent Solutions

Table 3: Essential Research Reagents for Studying Atypical Ubiquitination

Reagent Category	Specific Examples	Function/Application	Key Characteristics
Ubiquitin Mutants	K6-only, K11-only, K27-only, K29-only, K33-only, M1-only ubiquitin [8]	Determine linkage specificity in ubiquitination assays	All lysines except one mutated to arginine
Cell Lines	HEK293, THP-1, BMDMs, RNF167-KO HEK293 [8]	Provide cellular context for signaling studies	KO lines enable study of specific E3 function
Viral Stimuli	Sendai virus (SeV), Vesicular Stomatitis Virus (VSV), Encephalomyocarditis virus (EMCV) [8]	Activate RLR and other innate immune pathways	Different viruses preferentially activate specific sensors
Viral Mimetics	Poly(I:C) (low molecular weight for RIG-I; high molecular weight for MDA5) [76]	Specific activation of RNA sensing pathways	Synthetic double-stranded RNA analogs
E3 Ligase Tools	RNF167 overexpression plasmids, siRNA, CRISPR sgRNA [8]	Manipulate E3 ligase expression levels	Catalytically inactive mutants serve as crucial controls
Reporter Assays	IFN-β-promoter-luciferase, PRDIII-I-luciferase, ISRE-luciferase, NF-κB-luciferase [8] [76]	Quantify pathway activation	Enable high-throughput screening
Linkage-Specific Antibodies	Anti-K6, anti-K11, anti-K27, anti-linear ubiquitin antibodies [3] [8]	Detect specific ubiquitin chain types in immunoblot/IP	Essential for validating linkage specificity

Atypical Ubiquitin Chain Signaling Pathways

Diagram 1: Atypical Ubiquitin Regulation of RLR Signaling. This pathway illustrates how atypical ubiquitin chains differentially regulate RIG-I-like receptor (RLR) signaling. RNF167-mediated K6- and K11-linked ubiquitination targets RIG-I/MDA5 for degradation via autophagic and proteasomal pathways, respectively (negative regulation) [8]. TRIM23 installs K27-linked chains on NEMO to promote NF-κB activation (positive regulation) [3]. LUBAC-generated linear chains potentiate NF-κB signaling through NEMO but can inhibit type I IFN by disrupting the MAVS signalosome (context-dependent regulation) [3].

Atypical ubiquitin chains represent a sophisticated regulatory code that enables precise control over antiviral immune responses through chain-type-specific functions. K6-, K11-, K27-, and M1-linked ubiquitination collectively fine-tune signaling amplitude, duration, and outcome across RLR, cGAS-STING, and other innate immune pathways. The functional specialization of these modifications—with some promoting proteolytic degradation while others create platforms for signal activation—demonstrates remarkable evolutionary adaptation of the ubiquitin system for immune regulation. Future research elucidating the full spectrum of E3 ligases, DUBs, and ubiquitin-binding effectors specific to these atypical chains will undoubtedly reveal new therapeutic opportunities for manipulating immune responses in viral infection, autoimmunity, and cancer.

The intricate cross-talk between post-translational modifications (PTMs) forms a complex regulatory network that fine-tunes cellular signaling pathways. While the roles of classical ubiquitin chains and phosphorylation have been extensively studied, the functions of atypical ubiquitin chains (K6-, K11-, K27-, K29-, K33-linked) and their interplay with other PTMs, particularly SUMOylation and phosphorylation, remain emerging frontiers in cell signaling research. This interplay is especially critical in the context of antiviral immune responses, where precise regulation of signal transduction determines the outcome of host-pathogen interactions. This technical review comprehensively examines the molecular mechanisms governing the cross-talk between atypical ubiquitination, SUMOylation, and phosphorylation, with emphasis on experimental approaches for investigating these dynamic relationships and their implications for therapeutic development.

Protein function is extensively regulated through post-translational modifications, with ubiquitination and SUMOylation representing two crucial reversible modifications that control virtually every cellular process. The complexity of ubiquitination extends beyond the well-characterized K48- and K63-linked chains to include "atypical" ubiquitin linkages formed through K6, K11, K27, K29, and K33, as well as linear (M1-linked) chains [11]. These atypical chains create a sophisticated ubiquitin code that can direct diverse functional outcomes beyond proteasomal degradation, including protein activation, subcellular localization, and participation in complex signaling networks [3].

The functional landscape of PTMs is further complicated by extensive cross-talk, where one modification influences or is influenced by another. This review focuses specifically on the interplay between atypical ubiquitination and two other critical PTMs: SUMOylation and phosphorylation. Understanding this cross-talk is particularly relevant in antiviral innate immunity, where precise regulation of signaling pathways ensures effective pathogen clearance while preventing excessive inflammation and autoimmunity [24].

Atypical Ubiquitin Chains: Structure, Function, and Enzymatic Regulation

Classification and Structural Features

Atypical ubiquitin chains are defined by their non-K48/K63 linkage topology and exhibit distinct structural properties that determine their specific recognition by ubiquitin-binding domains (UBDs). The human genome encodes seven lysine residues in ubiquitin (K6, K11, K27, K29, K33, K48, K63) that can form polyubiquitin chains, plus the N-terminal methionine (M1) for linear chains [77]. While K48- and K63-linked chains are considered "classical," the remaining linkages (K6, K11, K27, K29, K33, M1) constitute the atypical ubiquitin family.

Structural studies have revealed that each linkage type generates unique chain conformations that are specifically recognized by dedicated receptor proteins. For instance, K11-linked chains adopt compact conformations that can target substrates for proteasomal degradation, similar to K48-linked chains, while K63-linked and linear chains form more extended structures that facilitate protein-protein interactions and signaling complex assembly [11].

Functional Roles in Cellular Signaling

Table 1: Functions of Atypical Ubiquitin Linkages in Innate Immune Signaling

Ubiquitin Linkage	E3 Ligase Examples	Substrate Examples	Functional Outcome	References
K6-linked	RNF167	RIG-I/MDA5	Targets substrates for autophagic degradation via p62 recognition	[8]
K11-linked	RNF26, RNF167	STING, RIG-I/MDA5	Regulates proteasomal degradation; modulates STING stability	[11] [8]
K27-linked	TRIM23, TRIM40	NEMO, RIG-I, MDA5	Activates NFκB and IRF3; can also target RIG-I/MDA5 for degradation	[11]
K29-linked	SKP1-Cullin-Fbx21	ASK1	Induces IFNβ and IL-6 production	[11]
K33-linked	RNF2	STAT1	Suppresses ISG transcription	[11]
Linear (M1-linked)	LUBAC	NEMO, MAVS	Potentiates NFκB signaling; inhibits type I IFN signaling	[11]

Atypical ubiquitin chains play particularly important roles in the regulation of antiviral innate immune responses. For example, RNF167-mediated K6- and K11-linked ubiquitination of RIG-I and MDA5 targets these viral RNA sensors for degradation through dual proteolytic pathways – K6-linked chains direct substrates to autolysosomes via the autophagy adaptor p62, while K11-linked chains facilitate proteasomal degradation [8]. This coordinated degradation mechanism represents an efficient negative feedback system to prevent excessive type I interferon activation.

Enzymatic Machinery

The ubiquitination cascade involves the sequential action of E1 (activating), E2 (conjugating), and E3 (ligating) enzymes. Humans encode two Ub-specific E1 enzymes (Uba1 and Uba6), approximately 35 E2 enzymes, and over 600 E3 ligases that provide substrate specificity [78] [79]. The E3 ligases are classified into three major families: RING (Really Interesting New Gene), HECT (Homologous to E6-associated protein C-terminus), and RBR (RING-in-Between-RING) types [78].

Deubiquitinating enzymes (DUBs) counterbalance ubiquitination by removing ubiquitin chains, with nearly 100 DUBs encoded in the human genome belonging to seven structural families [79]. The dynamic equilibrium between ubiquitination and deubiquitination allows for precise temporal control of signaling events.

Molecular Mechanisms of PTM Interplay

SUMOylation and Ubiquitination Cross-Talk

SUMOylation involves the covalent attachment of Small Ubiquitin-like Modifier (SUMO) proteins to lysine residues of target proteins through a cascade analogous to ubiquitination, comprising E1 (SAE1-SAE2), E2 (UBC9), and E3 ligases, with reversal by SENP proteases [80]. The SUMO family includes SUMO1-3, with SUMO2/3 sharing >97% sequence similarity but only 50% homology with SUMO1 [80].

Table 2: Mechanisms of Cross-Talk Between SUMOylation and Ubiquitination

Cross-Talk Mechanism	Molecular Basis	Functional Outcome	Example
SUMO-directed ubiquitination	SUMO modification creates recognition motif for SUMO-targeted ubiquitin ligases (STUbLs)	Targets substrate for proteasomal degradation	RNF4 recognizes SUMOylated proteins for ubiquitination
Competitive modification	SUMOylation and ubiquitination compete for the same lysine residue	Determines substrate stability and function	Simultaneous modification prevented by steric hindrance
Sequential modification	One modification primes the substrate for the other	Fine-tunes protein activity and interactions	SUMOylation preceding ubiquitination in DNA repair proteins
Modification-regulated enzyme activity	SUMOylation controls ubiquitin E3 ligase activity or vice versa	Alters global modification landscape	SUMOylation of E3 ligases affects their substrate specificity

In breast cancer models, SUMOylation interacts extensively with other PTMs, particularly ubiquitination. Typically, SUMOylation is regulated by phosphorylation and exerts feedback control on subsequent ubiquitination, acetylation, or methylation [80]. These cross-talk pairs can either promote or inhibit breast cancer progression in a protein-specific and site-specific manner. The molecular mechanisms underlying this cross-talk include alterations in amino acid side chain charges, protein conformations, or occupation of specific domains or sites [80].

Phosphorylation and Ubiquitination Interplay

Phosphorylation frequently serves as a priming event that directs subsequent ubiquitination, or vice versa, creating sophisticated regulatory circuits. In the context of antiviral immunity, phosphorylation events often regulate the activity of E3 ubiquitin ligases or determine the recognition of substrates by these ligases.

For instance, phosphorylation of Krüppel-like factor 8 (KLF8) at Ser-80 is required for its SUMOylation at Lys-67 upon DNA damage in breast cancer cells, representing a phosphorylation-directed SUMOylation mechanism that promotes DNA repair and cell survival [80]. While this example comes from cancer biology, similar mechanisms operate in immune signaling pathways.

Integrated PTM Cross-Talk in Antiviral Signaling

The RIG-I-like receptor (RLR) pathway, which detects viral RNA in the cytosol, exemplifies sophisticated PTM cross-talk. RIG-I activation involves TRIM25-mediated K63-linked ubiquitination, which is essential for its interaction with MAVS and downstream signaling. However, this process is counterbalanced by atypical ubiquitination events – RNF167-mediated K6- and K11-linked ubiquitination targets activated RIG-I and MDA5 for degradation through both proteasomal and autophagic pathways, preventing excessive interferon production [8].

Additionally, linear (M1-linked) ubiquitination by LUBAC complex modulates both RLR and NFκB signaling. LUBAC-mediated linear ubiquitination of NEMO potentiates NFκB activation while simultaneously disrupting the MAVS-TRAF3 interaction, thereby inhibiting IRF3 activation and creating a balanced immune response [11].

Diagram 1: PTM Cross-Talk in RLR-mediated Antiviral Signaling. Solid arrows represent activation; barred lines represent inhibition; dashed arrows illustrate cross-talk relationships between different PTMs.

Experimental Approaches for Investigating PTM Interplay

Proteomic Strategies for PTM Mapping

Advanced mass spectrometry (MS)-based proteomics has revolutionized the study of PTM cross-talk by enabling comprehensive identification and quantification of modification sites. Several specialized approaches have been developed:

Ubiquitin Remnant Profiling: Utilizes antibodies specific for diGlycine remnants left after tryptic digestion of ubiquitinated proteins to enrich and identify ubiquitination sites. This approach can be adapted to distinguish atypical chain linkages using linkage-specific antibodies or ubiquitin binding domains.

SUMO Proteomics: Employs SUMO mutants (e.g., His-HA-SUMO1/Q87R or SUMO2/Q87R) that resist deSUMOylation during purification, enabling efficient enrichment of SUMOylated proteins for MS analysis.

Sequential PTM Enrichment: Involves consecutive purification steps to isolate proteins containing multiple PTMs, enabling direct identification of cross-talk events.

Cross-Linking MS: Helps map interfaces between modified proteins and their effectors, providing structural insights into how PTMs regulate protein interactions.

Functional Validation Approaches

Linkage-Specific Ubiquitin Tools: The development of linkage-specific ubiquitin antibodies and ubiquitin-binding domains (UBDs) has enabled precise tracking of atypical chain formation. For example, the use of ubiquitin mutants where all lysines except one are mutated to arginine allows researchers to study the function of specific linkage types in isolation.

Chemical Biology Strategies: Activity-based probes (ABPs) that mimic ubiquitin or SUMO can capture active enzymes in the ubiquitination/SUMOylation machinery. DUB inhibitors with linkage specificity help dissect the functions of particular chain types.

Genetic Manipulation: CRISPR/Cas9-mediated knockout of specific E3 ligases, DUBs, or SUMO proteases, combined with reconstitution with wild-type or mutant forms, enables functional dissection of PTM cross-talk in relevant cellular models.

Research Reagent Solutions for PTM Studies

Table 3: Essential Research Tools for Investigating Atypical Ubiquitin and PTM Cross-Talk

Reagent Category	Specific Examples	Research Application	Technical Considerations
Linkage-Specific Antibodies	Anti-K6-Ub, Anti-K11-Ub, Anti-K27-Ub, Anti-K29-Ub, Anti-K33-Ub, Anti-M1-Ub	Immunoblotting, immunofluorescence, immunoprecipitation	Varying specificity and sensitivity across vendors; requires validation with linkage-specific standards
Ubiquitin Mutants	Ub-K6R, Ub-K11R, Ub-K27R, Ub-K48R, Ub-K63R, Ub-K0 (all lysines to arginine)	Define specific chain linkages in functional studies	Expression in tandem with wild-type ubiquitin to assess linkage specificity
Activity-Based Probes	HA-Ub-VS, HA-Ub-Br2, SUMO1/2/3-VS	Profiling E1/E2/E3 enzyme activities and DUB/SUMO protease substrates	Cell-permeable forms available for in situ labeling
PTM Inhibitors	MLN7243 (E1 inhibitor), Nutlin-3 (MDM2 inhibitor), G5 (USP7 inhibitor), 2-D08 (SUMO E1 inhibitor)	Functional dissection of specific PTM pathways	Varying selectivity; off-target effects should be controlled
CRISPR Libraries	Genome-wide sgRNA libraries, E3/DUB-focused sub-libraries	High-throughput identification of PTM regulators	Requires validation with complementary approaches
Mass Spec Standards	SILAC, TMT/iTRAQ with diGly peptide standards, SUMO peptide standards	Quantitative PTM proteomics	Heavy-labeled atypical ubiquitin reference peptides improve identification

Therapeutic Implications and Drug Discovery

Targeting PTM pathways represents a promising therapeutic strategy, particularly in oncology and inflammatory diseases. Several approaches have shown clinical potential:

Proteasome Inhibitors: Bortezomib, carfilzomib, and ixazomib are FDA-approved for multiple myeloma and mantle cell lymphoma, validating the ubiquitin-proteasome system as a drug target [77]. These compounds primarily affect the degradation of K48-linked ubiquitinated substrates but have indirect effects on other PTM pathways.

E1 Enzyme Inhibitors: MLN4924 (Pevonedistat) inhibits NEDD8-activating enzyme, disrupting Cullin-RING ligase activity, and has shown promise in clinical trials for hematological malignancies [81].

E3 Ligase Modulators: Nutlin-3 disrupts the MDM2-p53 interaction, stabilizing tumor suppressor p53 [77]. Similarly, compounds targeting the interaction between BRCA1 and BARD1 are under investigation.

DUB Inhibitors: Several DUB-targeting compounds are in preclinical development, including USP7, USP14, and UCHL1 inhibitors, with potential applications in cancer and neurodegenerative diseases [79].

PROTAC Technology: Proteolysis-Targeting Chimeras (PROTACs) harness the ubiquitin system to selectively degrade target proteins, with several candidates in clinical trials for cancer treatment [79].

The emerging understanding of atypical ubiquitin chains and their cross-talk with other PTMs opens new avenues for therapeutic intervention. For instance, developing inhibitors that specifically target the enzymes responsible for pro-inflammatory atypical ubiquitination events (e.g., K27-linked chains in NFκB activation) could provide more selective anti-inflammatory drugs with reduced side effects.

The complex interplay between atypical ubiquitin chains, SUMOylation, and phosphorylation represents a sophisticated regulatory layer that fine-tunes cellular signaling pathways, with particular importance in antiviral immunity and cancer biology. The functional outcomes of this cross-talk are highly context-dependent, influenced by cell type, subcellular localization, and the specific modification sites involved.

Future research directions should focus on developing more specific tools to manipulate individual PTM pathways without disrupting global cellular homeostasis, elucidating the structural basis of cross-talk recognition, and understanding how PTM networks are rewired in disease states. The integration of multi-omics approaches, including ubiquitin/SUMO proteomics, phosphoproteomics, and advanced imaging techniques, will provide unprecedented insights into the dynamic coordination of these essential regulatory mechanisms.

As our understanding of PTM cross-talk deepens, so too will opportunities for therapeutic intervention in cancer, autoimmune diseases, and infectious diseases where dysregulated PTM signaling contributes to pathogenesis.

The ubiquitin system, particularly its atypical chains, represents a crucial regulatory layer in the antiviral innate immune response. While the roles of K48- and K63-linked ubiquitin chains are well-established, recent research has illuminated the significance of atypical ubiquitin chains (K6-, K11-, K27-, K29-, K33-linked, and linear/M1-linked) in finely tuning immune signaling pathways. This technical review examines how mutations and dysregulations within the atypical ubiquitin system components contribute to disease pathogenesis, offering mechanistic insights into immune homeostasis. By synthesizing findings from recent studies, we provide a comprehensive framework for understanding how atypical ubiquitination controls antiviral defense mechanisms and how its disruption leads to pathological conditions, with direct implications for therapeutic development.

Ubiquitination is a sophisticated post-translational modification system that employs a diverse coding language to regulate protein function, localization, and stability. The process involves the sequential action of E1 activating, E2 conjugating, and E3 ligase enzymes that covalently attach ubiquitin to target proteins, while deubiquitinases (DUBs) provide the counterbalancing removal mechanism [12] [48]. What makes ubiquitination particularly complex is the ability of ubiquitin molecules to form polymers through different linkage types—connecting the C-terminus of one ubiquitin to specific lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminal methionine (M1) of another ubiquitin molecule [36] [41].

The so-called "atypical" ubiquitin chains encompass all non-K48-linked ubiquitin polymers, though some researchers now exclude K63-linked chains from this categorization as their functions become better characterized. These atypical linkages, including K6, K11, K27, K29, K33, and M1-linear chains, have emerged as critical regulators of innate immune signaling, operating through both proteolytic and non-proteolytic mechanisms [11] [36]. The functional diversity of these chains is remarkable—K11-linked chains are often associated with proteasomal degradation similar to K48-linked chains, while K63-linked and M1-linear chains typically facilitate protein-protein interactions and signaling complex assembly [82]. The more recently characterized atypical chains (K6, K27, K29, K33) exhibit a mixture of functions that are still being elucidated.

In the context of antiviral immunity, pattern recognition receptors (PRRs) including RIG-I-like receptors (RLRs), Toll-like receptors (TLRs), and cytosolic DNA sensors (e.g., cGAS) initiate signaling cascades that converge on transcription factors NF-κB and IRF3/7, driving the production of type I interferons (IFNs) and proinflammatory cytokines [11] [12]. Atypical ubiquitin chains precisely regulate each step of these pathways, from receptor activation to signal termination, ensuring an effective but controlled immune response. Disruption of this delicate balance through mutations in ubiquitin system components can lead to either inadequate antiviral defense or excessive inflammation and autoimmunity.

Molecular Mechanisms of Atypical Ubiquitin Chains in Immune Regulation

Linkage-Specific Functions and Regulatory Networks

Table 1: Functions of Atypical Ubiquitin Chains in Antiviral Innate Immunity

Ubiquitin Linkage	Modifying Enzyme	Substrate	Functional Outcome	References
Linear (M1)	LUBAC	NEMO	Potentiates NF-κB activation	[11]
K11	RNF26	STING	Inhibits STING degradation, enhancing IFN production	[11]
K27	TRIM23	NEMO	Activates NF-κB and IRF3 pathways	[11]
K27	RNF185	cGAS	Induces IRF3 activation and cytokine production	[11]
K27 & K29	RNF34	MAVS	Induces autophagy-mediated degradation of MAVS	[11]
K29	SKP1-Cullin-Fbx21	ASK1	Induces IFNβ and IL-6 production	[11]
K33	USP38 (DUB)	TBK1	Prevents TBK1 degradation, enhances IRF3 activation	[11]
K6 & K11	RNF167	RIG-I/MDA5	Targets RLRs for degradation via proteasome and autophagy	[8]

The regulatory functions of atypical ubiquitin chains in antiviral signaling are both linkage-specific and context-dependent. K27-linked ubiquitination exemplifies this specificity, with diverse outcomes depending on the substrate and cellular context. TRIM23-mediated K27-linked ubiquitination of NEMO activates both NF-κB and IRF3 signaling pathways, promoting antiviral gene expression [11]. Conversely, TRIM40 catalyzes K27-linked chains on RIG-I and MDA5, inducing their proteasomal degradation and thus negatively regulating the type I IFN response [11]. Similarly, MARCH8 uses K27-linkages to target MAVS for autophagy-mediated degradation, providing another mechanism for signal attenuation [11].

K11-linked chains have been implicated in the regulation of key immune adaptors. RNF26-mediated K11-linked ubiquitination of STING prevents its degradation, thereby enhancing type I IFN and cytokine production [11]. The K11 linkage appears to serve as a stabilization signal in this context, contrary to its more conventional association with proteasomal degradation in cell cycle regulation.

The emerging role of K6-linked ubiquitination in immune regulation has been highlighted by recent research on RNF167, which simultaneously facilitates both K6- and K11-linked polyubiquitination of RIG-I and MDA5 [8]. This dual modification strategy targets the viral RNA sensors for degradation through two distinct proteolytic pathways—K6-linked ubiquitination in the CARD domains recruits the autophagy cargo adaptor p62, directing substrates to autolysosomes for selective autophagic degradation, while K11-linked polyubiquitination in the CTD domains leads to proteasome-dependent degradation [8]. This coordinated mechanism represents an efficient strategy for controlling the amplitude and duration of IFN-I activation.

Branched ubiquitin chains containing multiple atypical linkages further expand the regulatory complexity. For instance, branched K48/K63 chains are produced through collaboration between TRAF6 and HUWE1 during NF-κB signaling, while UBR5 and ITCH generate similar branched chains on the apoptotic regulator TXNIP [41]. The order of linkage assembly can determine the functional outcome—conversion of non-degradative K63-linked chains to degradative K48-linked chains provides a temporal mechanism for switching from signal activation to termination.

Structural Basis of Atypical Ubiquitin Chain Signaling

The structural properties of atypical ubiquitin chains underlie their specific functions in immune signaling. Linear ubiquitin chains, uniquely synthesized by the linear ubiquitin chain assembly complex (LUBAC), adopt an extended conformation that enables specific recognition by ubiquitin-binding domains (UBDs) [11] [83]. The UBAN domain of NEMO exhibits strong binding preference for linear chains, and this interaction is essential for NF-κB activation [11]. Structural analyses reveal that Lys6-linked chains form compact structures through an asymmetric interface involving Ile44 and Ile36 hydrophobic patches of neighboring ubiquitin moieties [83]. These structural features create distinct surfaces that are recognized by specific effector proteins, allowing for precise regulation of immune signaling pathways.

Figure 1: Atypical ubiquitin chains regulate multiple steps in antiviral signaling pathways, providing both positive and negative regulatory checkpoints.

Disease-Associated Mutations and Dysregulations

Experimental Models Revealing Pathological Mechanisms

Table 2: Disease-Relevant Mutations in Atypical Ubiquitin System Components

Disease/Condition	Genetic Alteration	Molecular Consequence	Experimental Model	References
Autoimmune Susceptibility	RNF167 overexpression	Enhanced degradation of RIG-I/MDA5 via K6/K11 ubiquitination	RNF167-/- mice, Human cell lines	[8]
Viral Pathogenesis	Viral exploitation of host E3s	Subversion of immune signaling through atypical ubiquitination	Bacterial NleL studies, Viral infection models	[82] [83]
Inflammatory Disease	LUBAC dysregulation	Aberrant linear ubiquitination affecting NF-κB signaling	Cell-based signaling studies	[11]
Cancer Pathways	TRIM family mutations	Disrupted K27-linked signaling in immune regulation	Tumor models, CRISPR screens	[11] [8]

The generation of RNF167 knockout mouse models has provided crucial insights into how dysregulation of atypical ubiquitination leads to immune pathology. Rnf167-/- mice on a C57BL/6J background display enhanced antiviral responses and reduced viral replication following infection [8]. At the molecular level, RNF167 deficiency results in elevated mRNA levels of IFNB1 and downstream antiviral ISGs (CXCL10, IFIT1) and proinflammatory genes (CXCL1, IL-6) following viral challenge [8]. These findings position RNF167 as a critical negative regulator of RLR signaling whose dysregulation could contribute to autoimmune pathology.

The RNF167 mechanistic studies reveal a sophisticated degradation strategy for controlling RLR activity. RNF167 facilitates both K6- and K11-linked polyubiquitination of RIG-I and MDA5, but targets different protein domains for distinct degradation pathways [8]. K6-linked ubiquitination within the CARD domains recruits the autophagy cargo adaptor p62, directing RLRs to autolysosomes for selective autophagic degradation. Simultaneously, K11-linked polyubiquitination in the CTD domains leads to proteasome-dependent degradation [8]. This dual-pathway degradation represents a robust mechanism for preventing excessive IFN activation, and its disruption could underlie certain autoimmune conditions.

Viral exploitation of the atypical ubiquitin system represents another disease mechanism. Bacteria such as enterohaemorrhagic Escherichia coli O157:H7 utilize effector proteins like NleL (Non-Lee-encoded effector ligase) to assemble K6- and K48-linked ubiquitin chains, disrupting host immune responses [83]. NleL generates heterotypic Ub chains comprising both Lys6- and Lys48-linkages in the same polymer, creating atypical ubiquitin signals that interfere with normal immune signaling [83]. This microbial strategy highlights the therapeutic potential of targeting atypical ubiquitination in infectious disease.

Branched ubiquitin chains have been implicated in disease-relevant signaling mechanisms. For instance, UBR5-mediated formation of branched K48/K63 chains on TXNIP converts this non-degradative signal to a degradative mark, efficiently regulating the activation and inactivation of signaling proteins [41]. Disruption of this branching mechanism could lead to sustained inflammatory signaling and tissue damage.

Experimental Approaches and Methodologies

Advanced Techniques for Studying Atypical Ubiquitination

The study of atypical ubiquitin chains requires specialized methodologies due to their structural complexity and low abundance relative to conventional ubiquitin linkages. Linkage-specific deubiquitinases (DUBs) have emerged as powerful tools for "ubiquitin chain restriction analysis" analogous to DNA restriction enzymes [83]. OTUB1 (Lys48-specific) and OTUD3 (Lys6-preferential) can be used to differentially cleave heterotypic ubiquitin chains and determine their architecture [83]. This approach revealed that NleL-assembled free Ub chains comprise both Lys6- and Lys48-linkages, with Lys6-linkages predominating in longer stretches [83].

CRISPR/Cas9 screening platforms have enabled the systematic identification of ubiquitin system components regulating antiviral signaling. Genome-wide CRISPR screens identified RNF167 as a negative regulator of IFN-I signaling, highlighting the power of unbiased functional genomics approaches [8]. Subsequent validation in RNF167 knockout cell lines demonstrated enhanced viral infection-triggered antiviral gene expression and attenuated VSV replication, confirming the functional significance of this regulatory mechanism [8].

Structural biology techniques including crystallography and NMR spectroscopy have provided insights into the architecture of atypical ubiquitin chains. Analysis of Lys6-linked diUb reveals an asymmetric interface between Ile44 and Ile36 hydrophobic patches of neighbouring ubiquitin moieties, which is propagated in longer Lys6-linked Ub chains [83]. These structural insights help explain how specific UBDs recognize particular linkage types.

Biochemical assembly systems utilizing bacterial E3 ligases like NleL have enabled large-scale production of atypical ubiquitin chains for functional studies [83]. These systems overcome the limitations of chemical biology protocols and allow generation of sufficient material for detailed biophysical and functional characterization.

Figure 2: Experimental workflow for characterizing atypical ubiquitin chains, integrating biochemical, genetic, and structural approaches.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagents for Studying Atypical Ubiquitin Chains

Reagent Category	Specific Examples	Function/Application	Key Features
Linkage-Specific DUBs	OTUB1 (K48-specific), OTUD3 (K6-preferential), vOTU (broad specificity)	Ubiquitin chain restriction analysis; linkage determination	Selective cleavage of specific ubiquitin linkages
Ubiquitin Mutants	K6R, K11R, K27R, K48R ubiquitin point mutants	Determining linkage specificity of E3 ligases and DUBs	Prevents formation of specific linkage types
Recombinant E3 Ligases	NleL (bacterial, produces K6/K48 chains), LUBAC (linear chains)	Enzymatic synthesis of atypical ubiquitin chains	Large-scale production of specific linkage types
CRISPR Tools	RNF167 guide RNAs, knockout cell lines, Rnf167-/- mice	Functional validation of ubiquitin system components	Enables study of loss-of-function phenotypes
Linkage-Specific Antibodies	Anti-K27-linkage, anti-linear ubiquitin antibodies	Detection and quantification of specific chain types	Immunoblotting, immunofluorescence applications
Reporter Systems	IFN-β-promoter-luciferase, PRDI-III-I reporters	Assessing functional consequences of ubiquitination	High-throughput screening of regulatory effects

The research toolkit for investigating atypical ubiquitin chains has expanded significantly, enabling more precise interrogation of their biological functions. Linkage-specific DUBs serve as critical analytical tools, with OTUB1 specifically cleaving K48-linkages while OTUD3 shows preference for K6-linkages [83]. These enzymes allow "deconstruction" of heterotypic ubiquitin chains to determine their architecture and composition.

Ubiquitin mutant systems where specific lysine residues are mutated to arginine (e.g., K6R, K48R) prevent formation of particular linkage types, enabling researchers to determine the linkage specificity of E3 ligases and the functional requirements for specific chains in signaling pathways [83]. The double mutant K6R K48R ubiquitin completely abrogates NleL-mediated ubiquitin chain formation, confirming its linkage specificity [83].

Recombinant E3 ligases from bacterial sources have proven particularly valuable for producing atypical ubiquitin chains in sufficient quantities for structural and functional studies. NleL from EHEC O157:H7 efficiently assembles Lys6- and Lys48-linked Ub polymers, providing a reliable source of these atypical chains [83]. Similarly, the linear ubiquitin chain assembly complex (LUBAC) can be utilized to generate M1-linear chains.

CRISPR-based tools have revolutionized functional studies of the ubiquitin system. The generation of RNF167-deficient single cell clones using CRISPR/Cas9 revealed enhanced mRNA levels of IFNB1 and antiviral ISGs following viral infection, establishing RNF167 as a negative regulator of RLR signaling [8]. In vivo models including Rnf167-/- mice provide physiological context for these findings.

Therapeutic Implications and Future Perspectives

The intricate regulation of antiviral signaling by atypical ubiquitin chains presents numerous therapeutic opportunities. Components of the atypical ubiquitin system represent potential targets for manipulating immune responses in autoimmune diseases, chronic inflammatory conditions, and cancer. The development of small molecules targeting specific E3 ligases or DUBs could allow precise modulation of immune signaling pathways.

The discovery that RNF167 expression is induced by viral infection and IFN-I treatment suggests it functions as part of a negative feedback loop to prevent excessive immune activation [8]. Therapeutic inhibition of RNF167 could potentially enhance antiviral responses in immunocompromised individuals, while RNF167 augmentation might benefit patients with autoimmune conditions characterized by chronic IFN production.

The structural insights into atypical ubiquitin chains provide a foundation for rational drug design. The compact conformation of Lys6-linked chains and their distinct interfaces offer potential binding pockets for small molecule inhibitors [83]. Similarly, the extended structure of linear ubiquitin chains presents unique surfaces that could be targeted therapeutically.

Future research directions should include comprehensive profiling of atypical ubiquitin chain signatures in human diseases, development of more specific research tools and modulators, and exploration of combination therapies targeting multiple components of the ubiquitin system. The emerging understanding of branched ubiquitin chains and their functions in immune regulation represents another promising avenue for therapeutic intervention [41].

As our knowledge of atypical ubiquitin chains in antiviral immunity continues to expand, so too will opportunities for translating these insights into novel treatment strategies for immune-related diseases. The lessons from disease-associated mutations in atypical ubiquitin system components provide both fundamental biological insights and practical therapeutic guidance for targeting this sophisticated regulatory system.

Targeted protein degradation (TPD) has emerged as a transformative therapeutic paradigm that fundamentally shifts drug discovery from inhibiting protein function to eliminating disease-causing proteins entirely [84]. This approach harnesses the cell's natural protein quality control machinery—primarily the ubiquitin-proteasome system (UPS)—to selectively degrade proteins previously considered "undruggable" by conventional small-molecule inhibitors [84] [85]. The core TPD modalities include proteolysis-targeting chimeras (PROTACs), molecular glue degraders, and E3 ligase modulators, which collectively enable the targeted degradation of transcription factors, scaffolding proteins, and other non-enzymatic proteins that have historically evaded therapeutic intervention [84] [86]. These technologies create a paradigm shift in pharmaceutical development by exploiting the cell's intrinsic degradation machinery rather than merely blocking active sites.

The significance of TPD technologies extends across therapeutic areas, with substantial implications for antiviral strategies. The ubiquitin-proteasome system plays a critical role in regulating the antiviral innate immune response, where different ubiquitin linkage types create a complex regulatory code that either activates or suppresses immune signaling pathways [11] [12]. Atypical ubiquitin chains—those beyond the well-characterized K48 and K63 linkages—are increasingly recognized as key regulators of intracellular antiviral signaling [11]. By understanding and exploiting these mechanisms, researchers can design degraders that target viral proteins directly or modulate host proteins essential for viral replication, thereby opening new avenues for combating viral infections including SARS-CoV-2 [87] [88].

Molecular Mechanisms and Comparative Analysis of TPD Technologies

Fundamental Mechanisms of Action

PROTACs (Proteolysis-Targeting Chimeras) are heterobifunctional molecules consisting of three elements: a warhead that binds to the protein of interest (POI), a ligand that recruits an E3 ubiquitin ligase, and a chemical linker connecting these two moieties [84] [89]. The PROTAC mechanism involves the simultaneous engagement of both the target protein and an E3 ubiquitin ligase, forming a productive ternary complex that facilitates the transfer of ubiquitin chains to the target protein [86]. This ubiquitination marks the protein for recognition and degradation by the 26S proteasome [88]. A key advantage of PROTACs is their catalytic nature; after degrading one target molecule, they are released and can engage additional POI molecules, enabling potent depletion at sub-stoichiometric concentrations [84].

Molecular Glues represent a distinct class of monovalent degraders that typically function by inducing or stabilizing novel protein-protein interactions between an E3 ubiquitin ligase and a target protein [84] [85]. Unlike PROTACs, molecular glues are not necessarily bifunctional in design but instead act by subtly remodeling the interaction surfaces of proteins or E3 ligases, creating novel binding interfaces that would not otherwise occur naturally [84]. This surface remodeling induces proximity between an E3 ligase and a target protein, leading to ubiquitination and subsequent degradation [85]. Many molecular glues were discovered serendipitously, with immunomodulatory imide drugs (IMiDs) like thalidomide, lenalidomide, and pomalidomide serving as prototypical examples that recruit transcription factors to the cereblon E3 ligase complex [84] [86].

E3 Ligase Modulators encompass compounds that regulate the activity, specificity, or substrate recruitment of E3 ubiquitin ligases [87]. These modulators can either enhance or suppress the function of specific E3 ligases, thereby influencing the degradation of natural substrate proteins. In the context of antiviral immunity, numerous human E3 ligases play dual roles as both effectors and targets in the evolutionary battle between host and pathogen [87]. For instance, during SARS-CoV-2 infection, some E3 ligases function as part of the host antiviral defense, while others are exploited by the virus to suppress immune responses and promote viral replication [87].

Comparative Analysis of TPD Strategies

Table 1: Comparative Analysis of PROTACs and Molecular Glues

Characteristic	PROTACs	Molecular Glues
Molecular Structure	Heterobifunctional (POI ligand + E3 ligase ligand + linker) [84]	Monovalent, single small molecule [84] [85]
Molecular Weight	Typically >700 Da [84]	Relatively low molecular weight [84]
Mechanism of Action	Induces forced proximity via simultaneous binding to POI and E3 ligase [84] [89]	Surface remodeling to create novel protein-protein interfaces [84]
Design Approach	Rational, modular design [84]	Often serendipitous discovery; rational design challenging [84]
Permeability	Can face challenges due to larger size [84]	Generally favorable due to smaller size [84]
Catalytic Activity	Yes - operates sub-stoichiometrically [84]	Yes - operates sub-stoichiometrically [84]
Target Scope	Broad, but requires identifiable binding pocket on POI [84]	Can target proteins without classical binding pockets [84] [85]

Table 2: E3 Ligases Commonly Exploited in TPD

E3 Ligase	Natural Substrate	Role in Antiviral Immunity	TPD Applications
CRBN (Cereblon)	-	IMiDs modulate substrate specificity [86]	Molecular glues (thalidomide analogs); CRBN-recruiting PROTACs [86] [88]
VHL (Von Hippel-Lindau)	HIF-1α [86]	-	VHL-based PROTACs [86] [88]
MDM2	p53 [89]	-	MDM2-harnessing and MDM2-targeted PROTACs [89]
IAP (Inhibitor of Apoptosis)	Caspases [88]	-	IAP-based PROTACs (e.g., against BCL-xL, BCR-ABL) [88]
RNF185	SARS-CoV-2 envelope protein [87]	Attenuates viral infection by degrading viral envelope protein [87]	Potential for antiviral PROTAC development
TRIM Family	Various innate immune signaling components [12]	Multiple roles in regulating antiviral signaling pathways [12]	Emerging applications in antiviral TPD

Atypical Ubiquitin Chains in Antiviral Immune Signaling

The Ubiquitin Code in Innate Immunity

The ubiquitin system regulates virtually all aspects of cellular function through a complex code of monoubiquitination and polyubiquitin chains of different linkages [12]. While K48-linked chains typically target proteins for proteasomal degradation and K63-linked chains play roles in signal transduction, the so-called "atypical" ubiquitin chains (K6, K11, K27, K29, K33, and linear/M1 chains) are increasingly recognized as critical regulators of the antiviral innate immune response [11] [12]. These atypical chains can function as degradative signals or regulate protein activity, localization, and interactions in linkage-specific manners [11].

Virus infection triggers an immediate antiviral response characterized by the production of type I interferons (IFN-α/β), type III IFNs, proinflammatory cytokines, and chemokines [12]. This response is initiated by pattern recognition receptors (PRRs) that detect viral components and activate signaling cascades converging on transcription factors NF-κB and IRF3/7 [11] [12]. Ubiquitination plays a crucial role at multiple steps in these pathways, with different ubiquitin linkage types contributing to precise regulation of immune signaling magnitude and duration to ensure effective antiviral responses while preventing excessive inflammation [11].

Specific Roles of Atypical Ubiquitin Linkages

K27-Linked Ubiquitination has emerged as a particularly important regulator of antiviral signaling. Multiple E3 ligases, including TRIM23, TRIM26, TRIM40, and RNF185, conjugate K27-linked chains to various components of the innate immune system [11]. For example, TRIM23 mediates K27-linked ubiquitination of NEMO, leading to activation of both NF-κB and IRF3 pathways [11]. RNF185 catalyzes K27-linked ubiquitination of the SARS-CoV-2 envelope protein, targeting it for degradation and thereby restricting viral replication [87]. Interestingly, K27/K29-linked hybrid chains synthesized by RNF34 induce autophagy-mediated degradation of MAVS, providing a mechanism to restrict excessive type I IFN responses [11].

Linear (M1-Linked) Ubiquitination is uniquely catalyzed by the linear ubiquitin chain assembly complex (LUBAC) and plays a crucial role in NF-κB activation [11] [12]. Linear chains interact with the UBAN domain of NEMO, potentiating NF-κB signaling [11]. Additionally, LUBAC-mediated linear ubiquitination of NEMO disrupts the MAVS-TRAF3 complex, resulting in NF-κB activation while simultaneously inhibiting IRF3 activation and type I IFN signaling [11]. This illustrates how specific ubiquitin linkages can differentially regulate distinct arms of the antiviral response.

K11-Linked Ubiquitination is associated with both proteasomal degradation and non-proteolytic functions in innate immunity [11]. RNF26-mediated K11-linked ubiquitination of STING inhibits its degradation, leading to enhanced type I IFN and cytokine production [11]. Additionally, K11-linked ubiquitination of RIP1 facilitates its interaction with NEMO, contributing to NF-κB activation [11].

K29 and K33-linked ubiquitination also participate in regulating antiviral signaling. The SKP1-Cullin-Fbx21 complex mediates K29-linked ubiquitination of ASK1, promoting IFNβ and IL-6 production [11]. K33-linked ubiquitination of TBK1 by an unidentified E3 ligase prevents TBK1 degradation and enhances IRF3 activation, while USP38 removes these chains to fine-tune the response [11].

Diagram 1: Atypical Ubiquitin Chains in Antiviral Signaling Pathways. This diagram illustrates how various atypical ubiquitin linkages regulate key components of the innate immune response to viral infection, creating a complex regulatory network that either activates or suppresses antiviral signaling.

Experimental Approaches and Research Methodologies

Core Methodologies for TPD Development and Validation

Ternary Complex Analysis is essential for evaluating productive PROTAC interactions. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) provide quantitative data on binding affinities and stoichiometry within the POI-PROTAC-E3 ligase complex [84]. Additionally, X-ray crystallography and cryo-electron microscopy offer structural insights into ternary complex formation, informing rational optimization of PROTAC molecules [84] [86]. These approaches help researchers understand how linker length and composition influence the geometry and stability of the ternary complex, which directly impacts degradation efficiency [84] [89].

Cellular Degradation Assays form the cornerstone of TPD validation. Western blotting and immunofluorescence remain standard techniques for quantifying target protein depletion over time and across PROTAC concentrations [84]. These are complemented by cellular thermal shift assays (CETSA) that confirm target engagement through protein stabilization [86]. For high-throughput screening, luminescence-based reporters (e.g., NanoLuciferase) fused to POIs enable rapid quantification of degradation kinetics and potency (DC50 values) [86].

Ubiquitination-Specific Methodologies are critical for understanding mechanism of action. Tandem ubiquitin binding entities (TUBEs) combined with mass spectrometry allow linkage-specific identification of ubiquitin chains deposited on target proteins [11] [90]. Single-molecule FRET techniques have revealed that differently linked diubiquitin chains exist in distinct conformational states in solution, and that ubiquitin-binding proteins selectively recognize pre-existing conformations rather than inducing conformational changes [90]. This fundamental insight has important implications for degrader design.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for TPD and Ubiquitin Research

Reagent/Category	Specific Examples	Function/Application
E3 Ligase Ligands	Nutlin-3a (MDM2) [88], VHL ligand VH032 [86], CRBN ligands (lenalidomide, pomalidomide) [86]	Recruit specific E3 ligases in PROTAC design
Linker Libraries	PEG-based linkers, alkyl chains, piperazine-based linkers [84] [89]	Connect POI and E3 ligands; optimize ternary complex geometry
Ubiquitin Probes	TUBEs (Tandem Ubiquitin Binding Entities), linkage-specific antibodies [11] [90]	Detect and characterize ubiquitin chain types
DUB Inhibitors	PR-619 (pan-DUB inhibitor), USP7/14 inhibitors [12]	Probe ubiquitin dynamics and chain stability
Proteasome Inhibitors	MG132, bortezomib, carfilzomib [12]	Confirm proteasome-dependent degradation mechanism
Ubiquitin Mutants	K-only mutants (single lysine) [90], K-to-R mutants [90]	Determine linkage specificity in ubiquitination
Single-Molecule FRET Systems	Alexa488/Alexa647-labeled diUb [90]	Study ubiquitin chain conformations and dynamics

Diagram 2: Experimental Workflow for TPD Development. This workflow outlines the key stages in developing and characterizing targeted protein degraders, from initial design through functional validation in antiviral applications.

Application in Antiviral Research and Therapeutic Development

PROTACs as Antiviral Agents

The potential of PROTAC technology in antiviral therapy is rapidly emerging. PROTACs can be designed to target either viral proteins directly or host factors essential for viral replication [88]. This approach offers significant advantages over traditional antiviral inhibitors, including event-driven catalysis, potential efficacy against drug-resistant mutants, and the ability to target proteins with multiple functions [88]. The catalytic nature of PROTACs means they can be effective at lower concentrations than conventional inhibitors, potentially reducing toxicity and side effects [84] [88].

Several proof-of-concept studies have demonstrated the feasibility of antiviral PROTACs. For SARS-CoV-2, potential targets include the viral main protease (Mpro), RNA-dependent RNA polymerase, and various accessory proteins [87] [88]. Additionally, host factors such as ACE2, TMPRSS2, and components of the endosomal trafficking machinery represent attractive targets for host-directed antiviral therapy using PROTACs [87]. The extensive manipulation of the ubiquitin system by viruses provides numerous opportunities for therapeutic intervention using TPD strategies [87] [12].

Molecular Glues in Antiviral Immunity

Natural molecular glue mechanisms already play crucial roles in antiviral immunity. The phenomenon of "inducible degrons" represents a biological precedent for molecular glue action in immune regulation [85]. For example, the induction of certain viral proteins can create neo-interfaces that are recognized by cellular E3 ligases, leading to targeted degradation of both viral and cellular proteins [87].

Small-molecule glues can potentially mimic and enhance these natural mechanisms. For instance, compounds that stabilize the interaction between viral proteins and host E3 ligases could lead to enhanced viral protein degradation [85] [88]. Alternatively, glues that modulate the specificity of E3 ligases involved in immune signaling pathways could potentiate antiviral responses or suppress excessive inflammation [11] [12]. The serendipitous discovery of many molecular glues highlights the importance of phenotypic screening approaches in identifying novel antiviral agents that function through this mechanism [84] [85].

E3 Ligase Modulation in Antiviral Strategies

The "Janus-faced" role of many E3 ligases in viral infection presents both challenges and opportunities for therapeutic development [87]. Some E3 ligases function as restriction factors that attenuate viral infection, while others are exploited by viruses to suppress host antiviral defenses [87]. For example, during SARS-CoV-2 infection, RNF185 acts as a restriction factor by targeting the viral envelope protein for degradation, while other E3 ligases like NEDD4 and WWP1 are hijacked by the virus to promote infection [87].

Modulating the activity of these E3 ligases represents a promising antiviral strategy. Small-molecule enhancers of restriction factor E3 ligases could bolster intrinsic immunity, while inhibitors of proviral E3 ligases could prevent viral subversion of host machinery [87] [12]. The rich diversity of E3 ligases—with over 600 in the human genome—provides a substantial repertoire for therapeutic targeting, though only a handful have been exploited for TPD to date [89] [88].

The convergence of targeted protein degradation technologies with our growing understanding of atypical ubiquitin chains in antiviral immunity creates exciting opportunities for therapeutic innovation. PROTACs, molecular glues, and E3 ligase modulators represent complementary approaches to targeting previously undruggable components of the viral-host interface. The continued elucidation of linkage-specific functions of atypical ubiquitin chains will further inform the rational design of degraders that precisely modulate antiviral signaling pathways.

Future directions in this field include the expansion of the E3 ligase toolbox beyond the currently popular CRBN and VHL ligases, the development of tissue-specific and inducible degraders, and the integration of TPD with other therapeutic modalities [89] [88]. Additionally, advances in structural biology, computational modeling, and high-throughput screening will accelerate the discovery and optimization of novel degraders [84] [86]. As our understanding of the complex roles of ubiquitination in viral infection and immunity deepens, so too will our ability to harness this system for therapeutic benefit, potentially leading to new classes of antiviral agents that overcome the limitations of conventional approaches.

The intricate interplay between viral infections and the onset of autoimmune diseases represents a significant focus in immunology research. This whitepaper examines the validation of disease models that elucidate the mechanistic links between antiviral immune responses and autoimmune pathogenesis. Central to this discussion is the emerging role of atypical ubiquitin chains—non-canonical polyubiquitin linkages beyond the well-characterized K48 and K63 types—in regulating immune signaling pathways that bridge these conditions. We present a comprehensive technical analysis of experimental approaches, quantitative findings, and methodological frameworks for investigating how viral triggers, particularly SARS-CoV-2, disrupt immune tolerance and promote autoimmunity through ubiquitin-dependent mechanisms. The insights gathered herein provide researchers with validated models and tools to advance therapeutic development for virus-associated autoimmune pathologies.

Viral infections have long been hypothesized as environmental triggers for autoimmune diseases (AIDs), which occur when the immune system mistakenly attacks the body's own tissues [91]. Clinical evidence continues to accumulate demonstrating this connection, with recent research highlighting SARS-CoV-2 infection as a significant concern. Cohort studies have established that the severity of COVID-19 correlates with the production of specific autoantibodies, potentially predisposing patients to an increased risk for developing autoimmune conditions after a severe course of the disease [92]. A systematic review protocol registered to PROSPERO (CRD42024594446) aims to quantify this risk, seeking to determine the risk of incident autoimmune disease following SARS-CoV-2 infection among adults [93].

From a molecular perspective, viral infections can trigger autoimmunity through several mechanisms including molecular mimicry (viral antigens resembling self-structures), epitope spreading (diversification of immune responses to additional self-antigens), and bystander activation (non-specific activation of autoreactive immune cells) [91]. These mechanisms can lead to a breach in both central and peripheral immune tolerance, allowing autoreactive lymphocytes to attack host tissues [91]. Genetic predisposition interacts with these environmental triggers, with major histocompatibility complex (MHC) haplotypes and numerous other genetic loci (e.g., NOD2, PTPN22, CTLA4) identified as risk factors for various autoimmune conditions [91].

Table 1: Clinical Evidence Linking Viral Infections to Autoimmune Conditions

Evidence Type	Key Findings	Reference
SARS-CoV-2 Cohort Study	COVID-19 severity correlates with specific autoantibody production; severe cases show increased autoimmune risk	[92]
Systematic Review Protocol	Aims to quantify risk of new-onset autoimmune disease following SARS-CoV-2 infection in adults (≥18 years)	[93]
Mechanistic Review	Viral infections trigger autoimmunity via molecular mimicry, epitope spreading, and bystander activation	[91]
Genetic Studies	MHC haplotypes and multiple genetic loci (PTPN22, CTLA4, NOD2) contribute to autoimmune susceptibility	[91]

Atypical Ubiquitin Chains in Antiviral Immunity and Autoimmune Pathogenesis

Ubiquitination—the covalent attachment of ubiquitin to target proteins—serves as a critical post-translational modification regulating virtually all aspects of antiviral innate immunity [3] [24]. While the roles of K48-linked (proteasomal degradation) and K63-linked (signaling activation) polyubiquitin chains are well-established, recent advances have highlighted the importance of "atypical" ubiquitin chains linked through K6, K11, K27, K29, K33, and M1 (linear) residues in immune regulation [3].

These atypical ubiquitin chains function as sophisticated regulators of intracellular antiviral innate immune signaling pathways, including those initiated by RIG-I-like receptors (RLRs) and DNA sensors like cGAS [3]. For instance, linear ubiquitin chains assembled by the Linear Ubiquitin Chain Assembly Complex (LUBAC) are crucial for NF-κB activation but can also inhibit type I interferon signaling [3]. Meanwhile, K27-linked chains conjugated to NEMO by TRIM23 are required for the induction of both NF-κB and IRF3 upon RLR signaling activation [3].

The precise regulation of these ubiquitin-dependent pathways is essential for maintaining immune homeostasis. Dysregulation can lead to excessive or prolonged immune activation, potentially triggering autoimmune pathologies [8]. For example, RNF167-mediated K6- and K11-linked polyubiquitination of RIG-I and MDA5 directs their degradation through dual proteolytic pathways, representing a crucial negative feedback mechanism to prevent excessive interferon activation that could promote autoimmunity [8].

Table 2: Functions of Atypical Ubiquitin Chains in Immune Regulation

Ubiquitin Linkage	Key Functions in Immune Signaling	Regulating Enzymes	Pathological Consequences
Linear (M1)	Potentiates NF-κB signaling; inhibits type I IFN; regulates NEMO	LUBAC	Autoimmune conditions due to disrupted NF-κB/IFN balance
K11	Regulates degradation of innate immune factors (STING, Beclin-1); associated with proteasomal and autophagic degradation	RNF26, RNF167	Impaired viral clearance or excessive inflammation
K27	Balances immune activation/inhibition; creates platforms for signal regulation	TRIM23	Defects in immune tolerance; uncontrolled inflammation
K6	Targets RIG-I/MDA5 for autophagic degradation; regulates amplitude of IFN response	RNF167	Prolonged IFN activation potentially leading to autoimmunity

Validated Experimental Models and Methodologies

Animal Models of Virus-Induced Autoimmunity

Animal models provide indispensable platforms for validating the molecular mechanisms linking viral infections to autoimmune conditions. Several well-established systems offer unique insights:

The Experimental Autoimmune Encephalomyelitis (EAE) model has been instrumental in studying neuroinflammatory conditions such as multiple sclerosis (MS) [94]. This model has revealed specific immune cells, particularly T cells and B cells, as central players in the immune attack against self-antigens. Recent studies utilizing the EAE model have demonstrated that endurance exercise initiated after disease onset significantly attenuates disease severity, coinciding with a reduction in B cells, dendritic cells, and neutrophils in the central nervous system [94].

The roseolovirus infection model in mice has provided direct evidence for viral induction of autoimmunity through thymic infection. Neonatal infection with mouse roseolovirus leads to a transient depletion of CD4+ single positive and CD4+CD8+ double positive thymocytes, accompanied by a reduction in medullary thymic epithelial cells (mTECs), thymic dendritic cells, and AIRE and tissue-restricted antigen expression [91]. This thymic disruption results in the development of autoimmune gastritis 12 weeks post-infection, with affected mice producing autoantibodies of diverse specificity and harboring autoreactive CD4+ T cells [91].

The monophasic EAE model in female Dark Agouti rats has revealed significant perturbations in the growth hormone (GH) axis during acute disease phases [94]. Researchers observed significant upregulation of genes encoding GH, its receptor, and GH-releasing hormone in the pituitary gland, alongside increased serum GH levels and decreased insulin-like growth factor 1 concentrations—a state resembling GH resistance potentially resulting from inadequate nutrient intake during peak CNS inflammation [94].

Methodological Framework for Immune Repertoire Analysis

Advanced biophysical frameworks now enable quantitative analysis of immune repertoire dynamics through energy landscape optimization. This approach mathematically reconstructs immune repertoire evolution based on three fundamental principles [95]:

• Clonal emergence probabilities map to metastable states within the energy landscape, representing the likelihood of specific immune cell clones expanding in response to viral or self-antigens.

• Repertoire transitions obey non-equilibrium dynamics, allowing researchers to model the temporal evolution of immune responses following viral challenges.

• Inter-IR distances quantify distribution transformation costs via optimal transport theory, enabling precise measurement of how immune repertoires shift from homeostatic to autoimmune states.

This methodological framework allows for macroscopic immune state detection from as few as 10,000 cells by resolving critical fluctuations in sparse sampling regimes [95]. Experimental validation across murine and human cohorts has demonstrated precise unsupervised stratification of immune stages and disease states without prior clinical annotations, bridging stochastic somatic hypermutation kinetics with deterministic repertoire shifts [95].

Algorithmic Validation of Autoimmune Disease Identification

Validated identification algorithms are crucial for accurate autoimmune disease classification in clinical and research settings. Recent work has developed and validated computable phenotypes for five autoimmune diseases using electronic health records in Chinese populations [96]. The algorithms combined International Classification of Diseases (ICD-10) codes with Chinese medical terminology from outpatient, inpatient, and discharge records, with performance validated through chart reviews by clinical physicians.

Table 3: Performance Metrics of Autoimmune Disease Identification Algorithms

Autoimmune Disease	Optimal Algorithm Performance	Key Data Sources for Identification
Hashimoto's Thyroiditis	Sensitivity: 97.44%; PPV: 98.28%	ICD-10 codes and Chinese medical terminology
Rheumatoid Arthritis (RA)	Sensitivity: 100.00%; PPV: 76.92%	Combination of admission and outpatient records
Inflammatory Bowel Disease (IBD)	Sensitivity: 79.66%; PPV: 70.15%	Synthesis of multiple data sources required
Primary Immune Thrombocytopenia (ITP)	Sensitivity: 62.50%; PPV: 70.00%	Multiple data sources with moderate sensitivity
Type 1 Diabetes (T1D)	Sensitivity: 84.09%; PPV: 74.00%	Both admission and outpatient records

These algorithms demonstrate that a combination of data sources is crucial for accurate case identification in complex autoimmune conditions, providing an important methodological foundation for future real-world studies [96]. The implementation of such validated computable phenotypes enables researchers to extract valuable information from vast medical datasets, enhancing diagnostic and therapeutic efficiency in autoimmune disease research.

Detailed Experimental Protocols for Key Mechanisms

Protocol: Assessing RLR Regulation via Atypical Ubiquitination

This protocol outlines methods to investigate how atypical ubiquitination regulates RIG-I-like receptors (RLRs), based on established methodologies [8].

Cell Culture and Treatment

• Culture THP-1 cells (human monocytic leukemia cell line) in RPMI-1640 medium with 10% FBS.
• For stimulation, treat cells with:
  • RNA mimics poly(I:C) (1-10 μg/mL) for 4-24 hours
  • Sendai virus (SeV) at 100-200 HAU/mL for 12-48 hours
  • Encephalomyocarditis virus (EMCV) at MOI 1-5 for 12-48 hours
  • Herpes simplex virus type 1 (HSV-1) at MOI 1-5 for 12-48 hours
  • Human recombinant IFN-β (1000 U/mL) for 12-48 hours

Gene Manipulation Techniques

• For RNF167 knockout, use CRISPR/Cas9 system with guide RNAs targeting human RNF167 exons.
• Generate single-cell clones and validate knockout by Western blot and sequencing.
• For transient knockdown, transfert siRNA targeting human RNF167 (20-50 nM) using appropriate transfection reagents.
• For reconstitution experiments, use RNF167-expressing plasmid resistant to Cas9 cleavage.

Ubiquitination Assays

• Transfect HEK293 cells with plasmids encoding RIG-I/MDA5 and RNF167.
• Treat cells with MG132 (10 μM) for 6 hours before harvesting to inhibit proteasomal degradation.
• Lyse cells in RIPA buffer containing N-ethylmaleimide (10 mM) and protease inhibitors.
• Immunoprecipitate RIG-I/MDA5 using specific antibodies and protein A/G beads.
• Detect atypical K6- and K11-linked ubiquitination using linkage-specific antibodies via Western blot.

Functional Assays

• Measure IFN-β promoter activation using dual-luciferase reporter assays.
• Quantify mRNA levels of IFNB1, CXCL10, IFIT1, CXCL1, and IL-6 by qRT-PCR.
• Assess viral replication using VSV-GFP; measure fluorescence intensity and viral titer by plaque assay.

Protocol: Autoantibody Detection in COVID-19 Patients

This protocol details methods for detecting autoantibodies in COVID-19 patients across disease severity spectra, based on validated clinical approaches [92].

Patient Cohort Stratification

• Recruit COVID-19 patients and stratify by disease severity:
  • Mild: symptomatic without viral pneumonia or hypoxia
  • Moderate: clinical signs of pneumonia but no severe disease
  • Severe: severe pneumonia requiring oxygen support
  • Critical: acute respiratory distress syndrome requiring ECMO or ICU care
• Include control group with severe non-COVID-related diseases matched for age and sex.

Sample Collection and Processing

• Collect serum samples at multiple time points: acute phase (0-7 days post-diagnosis), convalescent phase (14-28 days), and long-term follow-up (3-6 months).
• Process samples within 2 hours of collection; separate serum by centrifugation and store at -80°C.

Comprehensive Autoantibody Panel

• Screen for autoantibodies using addressable laser bead immunoassay or similar multiplex platform.
• Include antigens associated with systemic autoimmune diseases:
  • Nuclear antigens (dsDNA, Smith, RNP, SSA/Ro, SSB/La)
  • Cytoplasmic antigens (ribosomal P, Jo-1)
  • Phospholipid-associated antigens (cardiolipin, β2-glycoprotein I)
  • Vasculitis-associated antigens (MPO, PR3)
• Confirm positive results by indirect immunofluorescence on HEp-2 cells.

Data Analysis

• Compare autoantibody profiles across severity groups using appropriate statistical tests (chi-square, ANOVA).
• Perform multivariate analysis to identify autoantibodies independently associated with COVID-19 severity.
• Calculate odds ratios for developing specific autoimmune conditions based on autoantibody profiles.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Essential Research Reagents for Studying Ubiquitination in Antiviral Immunity

Reagent/Category	Specific Examples	Research Application	Key Functions
Cell Lines	THP-1, HEK293, Raw264.7, L929, primary BMDMs	In vitro signaling studies, viral infection models	Provide cellular context for studying innate immune pathways and ubiquitination events
Viral Agonists	Sendai virus (SeV), Vesicular Stomatitis Virus (VSV), Encephalomyocarditis Virus (EMCV), HSV-1	Pathogen-associated molecular pattern (PAMP) delivery	Activate RIG-I-like receptor (RLR) and DNA sensing pathways to trigger innate immune responses
Pathogen Mimics	poly(I:C) (low and high molecular weight)	Synthetic activation of RLR and TLR pathways	Mimic viral RNA to stimulate MDA5 and TLR3 signaling without live virus requirements
Linkage-Specific Antibodies	Anti-K6 ubiquitin, Anti-K11 ubiquitin, Anti-linear ubiquitin	Detection of atypical ubiquitin chain types	Enable specific identification of non-canonical ubiquitination events in immunoprecipitation and Western blot
Ubiquitination System Components	E1 activating enzymes, E2 conjugating enzymes, E3 ligases (RNF167, TRIM23, LUBAC)	In vitro ubiquitination assays	Reconstitute ubiquitination cascades to identify specific enzymes responsible for atypical chain formation
Proteasome Inhibitors	MG132, Bortezomib, Lactacystin	Blockade of proteasomal degradation	Preserve ubiquitinated proteins for analysis by preventing their degradation
CRISPR/Cas9 Systems	Guide RNAs targeting RNF167, RIG-I, MDA5	Genetic knockout of specific immune components	Enable functional validation of specific genes in ubiquitination and immune signaling pathways
Luciferase Reporter Systems	IFN-β-promoter, PRDI-III, NF-κB reporters	Quantification of pathway activation	Measure downstream transcriptional activity of innate immune signaling pathways
Animal Models	C57BL/6J mice, Dark Agouti rats, NOD/ShiLtJ mice	In vivo validation of mechanisms	Provide whole-organism context for studying immune responses and autoimmune disease development

Integrated Signaling Pathways: From Viral Sensing to Autoimmunity

The molecular journey from viral infection to autoimmune development involves sophisticated signaling networks regulated by ubiquitination. The diagram below integrates key pathways and regulatory mechanisms, highlighting the crucial role of atypical ubiquitin chains in maintaining immune homeostasis or permitting autoimmune progression.

The validation of disease models connecting viral infections to autoimmune conditions through ubiquitin-regulated pathways represents a frontier in immunology with significant therapeutic implications. The evidence presented herein demonstrates that atypical ubiquitin chains serve as sophisticated molecular devices that calibrate antiviral immune responses, with dysregulation potentially leading to loss of self-tolerance. The experimental models, methodological frameworks, and technical protocols detailed in this whitepaper provide researchers with validated approaches to advance this field.

Future research directions should prioritize the development of linkage-specific ubiquitin tools to precisely manipulate atypical chain formation in physiological contexts, the integration of multi-omics approaches to map ubiquitin-regulated networks across diverse autoimmune conditions, and the translation of mechanistic insights into targeted therapies that modulate ubiquitin signaling without compromising essential immune functions. The established connection between SARS-CoV-2 infection and autoimmune risk further underscores the urgency of these efforts, as understanding the molecular basis of this relationship may inform strategies to mitigate long-term autoimmune consequences of pandemic infections.

As the field progresses, the cross-disciplinary integration of immunology, virology, and ubiquitin biology will be essential to develop the next generation of therapeutics for autoimmune diseases, particularly those triggered or exacerbated by viral infections. The models and methodologies validated in this whitepaper provide a robust foundation for these advances.

Conclusion

Atypical ubiquitin chains represent a complex and vital regulatory layer in the antiviral innate immune response, enabling precise control over the magnitude and duration of signaling through non-degradative and degradative mechanisms. The exploration of E3 ligases like RNF167 and TRIMs, alongside specialized DUBs, has revealed sophisticated mechanisms, such as dual degradation pathways and linkage-specific deubiquitination, that fine-tune immune homeostasis. Future research must focus on developing more specific tools to dissect this complexity and on translating these findings into novel therapeutic strategies. Harnessing the atypical ubiquitin code holds immense promise for creating next-generation antivirals and immunomodulators, particularly for diseases where conventional targets have proven elusive.

References

• 1. Beyond K48 and K63: non-canonical protein ubiquitination [https://cmbl.biomedcentral.com/articles/10.1186/s11658-020-00245-6]
• 2. Current methodologies in protein ubiquitination ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9373315/]
• 3. The Role of Atypical Ubiquitin Chains in the Regulation ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2019.00392/full]
• 4. Structural basis of K11/K48-branched ubiquitin chain ... [https://www.nature.com/articles/s41467-025-64719-x]
• 5. Structural visualization of HECT-type E3 ligase Ufd4 ... [https://www.nature.com/articles/s41467-025-59569-6]
• 6. 亲和分离在蛋白质泛素化修饰研究中的应用进展- PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9274849/]
• 7. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB ... [https://www.sciencedirect.com/science/article/pii/S1097276516305639]
• 8. RNF167 mediates atypical ubiquitylation and degradation ... [https://www.nature.com/articles/s41467-025-57245-3]
• 9. CN109563160B - 抗聚泛素多特异性抗体 [https://patents.google.com/patent/CN109563160B/zh]
• 10. The ubiquitin system: from cell signalling to disease ... [https://www.nature.com/articles/s41418-020-00703-w]
• 11. The Role of Atypical Ubiquitin Chains in the Regulation ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6987411/]
• 12. Ubiquitination in the Antiviral Immune Response - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4774549/]
• 13. E3 Ubiquitin Ligases: The Operators of the Ubiquitin Code ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9740615/]
• 14. E3 ubiquitin ligases, the powerful modulator of innate ... [https://www.sciencedirect.com/science/article/abs/pii/S0008874918303988]
• 15. Biochemistry, Pathophysiology, and Regulation of Linear ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8534859/]
• 16. E3 ligase HECTD3 promotes RNA virus replication and ... [https://www.nature.com/articles/s41419-023-05923-9]
• 17. Ubiquitin modifications | Cell Research [https://www.nature.com/articles/cr201639]
• 18. The Role of Deubiquitinases in Virus Replication and Host ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8908266/]
• 19. Cellular Deubiquitylating Enzyme: A Regulatory Factor of ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.805223/full]
• 20. Atypical ubiquitin chains: new molecular signals. 'Protein ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2427391/]
• 21. Genetic analysis reveals functions of atypical polyubiquitin ... [https://elifesciences.org/articles/42955]
• 22. Deubiquitinases: From mechanisms to their inhibition by ... [https://www.sciencedirect.com/science/article/pii/S1097276521009473]
• 23. Deubiquitinase USP47 attenuates virus-induced type I ... [https://www.sciencedirect.com/science/article/abs/pii/S1567576923003612]
• 24. Review Ubiquitination in the antiviral immune response [https://www.sciencedirect.com/science/article/pii/S0042682215000793]
• 25. Harnessing innate immune pathways for therapeutic ... [https://www.nature.com/articles/s41392-024-01765-9]
• 26. Targeting the cGAS-STING pathway: emerging strategies and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12183253/]
• 27. cGLRs are a diverse family of pattern recognition receptors ... [https://www.sciencedirect.com/science/article/pii/S0092867423005901]
• 28. The Role of Atypical Ubiquitin Chains in the Regulation ... [https://www.semanticscholar.org/paper/The-Role-of-Atypical-Ubiquitin-Chains-in-the-of-the-Huizen-Kikkert/6863ae8da05f02f2cf787be39873f2fb5d942652]
• 29. Branched Ubiquitination: Detection Methods, Biological ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7664869/]
• 30. Ubiquitin Chain Editing Revealed by Polyubiquitin Linkage ... [https://www.sciencedirect.com/science/article/pii/S0092867408009598]
• 31. Unraveling chain specific ubiquitination in cells using ... [https://www.nature.com/articles/s41598-025-07242-9]
• 32. The Emerging Role of Non-traditional Ubiquitination in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5339741/]
• 33. How to Detect the Ubiquitination Levels of a Specific Protein [https://www.mtoz-biolabs.com/how-to-detect-the-ubiquitination-levels-of-a-specific-protein.html]
• 34. Proteome and Ubiquitinome Analyses Reveal the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12413316/]
• 35. exploring the ubiquitin system for drug development [https://www.nature.com/articles/cr201631]
• 36. What are Atypical Ubiquitin Chains? [https://www.news-medical.net/life-sciences/What-are-Atypical-Ubiquitin-Chains.aspx]
• 37. Atypical ubiquitin chains: new molecular signals. 'Protein ... [https://pubmed.ncbi.nlm.nih.gov/18516089/]
• 38. Quantitative Proteomics Reveals the Function of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2668214/]
• 39. RNF167 activates mTORC1 and promotes tumorigenesis by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7887217/]
• 40. RNF167 mediates atypical ubiquitylation and degradation ... [https://pubmed.ncbi.nlm.nih.gov/39994288/]
• 41. Emerging functions of branched ubiquitin chains [https://www.nature.com/articles/s41421-020-00237-y]
• 42. Specificity in Ubiquitination Triggered by Virus Infection [https://www.mdpi.com/1422-0067/21/11/4088]
• 43. K63-linked polyubiquitination of LGP2 by Riplet regulates ... [https://pubmed.ncbi.nlm.nih.gov/36515138/]
• 44. Discovery and mechanism of K63-linkage-directed ... [https://www.nature.com/articles/s41589-024-01777-0]
• 45. New enzymes discovered for protein modification pruning [https://www.mpi-dortmund.mpg.de/news/new-enzymes-discovered]
• 46. 8C61: Structure of USP54 in complex with Lys63-linked ... [https://www.rcsb.org/structure/8c61]
• 47. Discovery and mechanism of K63-linkage-directed ... [https://pubmed.ncbi.nlm.nih.gov/39587316/]
• 48. Ubiquitin signaling in immune responses | Cell Research [https://www.nature.com/articles/cr201640]
• 49. Elucidation of TRIM25 ubiquitination targets involved in ... [https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010743]
• 50. A protein sequence-based deep transfer learning ... [https://www.nature.com/articles/s41467-024-48446-3]
• 51. Machine learning-based approaches for ubiquitination site ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10683244/]
• 52. PROTAC-Based Antivirals for Respiratory Viruses: A Novel ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12297968/]
• 53. BioE3 identifies specific substrates of ubiquitin E3 ligases [https://www.nature.com/articles/s41467-023-43326-8]
• 54. Data-independent acquisition method for ubiquitinome ... [https://www.nature.com/articles/s41467-020-20509-1]
• 55. Quantifying Ubiquitin Signaling - PMC - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC4441763/]
• 56. Structural insights into the human HRD1 ubiquitin ligase ... [https://www.nature.com/articles/s41467-025-61143-z]
• 57. Linkage via K27 bestows ubiquitin chains with unique ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4787624/]
• 58. Ubiquitin-chains dynamics and its role regulating crucial ... [https://www.sciencedirect.com/science/article/abs/pii/S1084952121003050]
• 59. Crosstalk and Interplay between the Ubiquitin-Proteasome ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5547213/]
• 60. The Ubiquitin–Proteasome System and the Autophagic– ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3405832/]
• 61. Review Ubiquitin—A structural perspective [https://www.sciencedirect.com/science/article/abs/pii/S1097276524010104]
• 62. Unraveling chain specific ubiquitination in cells using tandem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12217038/]
• 63. Autophagy and the Immune Response - PMC - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC7120363/]
• 64. Targeting autophagy increases the efficacy of proteasome ... [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-09775-y]
• 65. The role of ubiquitylation in immune defence and pathogen ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3864900/]
• 66. The Ubiquitin-Conjugating System: Multiple Roles in Viral ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4092849/]
• 67. Viral hijacking of the host ubiquitin system to evade ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2939720/]
• 68. Editorial: Ubiquitin and ubiquitin-like modifications in viral ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1148296/full]
• 69. Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7103382/]
• 70. The emerging roles of ubiquitin-like modifications in regulating ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12187746/]
• 71. Insights into ubiquitinome dynamics in the host‒pathogen ... [https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01887-1]
• 72. Regulation of antiviral innate immune signaling and viral ... [https://www.nature.com/articles/s12276-021-00691-y]
• 73. Ubiquitomics: An Overview and Future [https://www.mdpi.com/2218-273X/10/10/1453]
• 74. The Role of Protein Ubiquitination in the Onset and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12248740/]
• 75. State-of-the-Art and Future Directions in Structural Proteomics [https://pmc.ncbi.nlm.nih.gov/articles/PMC12546877/]
• 76. A Hierarchical Mechanism of RIG-I Ubiquitination Provides ... [https://www.nature.com/articles/srep29263]
• 77. The role of ubiquitination in tumorigenesis and targeted ... [https://www.nature.com/articles/s41392-020-0107-0]
• 78. Insights in Post-Translational Modifications: Ubiquitin and ... [https://www.mdpi.com/1422-0067/23/6/3281]
• 79. Emerging drug development technologies targeting ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7112620/]
• 80. Crosstalk between SUMOylation and other post-translational ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11316377/]
• 81. Function, mechanism and drug discovery of ubiquitin and ... [https://www.sciencedirect.com/science/article/pii/S2211383523002812]
• 82. Viruses utilize ubiquitination systems to escape TLR/RLR- ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1065211/full]
• 83. Assembly, analysis and architecture of atypical ubiquitin ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4176834/]
• 84. Review Molecular glues and PROTACs in targeted protein ... [https://www.sciencedirect.com/science/article/abs/pii/S0006295225005623]
• 85. Molecular glue-mediated targeted protein degradation [https://pmc.ncbi.nlm.nih.gov/articles/PMC11409024/]
• 86. PROTAC targeted protein degraders: the past is prologue [https://www.nature.com/articles/s41573-021-00371-6]
• 87. Human E3 ubiquitin ligases: accelerators and brakes for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11555711/]
• 88. Recent Advances in PROTAC-Based Antiviral Strategies [https://pmc.ncbi.nlm.nih.gov/articles/PMC9958553/]
• 89. Dual functionality of MDM2 in PROTACs expands the horizons ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12392632/]
• 90. Ubiquitin chain conformation regulates recognition and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3605796/]
• 91. The Role of Viral Infections in the Onset of Autoimmune Diseases - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10051805/]
• 92. Autoantibody development is associated with clinical severity of COVID-19: A cohort study - PubMed [https://pubmed.ncbi.nlm.nih.gov/40044018/]
• 93. New onset autoimmune disease following a SARS-CoV-2 infection: A systematic review protocol | PLOS One [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0335766]
• 94. Special Issue “Advances in Molecular Research on Autoimmune Diseases” - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC11546243/]
• 95. A quantitative framework for immune repertoire dynamics ... [https://www.sciencedirect.com/science/article/pii/S2667325825003000]
• 96. Development and validation of identification algorithms for ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1541203/full]